Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3958184,metabolic clearance rates (MCR),The LH bolus disappearance curves provided estimates of metabolic clearance rates (MCR) of 24.1 +/- 4.7 (+/- SD) ml/min for bioactive LH vs. 56.2 +/- 12 ml/min for immunoactive LH in the same men (P = 0.03).,Metabolic clearance of biologically active luteinizing hormone in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[ml] / [min],24.1,520,DB00624,Testosterone
,3958184,metabolic clearance rates (MCR),The LH bolus disappearance curves provided estimates of metabolic clearance rates (MCR) of 24.1 +/- 4.7 (+/- SD) ml/min for bioactive LH vs. 56.2 +/- 12 ml/min for immunoactive LH in the same men (P = 0.03).,Metabolic clearance of biologically active luteinizing hormone in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[ml] / [min],56.2,521,DB00624,Testosterone
,3958184,steady-state MCRs,"A lower MCR of bioactive LH compared with immunoactive LH was also observed during continuous infusions of physiological doses of LH; for example, the mean steady-state MCRs for bioactive and immunoactive LH were, respectively, 26.1 +/- 3.1 and 34.2 +/- 3.2 ml/min (P = 0.02).",Metabolic clearance of biologically active luteinizing hormone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[ml] / [min],26.1,522,DB00624,Testosterone
,3958184,steady-state MCRs,"A lower MCR of bioactive LH compared with immunoactive LH was also observed during continuous infusions of physiological doses of LH; for example, the mean steady-state MCRs for bioactive and immunoactive LH were, respectively, 26.1 +/- 3.1 and 34.2 +/- 3.2 ml/min (P = 0.02).",Metabolic clearance of biologically active luteinizing hormone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[ml] / [min],34.2,523,DB00624,Testosterone
,3958184,endogenous,"Based on the respective steady-state MCRs calculated at physiological plasma concentrations of immunoactive and bioactive LH, we estimate a mean endogenous production rate for bioactive hormone of 1,937 IU/24 h, and for immunoactive LH of 589 IU/24 h in normal men.",Metabolic clearance of biologically active luteinizing hormone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[iu] / [24·h],"1,937",524,DB00624,Testosterone
,3958184,endogenous,"Based on the respective steady-state MCRs calculated at physiological plasma concentrations of immunoactive and bioactive LH, we estimate a mean endogenous production rate for bioactive hormone of 1,937 IU/24 h, and for immunoactive LH of 589 IU/24 h in normal men.",Metabolic clearance of biologically active luteinizing hormone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[iu] / [24·h],589,525,DB00624,Testosterone
,3958184,production rate,"Based on the respective steady-state MCRs calculated at physiological plasma concentrations of immunoactive and bioactive LH, we estimate a mean endogenous production rate for bioactive hormone of 1,937 IU/24 h, and for immunoactive LH of 589 IU/24 h in normal men.",Metabolic clearance of biologically active luteinizing hormone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[iu] / [24·h],"1,937",526,DB00624,Testosterone
,3958184,production rate,"Based on the respective steady-state MCRs calculated at physiological plasma concentrations of immunoactive and bioactive LH, we estimate a mean endogenous production rate for bioactive hormone of 1,937 IU/24 h, and for immunoactive LH of 589 IU/24 h in normal men.",Metabolic clearance of biologically active luteinizing hormone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3958184/),[iu] / [24·h],589,527,DB00624,Testosterone
,16223868,affinities,All five analogs bound to guinea pig progesterone binding globulin with relatively high affinities (264-1020 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,264-1020,4000,DB00624,Testosterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,15,4001,DB00624,Testosterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,7,4002,DB00624,Testosterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,4,4003,DB00624,Testosterone
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,26,4004,DB00624,Testosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],0.82,5456,DB00624,Testosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.48,5457,DB00624,Testosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.31,5458,DB00624,Testosterone
,12236849,Fifty percent inhibitory concentrations (IC50),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],0.88,5459,DB00624,Testosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.8,5460,DB00624,Testosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.4,5461,DB00624,Testosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.0,5462,DB00624,Testosterone
,12236849,zero-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],10.7,5463,DB00624,Testosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.8,5464,DB00624,Testosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.4,5465,DB00624,Testosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],17.0,5466,DB00624,Testosterone
,12236849,kin,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[%] / [h],10.7,5467,DB00624,Testosterone
,12236849,first-order rate constants,"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.17,5468,DB00624,Testosterone
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.17,5469,DB00624,Testosterone
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.16,5470,DB00624,Testosterone
,12236849,kout),"Fifty percent inhibitory concentrations (IC50) of 0.82, 1.48, 1.31 and 0.88 micro g ml(-1), zero-order rate constants for the onset of plasma DHT concentration changes (kin) of 17.8, 17.4, 17.0 and 10.7% h(-1) and first-order rate constants for increase in plasma DHT concentrations to basal values (kout) of 0.17, 0.16, 0.17 and 0.10 h(-1) for the single study at doses of 25, 50, 75 and 100 mg, respectively, were attained.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),1/[h],0.10,5471,DB00624,Testosterone
,12236849,IC50s,"In the multiple-dose study, IC50s were 1.74 and 1.49 micro g ml(-1) for the 12.5 and 25 mg doses, respectively.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.74,5472,DB00624,Testosterone
,12236849,IC50s,"In the multiple-dose study, IC50s were 1.74 and 1.49 micro g ml(-1) for the 12.5 and 25 mg doses, respectively.","Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236849/),[μg] / [ml],1.49,5473,DB00624,Testosterone
,33383500,flow rate,"The analytes were extracted from plasma samples using liquid-liquid extraction (LLE) after addition of testosterone (internal standard) and chromatographed on an AQUITY UPLC Protein BEH C4 column (50 × 2.1 mm, i.d. 1.7 μm) thermostatted at 40 °C with acetonitrile-water (0.1% formic acid and 0.1 mM K2EDTA) as the gradient mobile phase at flow rate of 0.5 mL/min.",Determination of a novel photosensitizer sinoporphyrin sodium in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33383500/),[ml] / [min],0.5,5512,DB00624,Testosterone
,22212433,Systemic clearance,"Systemic clearance, the apparent volume of distribution and the duration of zero-order absorption were calculated to be 172.7 mL·kg(-1)·h(-1), 657.4 mL/kg and 10.47 h, respectively.",A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212433/),[ml] / [h·kg],172.7,8350,DB00624,Testosterone
,22212433,apparent volume of distribution,"Systemic clearance, the apparent volume of distribution and the duration of zero-order absorption were calculated to be 172.7 mL·kg(-1)·h(-1), 657.4 mL/kg and 10.47 h, respectively.",A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212433/),[ml] / [kg],657.4,8351,DB00624,Testosterone
,22212433,duration of zero-order absorption,"Systemic clearance, the apparent volume of distribution and the duration of zero-order absorption were calculated to be 172.7 mL·kg(-1)·h(-1), 657.4 mL/kg and 10.47 h, respectively.",A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212433/),h,10.47,8352,DB00624,Testosterone
,22212433,lag time,"The total enzyme activities of CYP3A1/2 were shown to increase by up to 2.79-fold, with a lag time of 40 h from the Tmax of the DEX plasma concentration.",A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22212433/),h,40,8353,DB00624,Testosterone
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,11 to 46,9556,DB00624,Testosterone
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,9.5 to 49.5,9557,DB00624,Testosterone
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,5.9 to 46.2,9558,DB00624,Testosterone
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,8.53,11633,DB00624,Testosterone
,30654691,T1/2,"3. The plasma concentration reached the Cmax within 1.0 h (inhalation) and descended with the T1/2 of 8.53 and 6.69 h for inhalation and i.v. administration, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),h,6.69,11634,DB00624,Testosterone
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,4.35,11635,DB00624,Testosterone
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,8.67,11636,DB00624,Testosterone
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,13.02,11637,DB00624,Testosterone
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,14.78,11638,DB00624,Testosterone
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,234.9,11639,DB00624,Testosterone
,30654691,IC50,"IC50 for inhibition of l-menthol on CYP 450 enzymes were 4.35 μM for 2D4, 8.67 μM for 1A2, 13.02 μM for 3A1, 14.78 μM for 2D1/2, 234.9 μM for 2C11 and 525.4 μM for 2E1, respectively.",Pharmacokinetics behaviors of l-menthol after inhalation and intravenous injection in rats and its inhibition effects on CYP450 enzymes in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30654691/),μM,525.4,11640,DB00624,Testosterone
,26804967,maximum concentration (Cmax ),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],8.06,15432,DB00624,Testosterone
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],7.69,15433,DB00624,Testosterone
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],5.66,15434,DB00624,Testosterone
,26804967,area under the plasma concentration-time curve (AUC),"Formulation 2 had a higher maximum concentration (Cmax ) for testosterone, 8.06 ng ml(-1) (95% confidence interval [CI] 6.84, 9.28) and higher area under the plasma concentration-time curve (AUC), 7.69 ng ml(-1) h (95% CI 6.22, 9.16) than formulation 1, 5.66 ng ml(-1) (95% CI 4.63, 6.69) and 5.12 ng ml(-1) h (95% CI 4.51, 5.73), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],5.12,15435,DB00624,Testosterone
,26804967,Cmax,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],173,15436,DB00624,Testosterone
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],476,15437,DB00624,Testosterone
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],",",15438,DB00624,Testosterone
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[ng] / [ml],268,15439,DB00624,Testosterone
,26804967,AUC,"Formulation 2 had a lower Cmax for sildenafil, 173 ng ml(-1) (95% CI 126, 220) and a lower AUC, 476 ng ml(-1) h (95% CI 401, 551) than formulation 1, 268 ng ml(-1) (95% CI 188, 348) and 577 ng ml(-1) h (95% CI 462, 692), respectively.",Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26804967/),[h·ng] / [ml],577,15440,DB00624,Testosterone
,33982429,apparent clearance (CL/F),"The apparent clearance (CL/F) was ~ 0.5 L/h, the mean terminal half-life (t½ ) ~ 45 h and the apparent distribution volume (Vz /F) ~ 30 L.",First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982429/),[l] / [h],0.5,17453,DB00624,Testosterone
,33982429,terminal half-life (t½ ),"The apparent clearance (CL/F) was ~ 0.5 L/h, the mean terminal half-life (t½ ) ~ 45 h and the apparent distribution volume (Vz /F) ~ 30 L.",First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982429/),h,45,17454,DB00624,Testosterone
,33982429,apparent distribution volume (Vz /F),"The apparent clearance (CL/F) was ~ 0.5 L/h, the mean terminal half-life (t½ ) ~ 45 h and the apparent distribution volume (Vz /F) ~ 30 L.",First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982429/),l,30,17455,DB00624,Testosterone
,33982429,CL/F,"In accordance with the differences in AUC, the CL/F was lower for CG beta (CL/F 0.5 vs. 0.8 L/h), explained by a longer t½ (47 vs. 32 h).",First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982429/),[l] / [h],0.5,17456,DB00624,Testosterone
,33982429,CL/F,"In accordance with the differences in AUC, the CL/F was lower for CG beta (CL/F 0.5 vs. 0.8 L/h), explained by a longer t½ (47 vs. 32 h).",First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982429/),[l] / [h],0.8,17457,DB00624,Testosterone
,33982429,t½,"In accordance with the differences in AUC, the CL/F was lower for CG beta (CL/F 0.5 vs. 0.8 L/h), explained by a longer t½ (47 vs. 32 h).",First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982429/),h,47,17458,DB00624,Testosterone
,33982429,t½,"In accordance with the differences in AUC, the CL/F was lower for CG beta (CL/F 0.5 vs. 0.8 L/h), explained by a longer t½ (47 vs. 32 h).",First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33982429/),h,32,17459,DB00624,Testosterone
,4010287,maximal concentrations,"Following intramuscular injection of either 50 mg 19-nortestosterone-3-(p-hexoxyphenyl)-propionate (NP) or 50 mg 19-nortestosterone-decanoate (ND) serum NT increased rapidly to maximal concentrations of 4.6 +/- 3.2 and 2.0 +/- 1.3 nmol/l (+/-SD), respectively, in the 6 volunteers.",Pharmacokinetics of 19-nortestosterone esters in normal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010287/),[nM] / [l],4.6,17657,DB00624,Testosterone
,4010287,maximal concentrations,"Following intramuscular injection of either 50 mg 19-nortestosterone-3-(p-hexoxyphenyl)-propionate (NP) or 50 mg 19-nortestosterone-decanoate (ND) serum NT increased rapidly to maximal concentrations of 4.6 +/- 3.2 and 2.0 +/- 1.3 nmol/l (+/-SD), respectively, in the 6 volunteers.",Pharmacokinetics of 19-nortestosterone esters in normal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010287/),[nM] / [l],2.0,17658,DB00624,Testosterone
,4010287,half-life time,The half-life time was 8 days for ND and 21 days for NP.,Pharmacokinetics of 19-nortestosterone esters in normal men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010287/),d,8,17659,DB00624,Testosterone
,4010287,half-life time,The half-life time was 8 days for ND and 21 days for NP.,Pharmacokinetics of 19-nortestosterone esters in normal men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010287/),d,21,17660,DB00624,Testosterone
,4010287,maximal concentrations,Serum NT levels increased gradually and maximal concentrations were reached in the 13th treatment week (20.2 +/- 3.4 nmol/l).,Pharmacokinetics of 19-nortestosterone esters in normal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010287/),[nM] / [l],20.2,17661,DB00624,Testosterone
,28673432,total testosterone concentration,"Mean baseline total testosterone concentration was 241.6 ng/dL (SD = 88.8 ng/dL; mean = 8.4 nmol/L, SD = 3.1 nmol/L).","Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28673432/),[ng] / [dl],241.6,20980,DB00624,Testosterone
,28673432,total testosterone concentration,"Mean baseline total testosterone concentration was 241.6 ng/dL (SD = 88.8 ng/dL; mean = 8.4 nmol/L, SD = 3.1 nmol/L).","Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28673432/),[nM] / [l],8.4,20981,DB00624,Testosterone
,24762108,terminal elimination half-life,"The maximum observed plasma concentration occurred after 0.25-0.5 hours, and median terminal elimination half-life was 1.4-5.3 hours.","Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24762108/),h,1.4-5.3,21949,DB00624,Testosterone
,1261510,MCR,"In the immunized animals the half-life of T was significantly longer, the MCR showed a 10-fold decrease (10.2 +/- 3.2 1/day compared to 108 +/- 43 1/day) and the PR was increased from 0.44 +/- 0.34 mg/day to 1.20 +/- 0.36 mg/day compared with the control group.",Testosterone metabolism in rabbits actively immunized with testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261510/),[1] / [d],10.2,25137,DB00624,Testosterone
,1261510,MCR,"In the immunized animals the half-life of T was significantly longer, the MCR showed a 10-fold decrease (10.2 +/- 3.2 1/day compared to 108 +/- 43 1/day) and the PR was increased from 0.44 +/- 0.34 mg/day to 1.20 +/- 0.36 mg/day compared with the control group.",Testosterone metabolism in rabbits actively immunized with testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261510/),[1] / [d],108,25138,DB00624,Testosterone
,1261510,PR,"In the immunized animals the half-life of T was significantly longer, the MCR showed a 10-fold decrease (10.2 +/- 3.2 1/day compared to 108 +/- 43 1/day) and the PR was increased from 0.44 +/- 0.34 mg/day to 1.20 +/- 0.36 mg/day compared with the control group.",Testosterone metabolism in rabbits actively immunized with testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261510/),[mg] / [d],0.44,25139,DB00624,Testosterone
,1261510,PR,"In the immunized animals the half-life of T was significantly longer, the MCR showed a 10-fold decrease (10.2 +/- 3.2 1/day compared to 108 +/- 43 1/day) and the PR was increased from 0.44 +/- 0.34 mg/day to 1.20 +/- 0.36 mg/day compared with the control group.",Testosterone metabolism in rabbits actively immunized with testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261510/),[mg] / [d],1.20,25140,DB00624,Testosterone
,4059201,half-life,A pharmacokinetic study showed that androgen half-life in the body increased from 1 h 35 min to 2 h 16 min under PE.,[Content and utilization of testosterone in the cardiac and skeletal muscles of male rats during physical exercise]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4059201/),h,1,25740,DB00624,Testosterone
,4059201,half-life,A pharmacokinetic study showed that androgen half-life in the body increased from 1 h 35 min to 2 h 16 min under PE.,[Content and utilization of testosterone in the cardiac and skeletal muscles of male rats during physical exercise]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4059201/),h,2,25741,DB00624,Testosterone
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.29,26054,DB00624,Testosterone
,1676661,partial clearance,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],1.90,26055,DB00624,Testosterone
,1676661,percentage,"However, BSO exposure increased the partial clearance of acetaminophen to acetaminophen glucuronide by 47% (1.29 +/- 0.08 vs. 1.90 +/- 0.23 ml/min/kg; p less than 0.01) and significantly (p less than 0.02) increased the percentage of the dose recovered as the glucuronide conjugate from 17.6 +/- 2.5 to 26.5 +/- 0.6",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),,17,26056,DB00624,Testosterone
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],4.46,26057,DB00624,Testosterone
,1676661,partial clearance,"The partial clearance of acetaminophen to acetaminophen sulfate was decreased, although not significantly, from 4.46 +/- 0.62 to 3.39 +/- 0.82 ml/min/kg.",Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1676661/),[ml] / [kg·min],3.39,26058,DB00624,Testosterone
,9194649,clearance rate,The mean +/- SE clearance rate was 1790 +/- 140 l/day.,Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9194649/),[l] / [d],1790,26333,DB00624,Testosterone
,22752248,overall survival,Median overall survival was 25.2 months.,Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752248/),month,25.2,27315,DB00624,Testosterone
,11239680,area under the plasma concentration-time curve,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[h·μM] / [l],11.2,27529,DB00624,Testosterone
,11239680,area under the plasma concentration-time curve,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[h·μM] / [l],82.3,27530,DB00624,Testosterone
,11239680,total body clearance,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[l] / [h·kg],0.640,27531,DB00624,Testosterone
,11239680,total body clearance,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[l] / [h·kg],0.903,27532,DB00624,Testosterone
,11239680,distribution half-life,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,4.13,27533,DB00624,Testosterone
,11239680,distribution half-life,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,8.23,27534,DB00624,Testosterone
,11239680,elimination half-life,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,54.9,27535,DB00624,Testosterone
,11239680,elimination half-life,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,58.6,27536,DB00624,Testosterone
,11239680,volume of the central compartment,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[l] / [kg],3.83,27537,DB00624,Testosterone
,11239680,volume of the central compartment,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[l] / [kg],13.9,27538,DB00624,Testosterone
,11239680,volume of distribution at steady state,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[l] / [kg],6.06,27539,DB00624,Testosterone
,11239680,volume of distribution at steady state,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[l] / [kg],26.8,27540,DB00624,Testosterone
,11239680,mean residence time,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,9.57,27541,DB00624,Testosterone
,11239680,mean residence time,"For the 2 and 20 mg/kg doses, respectively, the parameter values were, area under the plasma concentration-time curve (11.2 and 82.3 micromol h/l), total body clearance (0.640 and 0.903 l/h per kg), distribution half-life (4.13 and 8.23 h), elimination half-life (54.9 and 58.6 h), volume of the central compartment (3.83 and 13.9 l/kg), volume of distribution at steady state (6.06 and 26.8 l/kg), and the mean residence time (9.57 and 22.7 h).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,22.7,27542,DB00624,Testosterone
,11239680,peak concentration,"After oral administration, the following parameter values were assessed using a model-independent method, peak concentration (3.03 micromol/l), time of concentration peak (8.80 h), mean absorption time (13.8 h), and area under curve (AUC)(0-->infinity) (90.2 micromol h/l).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[μM] / [l],3.03,27543,DB00624,Testosterone
,11239680,time of concentration peak,"After oral administration, the following parameter values were assessed using a model-independent method, peak concentration (3.03 micromol/l), time of concentration peak (8.80 h), mean absorption time (13.8 h), and area under curve (AUC)(0-->infinity) (90.2 micromol h/l).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,8.80,27544,DB00624,Testosterone
,11239680,mean absorption time,"After oral administration, the following parameter values were assessed using a model-independent method, peak concentration (3.03 micromol/l), time of concentration peak (8.80 h), mean absorption time (13.8 h), and area under curve (AUC)(0-->infinity) (90.2 micromol h/l).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,13.8,27545,DB00624,Testosterone
,11239680,area under curve (AUC)(0-->infinity),"After oral administration, the following parameter values were assessed using a model-independent method, peak concentration (3.03 micromol/l), time of concentration peak (8.80 h), mean absorption time (13.8 h), and area under curve (AUC)(0-->infinity) (90.2 micromol h/l).",Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),[h·μM] / [l],90.2,27546,DB00624,Testosterone
,11239680,half-life,A two compartment model analysis of the average plasma concentration-time profile after oral administration showed that absorption followed first-order kinetics with a half-life of 4.7 h.,Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),h,4.7,27547,DB00624,Testosterone
,11239680,oral bioavailability,The oral bioavailability of methyltestosterone from food was about 70%.,Methyltestosterone pharmacokinetics and oral bioavailability in rainbow trout (Oncorhynchus mykiss). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11239680/),%,70,27548,DB00624,Testosterone
,15509184,plasma elimination half-life,It has a long plasma elimination half-life (1 week) and accumulates about 10-fold in plasma during daily administration.,Bicalutamide: clinical pharmacokinetics and metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509184/),week,1,30607,DB00624,Testosterone
,10717782,steady state MENT concentrations,"The mean steady state MENT concentrations in the one, two, and four implant groups were 0.6, 1.4, and 2.3 nmol/L, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10717782/),[nM] / [l],0.6,31163,DB00624,Testosterone
,10717782,steady state MENT concentrations,"The mean steady state MENT concentrations in the one, two, and four implant groups were 0.6, 1.4, and 2.3 nmol/L, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10717782/),[nM] / [l],1.4,31164,DB00624,Testosterone
,10717782,steady state MENT concentrations,"The mean steady state MENT concentrations in the one, two, and four implant groups were 0.6, 1.4, and 2.3 nmol/L, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10717782/),[nM] / [l],2.3,31165,DB00624,Testosterone
,10717782,release rate,"The release rate of MENT from one, two, and four implants was calculated to be approximately 0.3, 0.8, and 1.3 mg/day, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10717782/),[mg] / [d],0.3,31166,DB00624,Testosterone
,10717782,release rate,"The release rate of MENT from one, two, and four implants was calculated to be approximately 0.3, 0.8, and 1.3 mg/day, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10717782/),[mg] / [d],0.8,31167,DB00624,Testosterone
,10717782,release rate,"The release rate of MENT from one, two, and four implants was calculated to be approximately 0.3, 0.8, and 1.3 mg/day, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10717782/),[mg] / [d],1.3,31168,DB00624,Testosterone
,1385467,serum half-life,"The mean serum half-life values based on the terminal portion of the disappearance curves were 22.8 +/- 2.5 and 26.9 +/- 1.0 h, respectively, after 3- and 6-mg s.c. doses.",Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1385467/),h,22.8,31754,DB00624,Testosterone
,1385467,serum half-life,"The mean serum half-life values based on the terminal portion of the disappearance curves were 22.8 +/- 2.5 and 26.9 +/- 1.0 h, respectively, after 3- and 6-mg s.c. doses.",Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1385467/),h,26.9,31755,DB00624,Testosterone
,29434672,Cmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),[ng] / [ml],27,37909,DB00624,Testosterone
,29434672,Cmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),[ng] / [ml],19,37910,DB00624,Testosterone
,29434672,tmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),h,1.0,37911,DB00624,Testosterone
,29434672,tmax,"The initial surge of LA was higher for IM-LA than SC-LA (Cmax 27 ± 4.9 versus 19 ± 8.0 ng/ml, respectively), with a shorter tmax (1.0 ± 0.4 versus 2.1 ± 0.8 h).",Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29434672/),h,2.1,37912,DB00624,Testosterone
,23315354,AUC(0-24h),"The pharmacokinetics of dienogest were not time dependent, the observed accumulation (AUC(0-24h) 627 vs 483 μg/L · h) was as predicted from single-dose results (R(1) and R(theor) = 1.3).",Pharmacokinetics of estradiol valerate 2mg + dienogest 2mg (climodien® 2/2) after single and repeated oral administration in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23315354/),[μg] / [h·l],627,38228,DB00624,Testosterone
,23315354,AUC(0-24h),"The pharmacokinetics of dienogest were not time dependent, the observed accumulation (AUC(0-24h) 627 vs 483 μg/L · h) was as predicted from single-dose results (R(1) and R(theor) = 1.3).",Pharmacokinetics of estradiol valerate 2mg + dienogest 2mg (climodien® 2/2) after single and repeated oral administration in healthy postmenopausal women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23315354/),[μg] / [h·l],483,38229,DB00624,Testosterone
,26797061,steady-state T concentration,"Mean steady-state T concentration at week 6 was 422.4 and 895.5 ng/dL for the 50- and 100-mg SC TE arms, respectively.","Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26797061/),[ng] / [dl],422.4,39346,DB00624,Testosterone
,26797061,steady-state T concentration,"Mean steady-state T concentration at week 6 was 422.4 and 895.5 ng/dL for the 50- and 100-mg SC TE arms, respectively.","Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26797061/),[ng] / [dl],895.5,39347,DB00624,Testosterone
,11765025,Peak levels,Peak levels of testosterone total conjugates in urine (range 300-6000 microg/L) were attained a few hours after dosing.,Human nutritional supplements in the horse. Dehydroepiandrosterone versus androstenedione: comparative effects on the androgen profile and consequences for doping analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765025/),[μg] / [l],300-6000,39351,DB00624,Testosterone
<,15140340,total T,Patients were otherwise healthy T-deficient men with total T <or= 8.7 nmol/L (<or= 2.5 ng/mL).,Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),[nM] / [l],8.7,40308,DB00624,Testosterone
<,15140340,total T,Patients were otherwise healthy T-deficient men with total T <or= 8.7 nmol/L (<or= 2.5 ng/mL).,Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),[ng] / [ml],2.5,40309,DB00624,Testosterone
,15140340,C(ave(0-24)),"Of the evaluable patients, 92.3% of T buccal system and 83.3% of T-gel patients had C(ave(0-24)) within the normal range of 10.4-36.4 nmol/L (3.0-10.5 ng/mL).",Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),[nM] / [l],10.4-36.4,40310,DB00624,Testosterone
,15140340,C(ave(0-24),Mean total T values were not different in the T buccal system group (C(ave(0-24)) 16.7 +/- 4.7 nmol/L; 4.8 +/- 1.4 ng/mL) compared to the T-gel group (C(ave(0-24)) 15.9 +/- 4.8 nmol/L; 4.6 +/- 1.4 ng/mL).,Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),[nM] / [l],16.7,40311,DB00624,Testosterone
,15140340,C(ave(0-24),Mean total T values were not different in the T buccal system group (C(ave(0-24)) 16.7 +/- 4.7 nmol/L; 4.8 +/- 1.4 ng/mL) compared to the T-gel group (C(ave(0-24)) 15.9 +/- 4.8 nmol/L; 4.6 +/- 1.4 ng/mL).,Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),[ng] / [ml],4.8,40312,DB00624,Testosterone
,15140340,C(ave(0-24),Mean total T values were not different in the T buccal system group (C(ave(0-24)) 16.7 +/- 4.7 nmol/L; 4.8 +/- 1.4 ng/mL) compared to the T-gel group (C(ave(0-24)) 15.9 +/- 4.8 nmol/L; 4.6 +/- 1.4 ng/mL).,Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),[nM] / [l],15.9,40313,DB00624,Testosterone
,15140340,C(ave(0-24),Mean total T values were not different in the T buccal system group (C(ave(0-24)) 16.7 +/- 4.7 nmol/L; 4.8 +/- 1.4 ng/mL) compared to the T-gel group (C(ave(0-24)) 15.9 +/- 4.8 nmol/L; 4.6 +/- 1.4 ng/mL).,Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),[ng] / [ml],4.6,40314,DB00624,Testosterone
,15140340,T/DHT ratio,"Statistically significant differences were seen in the mean T/DHT ratio on Days 14 and 15 with the T buccal system (9.3) and T-gel (5.0) (normal 9-12) (Day 14, p < 0.00001; Day 15, p < 0.0001).",Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),,9.3,40315,DB00624,Testosterone
,15140340,T/DHT ratio,"Statistically significant differences were seen in the mean T/DHT ratio on Days 14 and 15 with the T buccal system (9.3) and T-gel (5.0) (normal 9-12) (Day 14, p < 0.00001; Day 15, p < 0.0001).",Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15140340/),,5.0,40316,DB00624,Testosterone
,19998576,AUC,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[h·ng] / [ml],226.77,42639,DB00624,Testosterone
,19998576,AUC,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[h·ng] / [ml],149.68,42640,DB00624,Testosterone
,19998576,Vd,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),l,6.70,42641,DB00624,Testosterone
,19998576,Vd,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),l,4.13,42642,DB00624,Testosterone
,19998576,t1/2,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),h,0.84,42643,DB00624,Testosterone
,19998576,t1/2,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),h,0.34,42644,DB00624,Testosterone
,19998576,CL,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[l] / [h],5.51,42645,DB00624,Testosterone
,19998576,CL,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[l] / [h],8.35,42646,DB00624,Testosterone
,19998576,elimination rate constant,The male rats had a 2.5 fold greater elimination rate constant than female rats (2.02 vs. 0.82 h(-1)).,Gender differences in the pharmacokinetics of rivastigmine in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),1/[h],2.02,42647,DB00624,Testosterone
,19998576,elimination rate constant,The male rats had a 2.5 fold greater elimination rate constant than female rats (2.02 vs. 0.82 h(-1)).,Gender differences in the pharmacokinetics of rivastigmine in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),1/[h],0.82,42648,DB00624,Testosterone
,17348894,limit of detection,The limit of detection of all analytes was 25 pg/mL.,Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[pg] / [ml],25,46406,DB00624,Testosterone
,17348894,absorption (t1/2 partial differential,"The median absorption (t1/2 partial differential) and elimination (t1/2e) half-lives for BL were 8.5 h and 123.0 h, respectively, and the area under the plasma concentration-time curve (AUCho) was 274.8 ng.h/mL.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),h,8.5,46407,DB00624,Testosterone
,17348894,elimination (t1/2e) half-lives,"The median absorption (t1/2 partial differential) and elimination (t1/2e) half-lives for BL were 8.5 h and 123.0 h, respectively, and the area under the plasma concentration-time curve (AUCho) was 274.8 ng.h/mL.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),h,123.0,46408,DB00624,Testosterone
,17348894,area under the plasma concentration-time curve (AUCho),"The median absorption (t1/2 partial differential) and elimination (t1/2e) half-lives for BL were 8.5 h and 123.0 h, respectively, and the area under the plasma concentration-time curve (AUCho) was 274.8 ng.h/mL.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[h·ng] / [ml],274.8,46409,DB00624,Testosterone
,17348894,t1/2e,The median t1/2e for ST was 82.1 h and the was 700.1 ng.h/mL.,Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),h,82.1,46410,DB00624,Testosterone
,17348894,t1/2e,The median t1/2e for ST was 82.1 h and the was 700.1 ng.h/mL.,Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[h·ng] / [ml],700.1,46411,DB00624,Testosterone
,17348894,Peak mean (X,"Peak mean (X+/-SD) plasma concentrations (Cmax) for BL and ST were 1127.8 and 4118.2 pg/mL, respectively.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[pg] / [ml],1127.8,46412,DB00624,Testosterone
,17348894,plasma concentrations (Cmax),"Peak mean (X+/-SD) plasma concentrations (Cmax) for BL and ST were 1127.8 and 4118.2 pg/mL, respectively.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[pg] / [ml],1127.8,46413,DB00624,Testosterone
,17348894,plasma concentrations (Cmax),"Peak mean (X+/-SD) plasma concentrations (Cmax) for BL and ST were 1127.8 and 4118.2 pg/mL, respectively.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[pg] / [ml],4118.2,46414,DB00624,Testosterone
,17348894,concentrations,"Testosterone (TES) concentrations mean (X+/-SE) in racing and nonracing intact males were 241.3+/-61.3 and 490.4+/-35.1 pg/mL, respectively.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),,241.3,46415,DB00624,Testosterone
,17348894,concentrations,"Testosterone (TES) concentrations mean (X+/-SE) in racing and nonracing intact males were 241.3+/-61.3 and 490.4+/-35.1 pg/mL, respectively.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),,490,46416,DB00624,Testosterone
,17348894,Plasma concentrations,"Plasma concentrations of endogenous 19-nortestosterone (nandrolone; NA) from racing and nonracing males were 50.2+/-5.5 and 71.8+/-4.6 pg/mL, respectively.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[pg] / [ml],50.2,46417,DB00624,Testosterone
,17348894,Plasma concentrations,"Plasma concentrations of endogenous 19-nortestosterone (nandrolone; NA) from racing and nonracing males were 50.2+/-5.5 and 71.8+/-4.6 pg/mL, respectively.",Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17348894/),[pg] / [ml],71.8,46418,DB00624,Testosterone
<,8796140,T,All patients (age range 18-61 years) suffered from primary or secondary hypogonadism (T < 3.6 nmol/l).,Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796140/),[nM] / [l],3.6,46855,DB00624,Testosterone
,8796140,peak concentration,"The pharmacokinetic study in 14 hypogonadal men revealed an initial short-lived burst release of T with a peak concentration of 49.0 +/- 3.7 nmol/l at 0.5 +/- 0.13 days which was followed by a stable plateau lasting until day 63 (day 2, 35.2 +/- 2.3; day 63, 34.8 +/- 2.6 nmol/l).",Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796140/),[nM] / [l],49.0,46856,DB00624,Testosterone
,8796140,Apparent terminal elimination half-life (t1/2),Apparent terminal elimination half-life (t1/2) was 70.8 +/- 10.7 days and apparent mean residence time 87.0 +/- 4.5 days.,Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796140/),d,70.8,46857,DB00624,Testosterone
,8796140,apparent mean residence time,Apparent terminal elimination half-life (t1/2) was 70.8 +/- 10.7 days and apparent mean residence time 87.0 +/- 4.5 days.,Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796140/),d,87.0,46858,DB00624,Testosterone
,8796140,absorption half-time,Absorption of T followed a zero-order release kinetic with an absorption half-time of 74.7 days (95% confidence interval: 71.1-78.5) and was almost complete by day 189 (95.9 +/- 0.84%).,Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796140/),d,74.7,46859,DB00624,Testosterone
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"25,976.5",48323,DB00624,Testosterone
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"30,685.5",48324,DB00624,Testosterone
,20435244,AUC(0-t),"Values for AUC(0-t) calculated from day 0 to day 28, days 28 to 56, and days 56 to 84 were 25,976.5 (7892.0), 30,685.5 (9348.4), and 31,030.9 (10,745.0) pg/mL per day, respectively.","Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435244/),[pg] / [d·ml],"31,030.9",48325,DB00624,Testosterone
,3504060,50% inhibition (IC50),Although fenarimol was not particularly potent in inhibiting rat ovarian microsome aromatase activity in vitro (50% inhibition (IC50) = 4.1 microM).,Discovery and development of a novel class of nonsteroidal aromatase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504060/),μM,4.1,50867,DB00624,Testosterone
,3504060,IC50,"Subsequent testing of a number of analogues led to the identification of LY56110 (alpha,alpha-bis(4-chlorophenyl)-5-methylpyrimidine) which exhibited an IC50 of 29 nM.",Discovery and development of a novel class of nonsteroidal aromatase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504060/),nM,29,50868,DB00624,Testosterone
,3504060,IC50,"LY113174 (8-chloro-5-(4-chlorophenyl)-5H-indeno less than 1, 2D greater than pyrimidine) was highly effective in vitro (IC50 = 24 nM) and in vivo but was far less potent than LY56110 with respect to induction of hepatic microsomal enzymes.",Discovery and development of a novel class of nonsteroidal aromatase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3504060/),nM,24,50869,DB00624,Testosterone
,19217534,K(i),"Letrozole (1-[bis-(4-cyanophenyl)methyl]-1H-1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor (K(i)=11.5 nM) that has Food and Drug Administration approval for breast cancer treatment.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),nM,11.5,55244,DB00624,Testosterone
,19217534,specific activity,"[(11)C-cyano]Letrozole was synthesized in 60 min with a radiochemical yield of 79-80%, with a radiochemical purity greater than 98% and a specific activity of 4.16+/-2.21 Ci/mumol at the end of bombardment (n=4).","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),[ci] / [μM],4.16,55245,DB00624,Testosterone
,19217534,free fraction,"The free fraction of letrozole in plasma was 48.9%, and log D was 1.84.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),%,48.9,55246,DB00624,Testosterone
,19217534,log D,"The free fraction of letrozole in plasma was 48.9%, and log D was 1.84.","Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217534/),,1.84,55247,DB00624,Testosterone
,27129008,Maximum serum concentrations (Cmax ),"Maximum serum concentrations (Cmax ) were 6.25 and 2.97 ng/mL, respectively, occurring ∼5-6 hours post-application on Day 1 versus Cmax of 1.71 ng/mL after ∼24 hours with Testogel, showing apparent zero-order absorption kinetics.",Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129008/),[ng] / [ml],6.25,55304,DB00624,Testosterone
,27129008,Maximum serum concentrations (Cmax ),"Maximum serum concentrations (Cmax ) were 6.25 and 2.97 ng/mL, respectively, occurring ∼5-6 hours post-application on Day 1 versus Cmax of 1.71 ng/mL after ∼24 hours with Testogel, showing apparent zero-order absorption kinetics.",Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129008/),[ng] / [ml],2.97,55305,DB00624,Testosterone
,27129008,Cmax,"Maximum serum concentrations (Cmax ) were 6.25 and 2.97 ng/mL, respectively, occurring ∼5-6 hours post-application on Day 1 versus Cmax of 1.71 ng/mL after ∼24 hours with Testogel, showing apparent zero-order absorption kinetics.",Pharmacokinetics and bioavailability of a new testosterone gel formulation in comparison to Testogel® in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129008/),[ng] / [ml],1.71,55306,DB00624,Testosterone
,15049991,testosterone concentration (C(avg)),The average testosterone concentration (C(avg)) was 6.52 microg/L and all men had a C(avg) of > 3.0 microg/L.,"Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049991/),[μg] / [l],6.52,55679,DB00624,Testosterone
>,15049991,C(avg),The average testosterone concentration (C(avg)) was 6.52 microg/L and all men had a C(avg) of > 3.0 microg/L.,"Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049991/),[μg] / [l],3.0,55680,DB00624,Testosterone
>,15049991,C(avg),The prediction of all men achieving a C(avg) of > 3.0 microg/L was 96%.,"Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049991/),[μg] / [l],3.0,55681,DB00624,Testosterone
,15049991,minimum concentration (C(min)),The mean minimum concentration (C(min)) was 3.83 microg/L and half the patients had a C(min) of > 3.0 microg/L.,"Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049991/),[μg] / [l],3.83,55682,DB00624,Testosterone
>,15049991,C(min),The mean minimum concentration (C(min)) was 3.83 microg/L and half the patients had a C(min) of > 3.0 microg/L.,"Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049991/),[μg] / [l],3.0,55683,DB00624,Testosterone
,8626843,steady state concentrations (C'ss),"The baseline-subtracted time-average steady state concentrations (C'ss) for T and BT were 18.1 +/- 7.49 (+/- SD) and 9.08 +/- 3.99 nmol/L, respectively.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),[nM] / [l],18.1,56189,DB00624,Testosterone
,8626843,steady state concentrations (C'ss),"The baseline-subtracted time-average steady state concentrations (C'ss) for T and BT were 18.1 +/- 7.49 (+/- SD) and 9.08 +/- 3.99 nmol/L, respectively.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),[nM] / [l],9.08,56190,DB00624,Testosterone
,8626843,ratios,"DHT/T and E2/T ratios, derived from the C'ss values, were 0.063 +/- 0.018 and 0.0033 +/- 0.0018, comparable to the precursor-product conversion ratios reported in healthy men.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),,0.063,56191,DB00624,Testosterone
,8626843,ratios,"DHT/T and E2/T ratios, derived from the C'ss values, were 0.063 +/- 0.018 and 0.0033 +/- 0.0018, comparable to the precursor-product conversion ratios reported in healthy men.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),,0.0033,56192,DB00624,Testosterone
,8626843,half-lives,"The estimated half-lives of each hormone were: T, 1.29 +/- 0.71 h; BT, 1.21 +/- 0.75 h; DHT, 2.83 +/- 0.97 h; and E2, 3.53 +/- 1.93 h.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),h,1.29,56193,DB00624,Testosterone
,8626843,half-lives,"The estimated half-lives of each hormone were: T, 1.29 +/- 0.71 h; BT, 1.21 +/- 0.75 h; DHT, 2.83 +/- 0.97 h; and E2, 3.53 +/- 1.93 h.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),h,1.21,56194,DB00624,Testosterone
,8626843,half-lives,"The estimated half-lives of each hormone were: T, 1.29 +/- 0.71 h; BT, 1.21 +/- 0.75 h; DHT, 2.83 +/- 0.97 h; and E2, 3.53 +/- 1.93 h.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),h,2.83,56195,DB00624,Testosterone
,8626843,half-lives,"The estimated half-lives of each hormone were: T, 1.29 +/- 0.71 h; BT, 1.21 +/- 0.75 h; DHT, 2.83 +/- 0.97 h; and E2, 3.53 +/- 1.93 h.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),h,3.53,56196,DB00624,Testosterone
,8626843,T,"From these data, T and BT clearance rates were estimated for each patient, averaging 1248 +/- 518 and 2435 +/- 778 L/day, respectively.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),[l] / [d],1248,56197,DB00624,Testosterone
,8626843,clearance rates,"From these data, T and BT clearance rates were estimated for each patient, averaging 1248 +/- 518 and 2435 +/- 778 L/day, respectively.",Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8626843/),[l] / [d],2435,56198,DB00624,Testosterone
,9091249,Cytochrome P450 content,Cytochrome P450 content in subjects from 20 to 29 years of age was 7.2 +/- 2.6 nmol.,Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),nM,7.2,56892,DB00624,Testosterone
,9091249,clearance rate,"The antipyrine (phenazone) clearance rate in young subjects was 46.4 +/- 18.5 ml.min-1, remained unaltered during the fourth decade, and declined after 40 years by a rate of 0.34 ml.min-1 per year toward old age (-29%, p < 0.001).",Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),[ml] / [min],46.4,56893,DB00624,Testosterone
,9091249,half-life,"The half-life in young subjects was 9.5 +/- 2.0 hours and increased after 30 years toward old age (+26%, p < 0.001).",Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),h,9.5,56894,DB00624,Testosterone
,9091249,volume of anti,"The volume of antipyrine distribution, 0.46 +/- 0.12 L.kg-1 in young subjects, decreased after 30 years (-11%).",Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091249/),[l] / [kg],0.46,56895,DB00624,Testosterone
,12443967,Peak concentrations,Peak concentrations 1 week after the fourth injection were 31 +/- 2 nmol/liter.,Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12443967/),[nM] / [l],31,57102,DB00624,Testosterone
,8033491,half-life,"Pharmacokinetics of MK-0591 were linear, with a half-life of approximately 6 hours.","Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033491/),h,6,58216,DB00624,Testosterone
,3705204,half-life,The pharmacokinetic investigations showed that androgen half-life in the organism decreased from 8 to 5 h under physical exercises.,[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),h,8,58373,DB00624,Testosterone
,3705204,half-life,The pharmacokinetic investigations showed that androgen half-life in the organism decreased from 8 to 5 h under physical exercises.,[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),h,5,58374,DB00624,Testosterone
,3705204,Kd,"Kd is 0.40 +/- 0.03 and 0.48 +/- 0.08 nM, respectively.",[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),nM,0.40,58375,DB00624,Testosterone
,3705204,Kd,"Kd is 0.40 +/- 0.03 and 0.48 +/- 0.08 nM, respectively.",[The steroid hormone levels and receptors of steroid hormone receptors in rat muscles during physical exertion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705204/),nM,0.48,58376,DB00624,Testosterone
,2513176,area under the serum concentration-time curve from zero to 35 days (AUC0-35 days),A significant dose-dependent increase in the area under the serum concentration-time curve from zero to 35 days (AUC0-35 days) from 541.7 to 1653.9 ng/ml.h was also noted (p less than 0.01).,"Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2513176/),[ng] / [h·ml],541.7 to 1653.9,60280,DB00624,Testosterone
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],11,61031,DB00624,Testosterone
,24981575,IC50,"ASP9521 inhibited conversion of AD into T by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L; IC50,monkey: 49 nmol/L).","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),[nM] / [l],49,61032,DB00624,Testosterone
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,35,61033,DB00624,Testosterone
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,78,61034,DB00624,Testosterone
,24981575,bioavailability,"The bioavailability of ASP9521 after oral administration (1 mg/kg) was 35 %, 78 % and 58 % in rats, dogs and monkeys, respectively.","In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24981575/),%,58,61035,DB00624,Testosterone
,4043727,volume of the inner compartment,The volume of the inner compartment was 3.4% for T and E2.,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),%,3,62198,DB00624,Testosterone
,4043727,biological half-life,The biological half-life was three to four times shorter for T (14.5 hr) than that for E2 (48.5 hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),h,14.5,62199,DB00624,Testosterone
,4043727,biological half-life,The biological half-life was three to four times shorter for T (14.5 hr) than that for E2 (48.5 hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),h,48.5,62200,DB00624,Testosterone
,4043727,MCR,The MCR for T (1.71 ml/kg body wt/hr) was higher than for E2 (0.51 ml/kg body wt/hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ml] / [body·h·kg·wt],1.71,62201,DB00624,Testosterone
,4043727,MCR,The MCR for T (1.71 ml/kg body wt/hr) was higher than for E2 (0.51 ml/kg body wt/hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ml] / [body·h·kg·wt],0.51,62202,DB00624,Testosterone
,4043727,protein-bound,"Free or protein-bound hormone levels were 0.12 and 0.31 ng/ml for T and E2, respectively.","[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ng] / [ml],0.12,62203,DB00624,Testosterone
,4043727,protein-bound,"Free or protein-bound hormone levels were 0.12 and 0.31 ng/ml for T and E2, respectively.","[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ng] / [ml],0.31,62204,DB00624,Testosterone
,4043727,production rates,No significant differences were observed between the production rates of T and E2 (0.24 ng/kg body wt/hr).,"[Plasma levels, metabolic clearance rates, and rates of secretion of testosterone and estradiol-l7 beta in the silver eel (Anguilla anguilla L.)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4043727/),[ng] / [body·h·kg·wt],0.24,62205,DB00624,Testosterone
,23527529,clearance,"Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h).","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),[l] / [h],24,62657,DB00624,Testosterone
,23527529,volume of distribution,"Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h).","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),l,469,62658,DB00624,Testosterone
,23527529,half-life,"Predicted human clearance using simple allometry is low (24 L h(-1)), predicted volume of distribution is high (469 L) and predicted half-life is long (20 h).","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),h,20,62659,DB00624,Testosterone
,23527529,KI,"IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,19,62660,DB00624,Testosterone
,23527529,KI,"IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,16,62661,DB00624,Testosterone
,23527529,KI,"IPI-926 is a moderate inhibitor of CYP2C19, 2D6 and 3A4 (midazolam) with KI values of 19, 16 and 4.5 µM, respectively.","The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,4.5,62662,DB00624,Testosterone
,23527529,IC50,IPI-926 is both a substrate and inhibitor (IC50 = 1.9 µM) of P-glycoprotein.,"The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23527529/),μM,1.9,62663,DB00624,Testosterone
,11210676,blood levels,"On the other hand, CyA blood levels (90.66 +/- 22.25 ng/ml) decreased after ovariectomy, even more in the case of gonadectomized female rats receiving estradiol replacement (67.83 +/- 24.15 ng/ml).",Effect of gonadectomy on cyclosporine pharmacokinetics in male and female rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210676/),[ng] / [ml],90,63012,DB00624,Testosterone
,1533090,peak steroid concentrations,"Mean peak steroid concentrations after 150 mg (300 mg) doses were dehydroepiandrosterone 1617 (2639) ng/dl, 7 (11.5)-fold above placebo; dehydroepiandrosterone S 1185 (1688) micrograms/dl, 14 (20)-fold above placebo; and testosterone 183 (311) ng/dl, 4 (7)-fold above placebo.",Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1533090/),[ng] / [dl],1617,66084,DB00624,Testosterone
,1533090,peak steroid concentrations,"Mean peak steroid concentrations after 150 mg (300 mg) doses were dehydroepiandrosterone 1617 (2639) ng/dl, 7 (11.5)-fold above placebo; dehydroepiandrosterone S 1185 (1688) micrograms/dl, 14 (20)-fold above placebo; and testosterone 183 (311) ng/dl, 4 (7)-fold above placebo.",Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1533090/),[μg] / [dl],1185,66085,DB00624,Testosterone
,1533090,peak steroid concentrations,"Mean peak steroid concentrations after 150 mg (300 mg) doses were dehydroepiandrosterone 1617 (2639) ng/dl, 7 (11.5)-fold above placebo; dehydroepiandrosterone S 1185 (1688) micrograms/dl, 14 (20)-fold above placebo; and testosterone 183 (311) ng/dl, 4 (7)-fold above placebo.",Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1533090/),[ng] / [dl],183,66086,DB00624,Testosterone
,966635,total amount of radioactivity excreted,The total amount of radioactivity excreted in the urine during the first week was 45-48%.,Lymphatic absorption and metabolism of orally administered testosterone undecanoate in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/966635/),%,45-48,66290,DB00624,Testosterone
,15555909,peak plasma level,"Following subcutaneous (s.c.) administration of 100mg/kg of VN/85-1, peak plasma level of 16.73 microg/ml occurred after 45 min, and the compound was cleared rapidly with a t(1/2) of 52.34 min.","Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15555909/),[μg] / [ml],16.73,67211,DB00624,Testosterone
,15555909,t(1/2),"Following subcutaneous (s.c.) administration of 100mg/kg of VN/85-1, peak plasma level of 16.73 microg/ml occurred after 45 min, and the compound was cleared rapidly with a t(1/2) of 52.34 min.","Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15555909/),min,52.34,67212,DB00624,Testosterone
,15555909,bioavailability,The bioavailability of VN/85-1 after s.c. administration was 83.0%.,"Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15555909/),%,83.0,67213,DB00624,Testosterone
,12721757,blood concentration,VX-710 blood concentration at the time of mitoxantrone administration averaged 4.52 microg/ml.,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721757/),[μg] / [ml],4.52,67381,DB00624,Testosterone
,12721757,time to PSA progression,The median time to PSA progression was 41 weeks (95% CI 34-68 weeks).,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721757/),weeks,41,67382,DB00624,Testosterone
,17371478,bioavaila,"The bioavailability of testosterone after a low-calorie meal containing 0.6 g lipid or 5 g lipid was relatively low, the area under the concentration-time curve (AUC(0-tlast)) for testosterone being 30.7 and 43.5 nmol h/l, respectively.",The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17371478/),[h·nM] / [l],30.7,67725,DB00624,Testosterone
,17371478,area under the concentration-time curve (AUC(0-tlast)),"The bioavailability of testosterone after a low-calorie meal containing 0.6 g lipid or 5 g lipid was relatively low, the area under the concentration-time curve (AUC(0-tlast)) for testosterone being 30.7 and 43.5 nmol h/l, respectively.",The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17371478/),[h·nM] / [l],30.7,67726,DB00624,Testosterone
,17371478,area under the concentration-time curve (AUC(0-tlast)),"The bioavailability of testosterone after a low-calorie meal containing 0.6 g lipid or 5 g lipid was relatively low, the area under the concentration-time curve (AUC(0-tlast)) for testosterone being 30.7 and 43.5 nmol h/l, respectively.",The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17371478/),[h·nM] / [l],43.5,67727,DB00624,Testosterone
,17371478,AUC(0-tlast),"The bioavailability of testosterone after a meal containing 19 g lipid was considerably higher (AUC(0-tlast) = 146 nmol h/l), whereas increasing the lipid content to 44 g lipid did not further increase the bioavailability of testosterone (AUC(0-tlast) = 154 nmol h/l).",The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17371478/),[h·nM] / [l],146,67728,DB00624,Testosterone
,17371478,AUC(0-tlast),"The bioavailability of testosterone after a meal containing 19 g lipid was considerably higher (AUC(0-tlast) = 146 nmol h/l), whereas increasing the lipid content to 44 g lipid did not further increase the bioavailability of testosterone (AUC(0-tlast) = 154 nmol h/l).",The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17371478/),[h·nM] / [l],154,67729,DB00624,Testosterone
,8419196,elimination half-lives,"Analysis of serum FSH levels revealed comparable elimination half-lives of 44 +/- 14 (mean +/- SD) and 32 +/- 12 hours in women and men volunteers, respectively.",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),h,44,67892,DB00624,Testosterone
,8419196,elimination half-lives,"Analysis of serum FSH levels revealed comparable elimination half-lives of 44 +/- 14 (mean +/- SD) and 32 +/- 12 hours in women and men volunteers, respectively.",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),h,32,67893,DB00624,Testosterone
,8419196,peak FSH concentrations,"In contrast, peak FSH concentrations were significantly lower in women than in men volunteers (4.3 +/- 1.7 versus 7.4 +/- 2.8 IU/L), and the time required to reach peak levels of FSH was significantly longer in women than in men (27 +/- 5 versus 14 +/- 8 hours).",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),[iu] / [l],4.3,67894,DB00624,Testosterone
,8419196,peak FSH concentrations,"In contrast, peak FSH concentrations were significantly lower in women than in men volunteers (4.3 +/- 1.7 versus 7.4 +/- 2.8 IU/L), and the time required to reach peak levels of FSH was significantly longer in women than in men (27 +/- 5 versus 14 +/- 8 hours).",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),[iu] / [l],7.4,67895,DB00624,Testosterone
,8419196,time required to reach peak levels,"In contrast, peak FSH concentrations were significantly lower in women than in men volunteers (4.3 +/- 1.7 versus 7.4 +/- 2.8 IU/L), and the time required to reach peak levels of FSH was significantly longer in women than in men (27 +/- 5 versus 14 +/- 8 hours).",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),h,27,67896,DB00624,Testosterone
,8419196,time required to reach peak levels,"In contrast, peak FSH concentrations were significantly lower in women than in men volunteers (4.3 +/- 1.7 versus 7.4 +/- 2.8 IU/L), and the time required to reach peak levels of FSH was significantly longer in women than in men (27 +/- 5 versus 14 +/- 8 hours).",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),h,14,67897,DB00624,Testosterone
,8419196,area under the serum level versus time curve,"The area under the serum level versus time curve tended to be smaller in women than in men volunteers (339 +/- 105 versus 452 +/- 183 IU/L x hours), but the difference did not reach statistical significance.",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),[iu] / [h·l],339,67898,DB00624,Testosterone
,8419196,area under the serum level versus time curve,"The area under the serum level versus time curve tended to be smaller in women than in men volunteers (339 +/- 105 versus 452 +/- 183 IU/L x hours), but the difference did not reach statistical significance.",Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8419196/),[iu] / [h·l],452,67899,DB00624,Testosterone
,27574509,C MAX,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],112.4,70205,DB00624,Testosterone
,27574509,C MAX,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],68.1,70206,DB00624,Testosterone
,27574509,AUC,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),,537.8,70207,DB00624,Testosterone
,27574509,T MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),h,0.25,70208,DB00624,Testosterone
,27574509,T MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),h,1,70209,DB00624,Testosterone
,27574509,C MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],109.1,70210,DB00624,Testosterone
,27574509,C MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],68.1,70211,DB00624,Testosterone
,27574509,AUC,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[h(∗)ug] / [l],339.7,70212,DB00624,Testosterone
,27574509,AUC,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[h(∗)ug] / [l],231.8,70213,DB00624,Testosterone
,2012251,effective half-life of plasma decay,"For the 2- and 20-micrograms doses, respectively, effective half-life of plasma decay was 47 +/- 4.9 and 109 +/- 21 min (P less than 0.05), apparent volume of distribution was 145 +/- 11 and 166 +/- 35 ml/kg, and metabolic clearance rate was 2.30 +/- 0.44 and 1.08 +/- 0.14 ml.min-1.kg-1 (P less than 0.01).","Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012251/),min,47,70490,DB00624,Testosterone
,2012251,effective half-life of plasma decay,"For the 2- and 20-micrograms doses, respectively, effective half-life of plasma decay was 47 +/- 4.9 and 109 +/- 21 min (P less than 0.05), apparent volume of distribution was 145 +/- 11 and 166 +/- 35 ml/kg, and metabolic clearance rate was 2.30 +/- 0.44 and 1.08 +/- 0.14 ml.min-1.kg-1 (P less than 0.01).","Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012251/),min,109,70491,DB00624,Testosterone
,2012251,apparent volume of distribution,"For the 2- and 20-micrograms doses, respectively, effective half-life of plasma decay was 47 +/- 4.9 and 109 +/- 21 min (P less than 0.05), apparent volume of distribution was 145 +/- 11 and 166 +/- 35 ml/kg, and metabolic clearance rate was 2.30 +/- 0.44 and 1.08 +/- 0.14 ml.min-1.kg-1 (P less than 0.01).","Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012251/),[ml] / [kg],145,70492,DB00624,Testosterone
,2012251,apparent volume of distribution,"For the 2- and 20-micrograms doses, respectively, effective half-life of plasma decay was 47 +/- 4.9 and 109 +/- 21 min (P less than 0.05), apparent volume of distribution was 145 +/- 11 and 166 +/- 35 ml/kg, and metabolic clearance rate was 2.30 +/- 0.44 and 1.08 +/- 0.14 ml.min-1.kg-1 (P less than 0.01).","Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012251/),[ml] / [kg],166,70493,DB00624,Testosterone
,2012251,metabolic clearance rate,"For the 2- and 20-micrograms doses, respectively, effective half-life of plasma decay was 47 +/- 4.9 and 109 +/- 21 min (P less than 0.05), apparent volume of distribution was 145 +/- 11 and 166 +/- 35 ml/kg, and metabolic clearance rate was 2.30 +/- 0.44 and 1.08 +/- 0.14 ml.min-1.kg-1 (P less than 0.01).","Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012251/),[ml] / [kg·min],2.30,70494,DB00624,Testosterone
,2012251,metabolic clearance rate,"For the 2- and 20-micrograms doses, respectively, effective half-life of plasma decay was 47 +/- 4.9 and 109 +/- 21 min (P less than 0.05), apparent volume of distribution was 145 +/- 11 and 166 +/- 35 ml/kg, and metabolic clearance rate was 2.30 +/- 0.44 and 1.08 +/- 0.14 ml.min-1.kg-1 (P less than 0.01).","Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012251/),[ml] / [kg·min],1.08,70495,DB00624,Testosterone
,20383596,t (max),"After oral administration of lancemaside A at 100 mg/kg body weight, the unmetabolized compound appeared rapidly in plasma (t (max) = 0.5 h).","Murine metabolism and absorption of lancemaside A, an active compound in the roots of Codonopsis lanceolata. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383596/),h,0.5,70643,DB00624,Testosterone
,20383596,bioavailability,Lancemaside A has a low bioavailability (1.1%) because of its metabolism by intestinal bacteria and its poor absorption in the gastrointestinal tract.,"Murine metabolism and absorption of lancemaside A, an active compound in the roots of Codonopsis lanceolata. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383596/),%,1.1,70644,DB00624,Testosterone
,20383596,t (max),"Among these metabolites, codonolaside II and echinocystic acid were detected in plasma, and their t (max) values were 4 and 8 h, respectively.","Murine metabolism and absorption of lancemaside A, an active compound in the roots of Codonopsis lanceolata. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383596/),h,4,70645,DB00624,Testosterone
,20383596,t (max),"Among these metabolites, codonolaside II and echinocystic acid were detected in plasma, and their t (max) values were 4 and 8 h, respectively.","Murine metabolism and absorption of lancemaside A, an active compound in the roots of Codonopsis lanceolata. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20383596/),h,8,70646,DB00624,Testosterone
,11474780,bioavailabilities,"Comparing the plasma concentration after intratracheal aerosolization with data of intravenous administration, the mean calculated bioavailabilities for the four formulations using the corrected dose (delivered--exhaled amount) were between 48.4 +/- 27.0% and 77.4 +/- 44.0%.",Systemic delivery of cetrorelix to rats by a new aerosol delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474780/),%,48.4,71549,DB00624,Testosterone
,11474780,bioavailabilities,"Comparing the plasma concentration after intratracheal aerosolization with data of intravenous administration, the mean calculated bioavailabilities for the four formulations using the corrected dose (delivered--exhaled amount) were between 48.4 +/- 27.0% and 77.4 +/- 44.0%.",Systemic delivery of cetrorelix to rats by a new aerosol delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11474780/),%,77.4,71550,DB00624,Testosterone
,9758680,flux,"After the sixth application of the Tes spray with PadO, the mean flux (+/-SE, n = 4) across swine skin in vivo was 2.12 +/- 0.35 microg/cm2.h, which gave a predicted flux in humans of 0.95 microg/cm2.h.",Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758680/),[μg] / [cm2·h],2.12,72011,DB00624,Testosterone
,9758680,flux,"After the sixth application of the Tes spray with PadO, the mean flux (+/-SE, n = 4) across swine skin in vivo was 2.12 +/- 0.35 microg/cm2.h, which gave a predicted flux in humans of 0.95 microg/cm2.h.",Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9758680/),[μg] / [cm2·h],0.95,72012,DB00624,Testosterone
,6374131,metabolic clearance rate,Annual variations of the testosterone metabolic clearance rate (litres/24 h/100 g body wt) were similar to those of testicular androgens; values were high in winter (6.7 +/- 0.7) and lowest in June (3.2 +/- 0.3).,Seasonal changes in testicular contents of testosterone and androstenedione and in the metabolic clearance rate of testosterone in the sand rat (Psammomys obesus). ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374131/),[l] / [100·24·h],6.7,72724,DB00624,Testosterone
,6374131,metabolic clearance rate,Annual variations of the testosterone metabolic clearance rate (litres/24 h/100 g body wt) were similar to those of testicular androgens; values were high in winter (6.7 +/- 0.7) and lowest in June (3.2 +/- 0.3).,Seasonal changes in testicular contents of testosterone and androstenedione and in the metabolic clearance rate of testosterone in the sand rat (Psammomys obesus). ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374131/),[l] / [100·24·h],3.2,72725,DB00624,Testosterone
,25556680,time to PSA progression,"Median time to PSA progression and radiographic disease progression was 6.7 and 12.9 months, respectively.","Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556680/),month,6.7,72965,DB00624,Testosterone
,12211225,Duration of,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,82,73287,DB00624,Testosterone
,12211225,Duration of,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,122,73288,DB00624,Testosterone
,12211225,maximum suppression,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,82,73289,DB00624,Testosterone
,12211225,maximum suppression,"Duration of atleasthalf-maximum suppression was after the first dose median of 82 hours and after the fourth dose median of 122 hours, respectively.",Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12211225/),h,122,73290,DB00624,Testosterone
,15867239,maximum tolerated dose,The maximum tolerated dose was 295 mg/m2.,"Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867239/),[mg] / [m2],295,74380,DB00624,Testosterone
,9283946,terminal half-life,"The average terminal half-life and the metabolic clearance rate (MCR) were calculated to be 40 minutes and 2,360 L/day, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9283946/),min,40,74895,DB00624,Testosterone
,9283946,metabolic clearance rate (MCR),"The average terminal half-life and the metabolic clearance rate (MCR) were calculated to be 40 minutes and 2,360 L/day, respectively.",Pharmacokinetics of 7 alpha-methyl-19-nortestosterone in men and cynomolgus monkeys. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9283946/),[l] / [d],"2,360",74896,DB00624,Testosterone
,18674917,IC(50),"Another rather potent and more selective inhibitor (compound 23, IC(50)=345 nM) was further examined in rats regarding plasma testosterone levels and pharmacokinetic properties.","Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674917/),nM,345,78974,DB00624,Testosterone
,18674917,plasma half-life,"Compared to the reference Abiraterone, 23 was more active in vivo, showed a longer plasma half-life (10h) and a higher bioavailability.","Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674917/),h,10,78975,DB00624,Testosterone
,16019172,adhesion time,The ratio Amioca/C 974P 70/30 showed the longest in vivo adhesion time (24.5+/-8.5 h).,Spray-dried Amioca starch/Carbopol 974P mixtures as buccal bioadhesive carriers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019172/),h,24.5,79056,DB00624,Testosterone
,16400081,area-under-the-curve,"In the fasting state, 24-hour area-under-the-curve of serum T after oral T administration was significantly greater with coadministration of either D or F compared with T-alone (126 +/- 36 nmol-h/L [T-alone] vs 287 +/- 98 nmol-h/L [T + F] vs 236 +/- 82 nmol-h/L [T + D]; P < .05 for T + F and T + D vs T-alone).",Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400081/),[nmol-h] / [l],126,79198,DB00624,Testosterone
,16400081,area-under-the-curve,"In the fasting state, 24-hour area-under-the-curve of serum T after oral T administration was significantly greater with coadministration of either D or F compared with T-alone (126 +/- 36 nmol-h/L [T-alone] vs 287 +/- 98 nmol-h/L [T + F] vs 236 +/- 82 nmol-h/L [T + D]; P < .05 for T + F and T + D vs T-alone).",Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400081/),[nmol-h] / [l],287,79199,DB00624,Testosterone
,16400081,area-under-the-curve,"In the fasting state, 24-hour area-under-the-curve of serum T after oral T administration was significantly greater with coadministration of either D or F compared with T-alone (126 +/- 36 nmol-h/L [T-alone] vs 287 +/- 98 nmol-h/L [T + F] vs 236 +/- 82 nmol-h/L [T + D]; P < .05 for T + F and T + D vs T-alone).",Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400081/),[nmol-h] / [l],236,79200,DB00624,Testosterone
,29367424,ALT,"The mean hemoglobin values at the first and final visits were 160 ± 9 and 153 ± 9 g/L, respectively (p > 0.05); the mean ALT values were 18 ± 6 and 21 ± 10 IU/L (p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[iu] / [l],18,79250,DB00624,Testosterone
,29367424,ALT,"The mean hemoglobin values at the first and final visits were 160 ± 9 and 153 ± 9 g/L, respectively (p > 0.05); the mean ALT values were 18 ± 6 and 21 ± 10 IU/L (p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[iu] / [l],21,79251,DB00624,Testosterone
,29367424,AUC,"Total testosterone exposure was comparable with subcutaneous versus i.m. injection (mean AUC, 1.7 ± 0.6 nmol·days/L/mg versus 1.9 ± 0.6 nmol·days/L/mg; p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[d·nM] / [l·mg],1.7,79252,DB00624,Testosterone
,29367424,AUC,"Total testosterone exposure was comparable with subcutaneous versus i.m. injection (mean AUC, 1.7 ± 0.6 nmol·days/L/mg versus 1.9 ± 0.6 nmol·days/L/mg; p > 0.05).","Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29367424/),[d·nM] / [l·mg],1.9,79253,DB00624,Testosterone
,2126737,fractional excretion,The release rate is monitored by urinary buserelin excretion (fractional excretion of 30% of the daily dose).,Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126737/),%,30,79985,DB00624,Testosterone
,2126737,half-life,"After high dose injection, buserelin has a half-life of 80 min, therapeutic plasma concentrations are maintained for 8-12 h.",Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126737/),min,80,79986,DB00624,Testosterone
,2126737,excretion,"In endometriosis and leiomyoma, the minimum release rate (urinary buserelin) required for maintenance of steroid suppression was established (buserelin excretion of about 0.5 microgram/g creatinine).",Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126737/),[μg] / [g],0.5,79987,DB00624,Testosterone
,22005007,m/z,Quantification was performed using multiple reaction monitoring (MRM) mode with transition of m/z 318.4→141.0 for butenafine hydrochloride and m/z 345.5→97.0 for testosterone propionate (IS).,Determination of butenafine hydrochloride in human plasma by liquid chromatography electrospray ionization-mass spectrometry following its topical administration in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22005007/),,318.4,82785,DB00624,Testosterone
,22005007,m/z,Quantification was performed using multiple reaction monitoring (MRM) mode with transition of m/z 318.4→141.0 for butenafine hydrochloride and m/z 345.5→97.0 for testosterone propionate (IS).,Determination of butenafine hydrochloride in human plasma by liquid chromatography electrospray ionization-mass spectrometry following its topical administration in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22005007/),,141.0,82786,DB00624,Testosterone
,22005007,m/z,Quantification was performed using multiple reaction monitoring (MRM) mode with transition of m/z 318.4→141.0 for butenafine hydrochloride and m/z 345.5→97.0 for testosterone propionate (IS).,Determination of butenafine hydrochloride in human plasma by liquid chromatography electrospray ionization-mass spectrometry following its topical administration in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22005007/),,345.5,82787,DB00624,Testosterone
,22005007,m/z,Quantification was performed using multiple reaction monitoring (MRM) mode with transition of m/z 318.4→141.0 for butenafine hydrochloride and m/z 345.5→97.0 for testosterone propionate (IS).,Determination of butenafine hydrochloride in human plasma by liquid chromatography electrospray ionization-mass spectrometry following its topical administration in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22005007/),,97.0,82788,DB00624,Testosterone
,8157756,E2,Transdermal administration of 25-50 micrograms 17 beta oestradiol generally produces a plasma E2 value in the early to mid-follicular phase range (100-300 pmol/l).,Pharmacokinetics of sex steroids in patients with beta thalassaemia major. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157756/),[pM] / [l],100-300,82855,DB00624,Testosterone
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,13.4,83627,DB00624,Testosterone
,9219927,peak plasma levels,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),μM,3.4,83628,DB00624,Testosterone
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,2.7,83629,DB00624,Testosterone
,9219927,terminal half-lives,"Following i.p. administration of 0.5 mmol/kg of CB7645 and CB7661, peak plasma levels of 13.4 and 3.4 microM, respectively, occurred after 2-4 h, both compounds were cleared rapidly (terminal half-lives 2.7 and 3.3 h, respectively) and neither was detectable at 24 h.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),h,3.3,83630,DB00624,Testosterone
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,10,83631,DB00624,Testosterone
,9219927,K(i),"When tested in vitro against the WHT testicular enzyme, the CB7645 and CB7661 were competitive inhibitors with K(i) values of 10 and 13 nM, respectively.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,13,83632,DB00624,Testosterone
,9219927,K(m),"However, the K(m) for the substrate progesterone was lower at 4.3 nM.",Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219927/),nM,4.3,83633,DB00624,Testosterone
,9698076,Km,"Kinetic studies on the P450 complex formation indicated that both methoxy and chlorine substitution affected the maximum complex formation rate (Vmax), while it had little effect on Km values (approximately 10 microM).",Metabolite-P450 complex formation by methylenedioxyphenyl HIV protease inhibitors in rat and human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698076/),μM,10,83935,DB00624,Testosterone
,18042506,peak free testosterone concentrations,"Mean peak free testosterone concentrations with intramuscular testosterone and testosterone gel were 42 pg/mL and 23 pg/mL, respectively, and mean peaktrough fluctuations in free testosterone were 26.7 +/- 12.8 pg/mL and 2.7 +/- 10.7 pg/mL, respectively (p < .001).",Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042506/),[pg] / [ml],42,84812,DB00624,Testosterone
,18042506,peak free testosterone concentrations,"Mean peak free testosterone concentrations with intramuscular testosterone and testosterone gel were 42 pg/mL and 23 pg/mL, respectively, and mean peaktrough fluctuations in free testosterone were 26.7 +/- 12.8 pg/mL and 2.7 +/- 10.7 pg/mL, respectively (p < .001).",Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042506/),[pg] / [ml],23,84813,DB00624,Testosterone
,18042506,peaktrough flu,"Mean peak free testosterone concentrations with intramuscular testosterone and testosterone gel were 42 pg/mL and 23 pg/mL, respectively, and mean peaktrough fluctuations in free testosterone were 26.7 +/- 12.8 pg/mL and 2.7 +/- 10.7 pg/mL, respectively (p < .001).",Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042506/),[pg] / [ml],26.7,84814,DB00624,Testosterone
,18042506,peaktrough flu,"Mean peak free testosterone concentrations with intramuscular testosterone and testosterone gel were 42 pg/mL and 23 pg/mL, respectively, and mean peaktrough fluctuations in free testosterone were 26.7 +/- 12.8 pg/mL and 2.7 +/- 10.7 pg/mL, respectively (p < .001).",Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18042506/),[pg] / [ml],2.7,84815,DB00624,Testosterone
,12920173,IC50,Subsequent studies showed that DPC 681 was a potent inhibitor of human CYP3A4 (IC50 = 0.039 microM) and rat CYP3A (IC50 = 1.62 microM).,Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),μM,0.039,85324,DB00624,Testosterone
,12920173,IC50,Subsequent studies showed that DPC 681 was a potent inhibitor of human CYP3A4 (IC50 = 0.039 microM) and rat CYP3A (IC50 = 1.62 microM).,Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),μM,1.62,85325,DB00624,Testosterone
,12920173,KI,"Moreover, DPC 681 was a mechanism-based inactivator of CYP3A4 with KI and kinact of 0.24 microM and 0.22 min-1, respectively.",Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),μM,0.24,85326,DB00624,Testosterone
,12920173,kinact,"Moreover, DPC 681 was a mechanism-based inactivator of CYP3A4 with KI and kinact of 0.24 microM and 0.22 min-1, respectively.",Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),1/[min],0.22,85327,DB00624,Testosterone
,14671195,terminal half-life,The terminal half-life was 8.9 h.,"Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671195/),h,8.9,86655,DB00624,Testosterone
,9626121,area under the concentration-time curve (AUC) 0-12 h,"Oral administration of 50 mg DHEA led to restoration of DHEA(S) baseline levels, whereas 100 mg induced supraphysiological concentrations [baseline vs. 50 mg DHEA vs. 100 mg DHEA: area under the concentration-time curve (AUC) 0-12 h DHEA: 280 +/- 85 vs.",Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),,280,87582,DB00624,Testosterone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],89.1,87583,DB00624,Testosterone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],139.6,87584,DB00624,Testosterone
,9626121,AUC 0-12 h,383 +/- 106 nmol/L x h; AUC 0-12 h DHEA(S): 89.1 +/- 48.4 vs. 139.6 +/- 43.5 vs. 213.3 +/- 21.6 mumol/L x h).,Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626121/),[μM] / [h·l],213.3,87585,DB00624,Testosterone
,21138344,zeta potentials,The zeta potentials varied between - 20 and - 40 mV.,Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138344/),mv,-,90250,DB00624,Testosterone
,21138344,zeta potentials,The zeta potentials varied between - 20 and - 40 mV.,Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138344/),mv,20,90251,DB00624,Testosterone
,21138344,zeta potentials,The zeta potentials varied between - 20 and - 40 mV.,Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21138344/),mv,40,90252,DB00624,Testosterone
,15579744,maximum concentration,Serum acyline levels peaked 90 min after the injection of 300 microg/kg acyline to a maximum concentration of 112.4 +/- 18 ng/ml (n = 7; t(1/2) = 4.9 d).,A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579744/),[ng] / [ml],112.4,91315,DB00624,Testosterone
,15579744,t(1/2),Serum acyline levels peaked 90 min after the injection of 300 microg/kg acyline to a maximum concentration of 112.4 +/- 18 ng/ml (n = 7; t(1/2) = 4.9 d).,A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579744/),d,4.9,91316,DB00624,Testosterone
,15579744,T,"Injections of 75 microg/kg acyline every 2 d for five doses suppressed gonadotropins for more than 20 d (nadir T, 1.06 +/- 0.17 nmol/liter; P < 0.05 compared with baseline).",A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579744/),[nM] / [l],1.06,91317,DB00624,Testosterone
,24854710,flow rate,The HPLC resolution was achieved on an Agilent ZORBAX SB-CN column with a gradient elution at a flow rate of 0.5mL/min using a mobile phase of 5-100% of acetonitrile with 0.5% formic acid (mobile phase B) in water (mobile phase A).,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),[ml] / [min],0.5,91375,DB00624,Testosterone
,24854710,precursor/product transitions,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,201.5,91376,DB00624,Testosterone
,24854710,precursor/product transitions,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,289.2,91377,DB00624,Testosterone
,24854710,m/z,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,201.5,91378,DB00624,Testosterone
,24854710,m/z,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,95.4,91379,DB00624,Testosterone
,24854710,m/z,The precursor/product transitions (m/z) in the positive ion mode [M+H](+) were m/z 201.5→95.4 for DEX and m/z 289.2→109.1 for IS.,"High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),,289.2,91380,DB00624,Testosterone
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,82.9-87.2,91381,DB00624,Testosterone
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,85.7-88.4,91382,DB00624,Testosterone
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,86.2-89.7,91383,DB00624,Testosterone
,24854710,overall recoveries,"The overall recoveries of DEX were 82.9-87.2%, 85.7-88.4%, 86.2-89.7% and 83.7-88.1% for maternal plasma, urine, fetal plasma and amniotic fluid, respectively.","High performance liquid chromatography-tandem mass spectrometric assay of dexmedetomidine in plasma, urine and amniotic fluid samples for pregnant ewe model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854710/),%,83.7-88.1,91384,DB00624,Testosterone
,10926349,elimination half-life (t1/2beta),"When administered as a solution, goserelin is rapidly absorbed and eliminated from serum with a mean elimination half-life (t1/2beta) of 4.2 hours in males and 2.3 hours in females.",Clinical pharmacokinetics of goserelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926349/),h,4.2,93314,DB00624,Testosterone
,10926349,elimination half-life (t1/2beta),"When administered as a solution, goserelin is rapidly absorbed and eliminated from serum with a mean elimination half-life (t1/2beta) of 4.2 hours in males and 2.3 hours in females.",Clinical pharmacokinetics of goserelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926349/),h,2.3,93315,DB00624,Testosterone
,10926349,t1/2beta,"Its pharmacokinetics are unaffected by hepatic impairment, but the mean t1/2beta increases to 12.1 hours in patients with severe renal impairment.",Clinical pharmacokinetics of goserelin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926349/),h,12.1,93316,DB00624,Testosterone
,16239357,concentrations,"At the end of 52 weeks, mean histrelin concentrations were 0.128 +/- 0.0652 ng/mL.",An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239357/),ng,0.128,94268,DB00624,Testosterone
,1619029,Peak plasma total T concentration,"Peak plasma total T concentration was achieved at 255 +/- 51 (SEM) min after the first 40 mg dose of TU, 300 +/- 76 min at 3 months, and 293 +/- 103 min at 6 months, the levels remaining elevated above baseline for at least 8 h after a single oral dose.",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),min,255,94387,DB00624,Testosterone
,1619029,Peak plasma total T concentration,"Peak plasma total T concentration was achieved at 255 +/- 51 (SEM) min after the first 40 mg dose of TU, 300 +/- 76 min at 3 months, and 293 +/- 103 min at 6 months, the levels remaining elevated above baseline for at least 8 h after a single oral dose.",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),min,300,94388,DB00624,Testosterone
,1619029,Peak plasma total T concentration,"Peak plasma total T concentration was achieved at 255 +/- 51 (SEM) min after the first 40 mg dose of TU, 300 +/- 76 min at 3 months, and 293 +/- 103 min at 6 months, the levels remaining elevated above baseline for at least 8 h after a single oral dose.",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),min,293,94389,DB00624,Testosterone
,1619029,peak,"Plasma dihydrotestosterone concentrations were elevated after the first dose (mean 5.4 +/- 1.3; peak 11.0 +/- 2.5 nmol/L), the extent of this rise being less after 6 months (mean 4.1 +/- 0.8; peak 7.1 +/- 1.1 nmol/L) as was the case with mean estradiol (51.5 +/- 8.9 to 38.1 +/- 3.7 pmol/L).",Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),,7.1,94390,DB00624,Testosterone
,1619029,Height velocity,Height velocity rose from 3.2 +/- 0.3 cm/yr (pretreatment) to 7.2 +/- 1.0 cm/yr in the first year and was maintained at 7.3 +/- 0.4 cm/yr despite cessation of therapy during the second year.,Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),[cm] / [yr],3.2,94391,DB00624,Testosterone
,1619029,Height velocity,Height velocity rose from 3.2 +/- 0.3 cm/yr (pretreatment) to 7.2 +/- 1.0 cm/yr in the first year and was maintained at 7.3 +/- 0.4 cm/yr despite cessation of therapy during the second year.,Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),[cm] / [yr],7.2,94392,DB00624,Testosterone
,1619029,Height velocity,Height velocity rose from 3.2 +/- 0.3 cm/yr (pretreatment) to 7.2 +/- 1.0 cm/yr in the first year and was maintained at 7.3 +/- 0.4 cm/yr despite cessation of therapy during the second year.,Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1619029/),,7.3,94393,DB00624,Testosterone
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],76-324,94436,DB00624,Testosterone
,22789530,apparent clearance (CL/F),"In the first study (study 1, n = 20), semagacestat increased the mean apparent clearance (CL/F) of oral midazolam (76-324 l/h) and nifedipine (63-229 l/h) as predicted from hepatocytes.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],63-229,94437,DB00624,Testosterone
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],22,94438,DB00624,Testosterone
,22789530,CL/F,"In a second (steady-state) study (study 2, n = 20), semagacestat CL/F increased from 22 after a single dose to 31 l/h.","The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22789530/),[l] / [h],31,94439,DB00624,Testosterone
,25583642,circulation half-life,"Compared to the soluble peptide, the leuprolide-entrapped CCL-PMs showed a prolonged circulation half-life (14.4h) following a single intravenous injection in healthy rats and the released leuprolide was detected in blood for 3days.",A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25583642/),h,14.4,97545,DB00624,Testosterone
,8549229,half-life,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),h,1.150,98700,DB00624,Testosterone
,8549229,excretion constant,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ke] / [h],0.686,98701,DB00624,Testosterone
,8549229,volume of distribution,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [kg],607,98702,DB00624,Testosterone
,8549229,clearance rate,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [h·kg],374,98703,DB00624,Testosterone
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.39,99307,DB00624,Testosterone
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.27,99308,DB00624,Testosterone
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.28,99309,DB00624,Testosterone
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.25,99310,DB00624,Testosterone
,11883648,Km,"The Km values were similar in male and female human, female rat liver microsomes, and expressed CYP3A4 and CYP3A5 (0.39, 0.27, 0.28, 0.25, and 0.26 microM, respectively).",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,0.26,99311,DB00624,Testosterone
,11883648,Km,"The Km in male rat liver microsomes was 1.5 microM, suggesting that in male and female rats AG-045572 is metabolized by different CYP3A isozymes.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),μM,1.5,99312,DB00624,Testosterone
,11883648,oral bioavailability,"The oral bioavailability of AG-045572 in intact male rats was 8%, while in female or castrated male rats it was 24%.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),%,8,99313,DB00624,Testosterone
,11883648,oral bioavailability,"The oral bioavailability of AG-045572 in intact male rats was 8%, while in female or castrated male rats it was 24%.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),%,24,99314,DB00624,Testosterone
,11883648,oral bioavailability,"Pretreatment of intact male rats with AG-045572 i.m. for 4 days resulted in suppression of testosterone to castrate levels, accompanied by an increase in oral bioavailability of AG-045572 to 27%.",Effect of testosterone suppression on the pharmacokinetics of a potent gnRH receptor antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11883648/),%,27,99315,DB00624,Testosterone
,21979302,testosterone concentration (C(avg),"On day 90, mean testosterone concentration (C(avg) [0-24 hours] ± SD) was 438.6 ± 162.5 ng/dL.",A novel testosterone 2% gel for the treatment of hypogonadal males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21979302/),[ng] / [dl],438.6,101263,DB00624,Testosterone
,21979302,C(max),"On day 90, mean testosterone C(max) (± SD) was 827.6 ± 356.5 ng/dL.",A novel testosterone 2% gel for the treatment of hypogonadal males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21979302/),[ng] / [dl],827.6,101264,DB00624,Testosterone
,21979302,C(max),"On day 90, a total of 122 patients (94.6%) had C(max) levels of 1500 ng/dL or less and 2 patients (1.6%) had values between 1800 and 2500 ng/dL.",A novel testosterone 2% gel for the treatment of hypogonadal males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21979302/),[ng] / [dl],1500,101265,DB00624,Testosterone
,21979302,C(max),"On day 90, a total of 122 patients (94.6%) had C(max) levels of 1500 ng/dL or less and 2 patients (1.6%) had values between 1800 and 2500 ng/dL.",A novel testosterone 2% gel for the treatment of hypogonadal males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21979302/),[ng] / [dl],1800 and 2500,101266,DB00624,Testosterone
,19470631,time to reach maximum concentration,"Anastrozole was rapidly absorbed orally (time to reach maximum concentration, 1 h) with a slow apparent clearance of 1.54 liters/h and a terminal half-life of 46.8 h.",Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19470631/),h,1,101373,DB00624,Testosterone
,19470631,apparent clearance,"Anastrozole was rapidly absorbed orally (time to reach maximum concentration, 1 h) with a slow apparent clearance of 1.54 liters/h and a terminal half-life of 46.8 h.",Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19470631/),[l] / [h],1.54,101374,DB00624,Testosterone
,19470631,terminal half-life,"Anastrozole was rapidly absorbed orally (time to reach maximum concentration, 1 h) with a slow apparent clearance of 1.54 liters/h and a terminal half-life of 46.8 h.",Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19470631/),h,46.8,101375,DB00624,Testosterone
,26372815,efflux ratio,"Reduction in testosterone and DTX metabolism (twofold increase in half-life) by PPL was comparable to the standard CYP3A4 inhibitor, cyclosporine A. P-gp efflux ratio of DTX across caco-2 monolayer was reduced from 2.37 to 1.52 on co-incubation with PPL.",Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26372815/),,2.37,102339,DB00624,Testosterone
,26372815,efflux ratio,"Reduction in testosterone and DTX metabolism (twofold increase in half-life) by PPL was comparable to the standard CYP3A4 inhibitor, cyclosporine A. P-gp efflux ratio of DTX across caco-2 monolayer was reduced from 2.37 to 1.52 on co-incubation with PPL.",Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26372815/),,1.52,102340,DB00624,Testosterone
below,26372815,combination index,The IC50 value of DTX was reduced three to five times and combination index values in all the cell lines were below 0.6.,Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26372815/),,0.6,102341,DB00624,Testosterone
,18671713,E,5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),mg,8.,104108,DB00624,Testosterone
,18671713,EC(50),5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],1.8,104109,DB00624,Testosterone
,18671713,ED(50),5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[mg] / [kg],10.6,104110,DB00624,Testosterone
,18671713,EC(50),5. Morphine ED(50) and EC(50) values (95% confidence intervals) for antinociception in the hot plate test were significantly lower (P < 0.05) in male rats (ED(50) 8.4 mg/kg (7.6-9.2); EC(50) 1.8 nmol/L (1.5-2.1)) compared with female rats (ED(50) 10.6 mg/kg (9.1-12.0); EC(50) 3.7 nmol/L (3.4-4.1)).,Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],3.7,104111,DB00624,Testosterone
,18671713,ED(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[mg] / [kg],1.8,104112,DB00624,Testosterone
,18671713,ED(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[mg] / [kg],1.4,104113,DB00624,Testosterone
,18671713,EC(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],0.5,104114,DB00624,Testosterone
,18671713,EC(50),"However, in the tail flick test, there was no significant difference between male and female rats in ED(50) (1.8 (0.4-3.3) and 1.4 mg/kg (0.4-2.5), respectively) or EC(50) (0.5 (0.3-0.6) and 0.4 nmol/L (0.2-0.5), respectively) values.",Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18671713/),[nM] / [l],0.4,104115,DB00624,Testosterone
,9471040,half-life,"Casodex has a half-life of approximately 1 week, enabling once-daily dosing with no effect of age or renal impairment on its pharmacokinetics.","Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9471040/),week,1,105185,DB00624,Testosterone
,1166480,metabolic clearance rate,The estrogen administration increased the T metabolic clearance rate from 17.5 1/24 h/100 g body wt to 22.6 1/24 h/100 g body wt.,In vivo metabolism of 3H-testosterone in adult male rats: effects of estrogen administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1166480/),[1] / [100·24·g·h],17.5,106623,DB00624,Testosterone
,1166480,metabolic clearance rate,The estrogen administration increased the T metabolic clearance rate from 17.5 1/24 h/100 g body wt to 22.6 1/24 h/100 g body wt.,In vivo metabolism of 3H-testosterone in adult male rats: effects of estrogen administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1166480/),[1] / [100·24·g·h],22.6,106624,DB00624,Testosterone
,25056809,gel drying time,"Median gel drying time was 2.4 min (95% confidence interval (CI), 1.7-3.4 min; n = 31).","Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25056809/),min,2.4,107635,DB00624,Testosterone
,25056809,time,"Serum TT concentrations reached the target eugonadal range with a median time of 2.9 h (95% CI, 1.9-4.3 h; n = 24).","Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25056809/),h,2.9,107636,DB00624,Testosterone
,25056809,time to steady-state serum TT concentration,"Median time to steady-state serum TT concentration was 1.1 days (95% CI, 0.7-3.4 days; n = 31).","Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25056809/),d,1.1,107637,DB00624,Testosterone
more,10999810,apparent terminal half-life,"1) Blood DHEA had an apparent terminal half-life of more than 20 h, the same order of magnitude as that of blood DHEAS, a result explainable by back-hydrolysis of the large amount of DHEAS formed after oral administration of DHEA, a mechanism providing long-lived unconjugated DHEA and metabolites.",Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999810/),h,20,110446,DB00624,Testosterone
,19536068,renal clearances,"Carriers of zero, one, and two low-activity OCT1 alleles (Arg61Cys, Gly401Ser, 420del, or Gly465Arg) had mean renal clearances of 30.6, 33.1, and 37.1 l/h, respectively (P = 0.04, after adjustment for creatinine clearance and age).","The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19536068/),[l] / [h],30.6,111715,DB00624,Testosterone
,19536068,renal clearances,"Carriers of zero, one, and two low-activity OCT1 alleles (Arg61Cys, Gly401Ser, 420del, or Gly465Arg) had mean renal clearances of 30.6, 33.1, and 37.1 l/h, respectively (P = 0.04, after adjustment for creatinine clearance and age).","The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19536068/),[l] / [h],33.1,111716,DB00624,Testosterone
,19536068,renal clearances,"Carriers of zero, one, and two low-activity OCT1 alleles (Arg61Cys, Gly401Ser, 420del, or Gly465Arg) had mean renal clearances of 30.6, 33.1, and 37.1 l/h, respectively (P = 0.04, after adjustment for creatinine clearance and age).","The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19536068/),[l] / [h],37.1,111717,DB00624,Testosterone
,15359582,systemic clearance,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),[ml] / [kg·min],63,112742,DB00624,Testosterone
,15359582,terminal plasma half-life,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),min,23,112743,DB00624,Testosterone
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,95,112744,DB00624,Testosterone
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,39,112745,DB00624,Testosterone
,15359582,BA,Low oral BA of propranolol was due in part to first-pass hepatic extraction (IPV BA of 36%).,Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,36,112746,DB00624,Testosterone
,27013798,half maximal inhibitory concentration,"In the in vitro CYP inhibition study, CUR inhibited the CYP3A-mediated metabolism of testosterone (TES) with a half maximal inhibitory concentration of 11.0 ± 3.3 μM.",Modulation of Hepatic Cytochrome P450 Enzymes by Curcumin and its Pharmacokinetic Consequences in Sprague-dawley Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27013798/),μM,11.0,114859,DB00624,Testosterone
,7705098,terminal half-life,"Following single dose administration, a mean terminal half-life of 22 h was observed for LNG.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),h,22,115032,DB00624,Testosterone
,7705098,total clearance,The total clearance was 1.0 ml x min-1 x kg-1 and the volume of distribution was 128 l.,Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],1.0,115033,DB00624,Testosterone
,7705098,volume of distribution,The total clearance was 1.0 ml x min-1 x kg-1 and the volume of distribution was 128 l.,Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),l,128,115034,DB00624,Testosterone
,7705098,total,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],0.5,115035,DB00624,Testosterone
,7705098,free clearance,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],50,115036,DB00624,Testosterone
,7705098,volume of distribution,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),l,52,115037,DB00624,Testosterone
,7705098,free fraction,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,1.4,115038,DB00624,Testosterone
,7705098,fractions bound,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,55.0,115039,DB00624,Testosterone
,7705098,fractions bound,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,43.6,115040,DB00624,Testosterone
,7705098,free fraction,"At the end of cycle one, the free fraction was only 1.0% and the fractions bound to SHBG and albumin were 69.4% and 30.0%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,1.0,115041,DB00624,Testosterone
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],331.2,115042,DB00624,Testosterone
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],369.6,115043,DB00624,Testosterone
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],298.3,115044,DB00624,Testosterone
,10709155,absolute bioavailability,Average absolute bioavailability after SC administration was 85%.,Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709155/),%,85,115437,DB00624,Testosterone
,10611135,urinary excretions,"The renal clearance of the unchanged drug in males was 21 times lower than that in females, and the urinary excretions in males and females were 2.1 and 39.5% of dose, respectively.",Sex-related differences in urinary excretion of egualen sodium in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611135/),%,2.1,115922,DB00624,Testosterone
,10611135,urinary excretions,"The renal clearance of the unchanged drug in males was 21 times lower than that in females, and the urinary excretions in males and females were 2.1 and 39.5% of dose, respectively.",Sex-related differences in urinary excretion of egualen sodium in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10611135/),%,39.5,115923,DB00624,Testosterone
,18061460,IC50,"Two potent inhibitors (27, IC50 = 373 nM/28, IC50 = 953 nM) were further examined in rats regarding their effects on plasma testosterone levels and their pharmacokinetic properties.","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),nM,373,118459,DB00624,Testosterone
,18061460,IC50,"Two potent inhibitors (27, IC50 = 373 nM/28, IC50 = 953 nM) were further examined in rats regarding their effects on plasma testosterone levels and their pharmacokinetic properties.","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),nM,953,118460,DB00624,Testosterone
,18061460,"bioavailability,","Compound 28 was similarly active as abiraterone and showed better pharmacokinetic properties (higher bioavailability, t(1/2) 9.5 h vs 1.6 h).","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),h,9.5,118461,DB00624,Testosterone
,18061460,t(1/2),"Compound 28 was similarly active as abiraterone and showed better pharmacokinetic properties (higher bioavailability, t(1/2) 9.5 h vs 1.6 h).","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),h,9.5,118462,DB00624,Testosterone
,18061460,t(1/2),"Compound 28 was similarly active as abiraterone and showed better pharmacokinetic properties (higher bioavailability, t(1/2) 9.5 h vs 1.6 h).","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),h,1.6,118463,DB00624,Testosterone
,15596419,free testosterone index (FTI),"Testosterone undecanoate (TU, 80 mg bid) or placebo was administered for one year to 76 healthy men, 60 years or older, with a free testosterone index (FTI) of 0.3-0.5 and significant symptoms on a questionnaire designed to evaluate androgen deficiency (ADAM).",Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15596419/),,0.3-0.5,118586,DB00624,Testosterone
,15713724,serum T,"Coadministration of D with oral T or TE significantly increased the 24-hr average serum T levels compared with administration of T or TE alone [average serum T after 400 mg dose, 8.7 +/- 3.0 nmol/l (T) and 8.3 +/- 5.7 nmol/l (TE) vs. 16.1 +/- 5.8 nmol/l (T +D) and 15.0 +/- 8.8 nmol/l (TE + D); P < 0.05 for T vs. T and D].",Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15713724/),[nM] / [l],8.7,119553,DB00624,Testosterone
,15713724,serum T,"Coadministration of D with oral T or TE significantly increased the 24-hr average serum T levels compared with administration of T or TE alone [average serum T after 400 mg dose, 8.7 +/- 3.0 nmol/l (T) and 8.3 +/- 5.7 nmol/l (TE) vs. 16.1 +/- 5.8 nmol/l (T +D) and 15.0 +/- 8.8 nmol/l (TE + D); P < 0.05 for T vs. T and D].",Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15713724/),[nM] / [l],8.3,119554,DB00624,Testosterone
,15713724,serum T,"Coadministration of D with oral T or TE significantly increased the 24-hr average serum T levels compared with administration of T or TE alone [average serum T after 400 mg dose, 8.7 +/- 3.0 nmol/l (T) and 8.3 +/- 5.7 nmol/l (TE) vs. 16.1 +/- 5.8 nmol/l (T +D) and 15.0 +/- 8.8 nmol/l (TE + D); P < 0.05 for T vs. T and D].",Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15713724/),[nM] / [l],16.1,119555,DB00624,Testosterone
,15713724,serum T,"Coadministration of D with oral T or TE significantly increased the 24-hr average serum T levels compared with administration of T or TE alone [average serum T after 400 mg dose, 8.7 +/- 3.0 nmol/l (T) and 8.3 +/- 5.7 nmol/l (TE) vs. 16.1 +/- 5.8 nmol/l (T +D) and 15.0 +/- 8.8 nmol/l (TE + D); P < 0.05 for T vs. T and D].",Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15713724/),[nM] / [l],15.0,119556,DB00624,Testosterone
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB00624,Testosterone
,27085586,Tmax,"PF-06260414 had fast absorption (median Tmax, approximately 1-2 hours), a mean t½ of approximately 6.9 to 12.8 hours, time-independent PK properties and dose proportionality.","Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085586/),h,1-2,120409,DB00624,Testosterone
,27085586,t½,"PF-06260414 had fast absorption (median Tmax, approximately 1-2 hours), a mean t½ of approximately 6.9 to 12.8 hours, time-independent PK properties and dose proportionality.","Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085586/),h,6.9 to 12.8,120410,DB00624,Testosterone
,11397836,steady state,"Time-average, steady state (total testosterone, 506 +/- 88 vs.",Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397836/),,506,121290,DB00624,Testosterone
,11397836,half-life of testosterone elimination (t(1/2),"Increments in total and free testosterone concentrations above baseline, baseline-subtracted areas under the total and free testosterone curves, and half-life of testosterone elimination (t(1/2), 2.1 +/- 0.1 vs.",Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397836/),,2.1,121291,DB00624,Testosterone
,28225313,testosterone concentration (Cave (0-24)),"The primary endpoint included the percentage of subjects with average testosterone concentration (Cave (0-24)) between 300 and 1,050 ng/dL on Day 90.",EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28225313/),[ng] / [dl],"300 and 1,050",121946,DB00624,Testosterone
,28225313,Cave,"Overall, 76% of subjects achieved Cave between 300 and 1,050 ng/dL with Tgel.",EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28225313/),[ng] / [dl],"300 and 1,050",121947,DB00624,Testosterone
,24845394,C avg,"After the single-dose application of 5 mg of TTC on day 22, the median uncorrected TT C avg was found to be 0.54 ng/mL (range, 0.43-1.31), and the median uncorrected fT C avg was found to be 4.14 pg/mL (range, 2.41-9.72).",Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845394/),[ng] / [ml],0.54,122484,DB00624,Testosterone
,24845394,fT C avg,"After the single-dose application of 5 mg of TTC on day 22, the median uncorrected TT C avg was found to be 0.54 ng/mL (range, 0.43-1.31), and the median uncorrected fT C avg was found to be 4.14 pg/mL (range, 2.41-9.72).",Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845394/),[pg] / [ml],4.14,122485,DB00624,Testosterone
,24845394,C avg,"Doubling of the dose only resulted in a 30% increase in baseline-corrected TT C avg (0.52 vs 0.69 ng/mL for 5 and 10 mg, respectively) and a 31% increase in baseline-corrected fT C avg (4.75 vs 6.24 pg/mL for 5 and 10 mg, respectively).",Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845394/),[ng] / [ml],0.52,122486,DB00624,Testosterone
,24845394,C avg,"Doubling of the dose only resulted in a 30% increase in baseline-corrected TT C avg (0.52 vs 0.69 ng/mL for 5 and 10 mg, respectively) and a 31% increase in baseline-corrected fT C avg (4.75 vs 6.24 pg/mL for 5 and 10 mg, respectively).",Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845394/),[ng] / [ml],0.69,122487,DB00624,Testosterone
,24845394,C avg,"Doubling of the dose only resulted in a 30% increase in baseline-corrected TT C avg (0.52 vs 0.69 ng/mL for 5 and 10 mg, respectively) and a 31% increase in baseline-corrected fT C avg (4.75 vs 6.24 pg/mL for 5 and 10 mg, respectively).",Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845394/),[pg] / [ml],4.75,122488,DB00624,Testosterone
,24845394,C avg,"Doubling of the dose only resulted in a 30% increase in baseline-corrected TT C avg (0.52 vs 0.69 ng/mL for 5 and 10 mg, respectively) and a 31% increase in baseline-corrected fT C avg (4.75 vs 6.24 pg/mL for 5 and 10 mg, respectively).",Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845394/),[pg] / [ml],6.24,122489,DB00624,Testosterone
,8533624,Cmax,"Single-dose Cmax of 65 pg/ml and AUC of 612 pg h ml(-1) increased by 40-60% during treatment cycles as a result of accumulation EE2 induced basal SHBG (102nmol/L) and CBG (42 microgram/ml) serum levels to about 220 nmol/L and 87 microgram/ml, respectively, at the end of treatment cycles 1 and 3.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[pg] / [ml],65,124506,DB00624,Testosterone
,8533624,AUC,"Single-dose Cmax of 65 pg/ml and AUC of 612 pg h ml(-1) increased by 40-60% during treatment cycles as a result of accumulation EE2 induced basal SHBG (102nmol/L) and CBG (42 microgram/ml) serum levels to about 220 nmol/L and 87 microgram/ml, respectively, at the end of treatment cycles 1 and 3.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[h·pg] / [ml],612,124507,DB00624,Testosterone
,8533624,Cmax,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[ng] / [ml],3.5,124508,DB00624,Testosterone
,8533624,AUC 0-24 h,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[h·ng] / [ml],22,124509,DB00624,Testosterone
,8533624,steady-state levels,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[ng] / [ml],8-8.7,124510,DB00624,Testosterone
,8533624,steady-state levels,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[h·ng] / [ml],90-106,124511,DB00624,Testosterone
,25109454,zeta potential,"Drug loading, particle size (diameter), polydispersity index and zeta potential of these alginate nanocapsules were measured 30.22 ± 1.90%, 34.53 ± 1.72 nm, 0.22 ± 0.04 and -5 mV, respectively.",Pharmacokinetic evaluation of testosterone-loaded nanocapsules in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25109454/),m,-,125446,DB00624,Testosterone
,25109454,zeta potential,"Drug loading, particle size (diameter), polydispersity index and zeta potential of these alginate nanocapsules were measured 30.22 ± 1.90%, 34.53 ± 1.72 nm, 0.22 ± 0.04 and -5 mV, respectively.",Pharmacokinetic evaluation of testosterone-loaded nanocapsules in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25109454/),m,5,125447,DB00624,Testosterone
,25109454,Cmax,"Cmax, Tmax and AUC0-24 vales were estimated 38.63ng/ml, 2h and 317.93 ng ml(-1) h(-1), respectively.",Pharmacokinetic evaluation of testosterone-loaded nanocapsules in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25109454/),[ng] / [ml],38.63,125448,DB00624,Testosterone
,25109454,Tmax,"Cmax, Tmax and AUC0-24 vales were estimated 38.63ng/ml, 2h and 317.93 ng ml(-1) h(-1), respectively.",Pharmacokinetic evaluation of testosterone-loaded nanocapsules in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25109454/),h,2,125449,DB00624,Testosterone
,25109454,AUC0-24 vales,"Cmax, Tmax and AUC0-24 vales were estimated 38.63ng/ml, 2h and 317.93 ng ml(-1) h(-1), respectively.",Pharmacokinetic evaluation of testosterone-loaded nanocapsules in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25109454/),[ng] / [h·ml],317.93,125450,DB00624,Testosterone
>,11853929,T,A chemically modified grafted starch could sustain the 3 ng/ml plasma testosterone target concentration during +/- 8 h (T(>3 ng/ml)).,Ex vivo bioadhesion and in vivo testosterone bioavailability study of different bioadhesive formulations based on starch-g-poly(acrylic acid) copolymers and starch/poly(acrylic acid) mixtures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853929/),[ng] / [ml],3,130155,DB00624,Testosterone
,11853929,adhesion time,"By lyophilization of a partially neutralized irradiated grafted starch, the in vivo adhesion time (22.0 +/- 7.2 h) and the T(>3 ng/ml) (13.5 +/- 1.3 h) could be increased.",Ex vivo bioadhesion and in vivo testosterone bioavailability study of different bioadhesive formulations based on starch-g-poly(acrylic acid) copolymers and starch/poly(acrylic acid) mixtures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853929/),h,22.0,130156,DB00624,Testosterone
>,11853929,T,"By lyophilization of a partially neutralized irradiated grafted starch, the in vivo adhesion time (22.0 +/- 7.2 h) and the T(>3 ng/ml) (13.5 +/- 1.3 h) could be increased.",Ex vivo bioadhesion and in vivo testosterone bioavailability study of different bioadhesive formulations based on starch-g-poly(acrylic acid) copolymers and starch/poly(acrylic acid) mixtures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853929/),[ng] / [ml],3,130157,DB00624,Testosterone
,11853929,T,"By lyophilization of a partially neutralized irradiated grafted starch, the in vivo adhesion time (22.0 +/- 7.2 h) and the T(>3 ng/ml) (13.5 +/- 1.3 h) could be increased.",Ex vivo bioadhesion and in vivo testosterone bioavailability study of different bioadhesive formulations based on starch-g-poly(acrylic acid) copolymers and starch/poly(acrylic acid) mixtures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11853929/),h,13.5,130158,DB00624,Testosterone
,3199063,plasma half-life,The plasma half-life of the LH bioactivity (with 95% confidence limits) was estimated to be 42.4 (35.3-49.5) min for IRP 68/40 and 41.3 (31.5-51.0) min for IRP 78/549.,Plasma clearance in the rat of the LH bioactivity of two human LH standards of differing molecular composition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199063/),min,42.4,130728,DB00624,Testosterone
,3199063,plasma half-life,The plasma half-life of the LH bioactivity (with 95% confidence limits) was estimated to be 42.4 (35.3-49.5) min for IRP 68/40 and 41.3 (31.5-51.0) min for IRP 78/549.,Plasma clearance in the rat of the LH bioactivity of two human LH standards of differing molecular composition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3199063/),min,41.3,130729,DB00624,Testosterone
,21366623,terminal half-life,The median terminal half-life was 39 h.,An interlaboratory study of the pharmacokinetics of testosterone following intramuscular administration to Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366623/),h,39,132388,DB00624,Testosterone
,663978,MCRT,The MCRT was 675 +/- 108 (mean +/- SC) L/day and MCRDHT was 409 +/- 68 L/day.,The extrasplanchnic origin of blood dihydrotestosterone in elderly men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/663978/),[l] / [d],675,132705,DB00624,Testosterone
,663978,MCRDHT,The MCRT was 675 +/- 108 (mean +/- SC) L/day and MCRDHT was 409 +/- 68 L/day.,The extrasplanchnic origin of blood dihydrotestosterone in elderly men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/663978/),[l] / [d],409,132706,DB00624,Testosterone
,663978,SET,SET was 45.9 +/- 7.0% and SEDHT was 18.5 +/- 5.4%.,The extrasplanchnic origin of blood dihydrotestosterone in elderly men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/663978/),%,45.9,132707,DB00624,Testosterone
,663978,SCT,"The calculated SCT and ESCT were 355 +/- 72 L/day and 320 +/- 86 L/day, respectively.",The extrasplanchnic origin of blood dihydrotestosterone in elderly men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/663978/),[l] / [d],355,132708,DB00624,Testosterone
,663978,ESCT,"The calculated SCT and ESCT were 355 +/- 72 L/day and 320 +/- 86 L/day, respectively.",The extrasplanchnic origin of blood dihydrotestosterone in elderly men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/663978/),[l] / [d],320,132709,DB00624,Testosterone
,8104128,Total clearance,Total clearance of zenarestat significantly increased in male chronic diabetic rats (15.3-->42.2 ml/hr/kg).,"Pharmacokinetics of zenarestat, an aldose reductase inhibitor, in male and female diabetic rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104128/),[ml] / [h·kg],15.3,132832,DB00624,Testosterone
,8104128,Total clearance,Total clearance of zenarestat significantly increased in male chronic diabetic rats (15.3-->42.2 ml/hr/kg).,"Pharmacokinetics of zenarestat, an aldose reductase inhibitor, in male and female diabetic rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104128/),[ml] / [h·kg],42.2,132833,DB00624,Testosterone
,8014594,elimination half-life,Maximum serum hFSH levels were obtained 4-6 h after administration and the elimination half-life of hFSH was on average 18-22 h.,Pharmacokinetics and pharmacodynamics of recombinant and urinary human FSH in the male monkey (Macaca fascicularis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8014594/),h,18-22,136033,DB00624,Testosterone
,4039394,PCRA,In premenopausal normal women the PCRA is 1950 +/- 184 1/24 h (n = 5) and the PCRT is 484 +/- 82 1/24 h (n = 7).,Deuterium labelled steroid hormones: tracers for the measurement of androgen plasma clearance rates in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039394/),[1] / [24·h],1950,136270,DB00624,Testosterone
,9040091,minimum detectable dose,"The assay was validated in terms of accuracy (recovery range, 94.0-105.4%), in terms of precision (intra- and interassay variations of 10.0-12.4% and 8.6-11.3%, respectively), and in terms of sensitivity (minimum detectable dose of 2.7 pg/assay).",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),[pg] / [assay],2.7,136774,DB00624,Testosterone
,9040091,distribution,"Following iv acute administration, a biexponential decline of plasma meterelin levels was observed, with distribution and elimination half-lives of 5.9 +/- 2.5 and 106 +/- 22 min, respectively.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),min,5.9,136775,DB00624,Testosterone
,9040091,elimination half-lives,"Following iv acute administration, a biexponential decline of plasma meterelin levels was observed, with distribution and elimination half-lives of 5.9 +/- 2.5 and 106 +/- 22 min, respectively.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),min,106,136776,DB00624,Testosterone
,9040091,elimination half-life,"After sc acute administration, the elimination half-life was in the range of 103 to 173 min.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),min,103 to 173,136777,DB00624,Testosterone
,9040091,systemic clearance (CLT),"The systemic clearance (CLT) ranged from 1.6 to 2.6 mL/min/kg, and the volume of distribution at steady state (Vdss) varied from 285 to 438 mL/kg.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),[ml] / [kg·min],1.6 to 2.6,136778,DB00624,Testosterone
,9040091,volume of distribution at steady state (Vdss),"The systemic clearance (CLT) ranged from 1.6 to 2.6 mL/min/kg, and the volume of distribution at steady state (Vdss) varied from 285 to 438 mL/kg.",Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040091/),[ml] / [kg],285 to 438,136779,DB00624,Testosterone
,12455471,skin permeation rate,"Thus, the highest skin permeation rate (4.14 micrograms/cm2/hr) was achieved when 2% TS was loaded in DuroTak 87-2516 together with 10% Span 80 and 3% dodecylamine, the permeation enhancer.",The effects of pressure-sensitive adhesives and solubilizers on the skin permeation of testosterone from a matrix-type transdermal delivery system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12455471/),[μg] / [cm2·h],4.14,137673,DB00624,Testosterone
,12970301,metabolic clearance rate,"After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),[l] / [d],99.9,138125,DB00624,Testosterone
,12970301,terminal half-life,"After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),h,4.5,138126,DB00624,Testosterone
,12970301,systemic availability,"Following a 50-mg DHEA PO dose, systemic availability was only 3.1 +/- 0.4%.",Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12970301/),%,3.1,138127,DB00624,Testosterone
,24684468,serum N,Daily serum N peaked 2.50 ± 0.25 (SEM) ng/mL at a median (range) of 6 (4-13) days causing a reduction in serum T from 3.50 ± 0.57 ng/mL at baseline to a nadir of 0.38 ± 0.13 (SEM) ng/mL (89 ± 3% suppression) at a median (range) of 8 (5-16) days.,Pharmacokinetic-pharmacodynamic study of subcutaneous injection of depot nandrolone decanoate using dried blood spots sampling coupled with ultrapressure liquid chromatography tandem mass spectrometry assays. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684468/),[ng] / [ml],2.50,139671,DB00624,Testosterone
,24684468,serum T,Daily serum N peaked 2.50 ± 0.25 (SEM) ng/mL at a median (range) of 6 (4-13) days causing a reduction in serum T from 3.50 ± 0.57 ng/mL at baseline to a nadir of 0.38 ± 0.13 (SEM) ng/mL (89 ± 3% suppression) at a median (range) of 8 (5-16) days.,Pharmacokinetic-pharmacodynamic study of subcutaneous injection of depot nandrolone decanoate using dried blood spots sampling coupled with ultrapressure liquid chromatography tandem mass spectrometry assays. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684468/),[ng] / [ml],3.50,139672,DB00624,Testosterone
,24684468,serum T,Daily serum N peaked 2.50 ± 0.25 (SEM) ng/mL at a median (range) of 6 (4-13) days causing a reduction in serum T from 3.50 ± 0.57 ng/mL at baseline to a nadir of 0.38 ± 0.13 (SEM) ng/mL (89 ± 3% suppression) at a median (range) of 8 (5-16) days.,Pharmacokinetic-pharmacodynamic study of subcutaneous injection of depot nandrolone decanoate using dried blood spots sampling coupled with ultrapressure liquid chromatography tandem mass spectrometry assays. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684468/),[ng] / [ml],0.38,139673,DB00624,Testosterone
,2940625,minimum detectable concentration,This assay allowed measurement of the LHRH analog in unextracted plasma with a minimum detectable concentration of 10 pg/ml.,Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940625/),[pg] / [ml],10,140779,DB00624,Testosterone
superior,2940625,elimination half-life,"In both cases, the LHRH analog showed longer plasma half-life than native LHRH with an elimination half-life superior to 80 min.",Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2940625/),min,80,140780,DB00624,Testosterone
,12627930,maximum serum concentration,"For testosterone, the maximum serum concentration and area under the plasma concentration-time curve were 0.67 ng/ml and 5.37 ng x hr/ml, respectively, in the fasting state, versus 10.7 ng/ml and 56.4 ng x hr/ml, respectively, in the fed state.",Important effect of food on the bioavailability of oral testosterone undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12627930/),[ng] / [ml],0.67,141091,DB00624,Testosterone
,12627930,maximum serum concentration,"For testosterone, the maximum serum concentration and area under the plasma concentration-time curve were 0.67 ng/ml and 5.37 ng x hr/ml, respectively, in the fasting state, versus 10.7 ng/ml and 56.4 ng x hr/ml, respectively, in the fed state.",Important effect of food on the bioavailability of oral testosterone undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12627930/),[ng] / [ml],10.7,141092,DB00624,Testosterone
,12627930,area under the plasma concentration-time curve,"For testosterone, the maximum serum concentration and area under the plasma concentration-time curve were 0.67 ng/ml and 5.37 ng x hr/ml, respectively, in the fasting state, versus 10.7 ng/ml and 56.4 ng x hr/ml, respectively, in the fed state.",Important effect of food on the bioavailability of oral testosterone undecanoate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12627930/),[h·ng] / [ml],5.37,141093,DB00624,Testosterone
,12627930,area under the plasma concentration-time curve,"For testosterone, the maximum serum concentration and area under the plasma concentration-time curve were 0.67 ng/ml and 5.37 ng x hr/ml, respectively, in the fasting state, versus 10.7 ng/ml and 56.4 ng x hr/ml, respectively, in the fed state.",Important effect of food on the bioavailability of oral testosterone undecanoate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12627930/),[h·ng] / [ml],56.4,141094,DB00624,Testosterone
,16681480,peak levels,Mean peak levels of testosterone were 7.71 nmol/L after testosterone propionate and 2.99 nmol/L after placebo (P < 0.005).,Vaginal application of testosterone: A study on pharmacokinetics and the sexual response in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681480/),[nM] / [l],7.71,141478,DB00624,Testosterone
,16681480,peak levels,Mean peak levels of testosterone were 7.71 nmol/L after testosterone propionate and 2.99 nmol/L after placebo (P < 0.005).,Vaginal application of testosterone: A study on pharmacokinetics and the sexual response in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681480/),[nM] / [l],2.99,141479,DB00624,Testosterone
,16681480,peak levels,Mean peak levels of free testosterone were 0.12 nmol/L after testosterone propionate and 0.04 nmol/L after placebo (P < 0.005).,Vaginal application of testosterone: A study on pharmacokinetics and the sexual response in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681480/),[nM] / [l],0.12,141480,DB00624,Testosterone
,16681480,peak levels,Mean peak levels of free testosterone were 0.12 nmol/L after testosterone propionate and 0.04 nmol/L after placebo (P < 0.005).,Vaginal application of testosterone: A study on pharmacokinetics and the sexual response in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681480/),[nM] / [l],0.04,141481,DB00624,Testosterone
,12954663,maximum serum testosterone concentrations,Oral TTC resulted in higher maximum serum testosterone concentrations than oral TU at 8 mg/kg (TTC: 28.6 +/- 7.9 nmol/L vs TU: 11.9 +/- 2.1 nmol/L; P <.001) and 4 mg/kg (TTC: 11.5 +/- 4.2 nmol/L vs TU: 3.6 +/- 1.0 nmol/L; P <.001).,Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954663/),[nM] / [l],28.6,142281,DB00624,Testosterone
,12954663,maximum serum testosterone concentrations,Oral TTC resulted in higher maximum serum testosterone concentrations than oral TU at 8 mg/kg (TTC: 28.6 +/- 7.9 nmol/L vs TU: 11.9 +/- 2.1 nmol/L; P <.001) and 4 mg/kg (TTC: 11.5 +/- 4.2 nmol/L vs TU: 3.6 +/- 1.0 nmol/L; P <.001).,Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954663/),[nM] / [l],11.9,142282,DB00624,Testosterone
,12954663,maximum serum testosterone concentrations,Oral TTC resulted in higher maximum serum testosterone concentrations than oral TU at 8 mg/kg (TTC: 28.6 +/- 7.9 nmol/L vs TU: 11.9 +/- 2.1 nmol/L; P <.001) and 4 mg/kg (TTC: 11.5 +/- 4.2 nmol/L vs TU: 3.6 +/- 1.0 nmol/L; P <.001).,Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954663/),[nM] / [l],11.5,142283,DB00624,Testosterone
,12954663,maximum serum testosterone concentrations,Oral TTC resulted in higher maximum serum testosterone concentrations than oral TU at 8 mg/kg (TTC: 28.6 +/- 7.9 nmol/L vs TU: 11.9 +/- 2.1 nmol/L; P <.001) and 4 mg/kg (TTC: 11.5 +/- 4.2 nmol/L vs TU: 3.6 +/- 1.0 nmol/L; P <.001).,Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954663/),[nM] / [l],3.6,142284,DB00624,Testosterone
,12954663,terminal half-life,The terminal half-life for both TU and TTC was between 3 and 5 hours and was not significantly different.,Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954663/),h,3 and 5,142285,DB00624,Testosterone
,12187267,breakthrough response,A patient with a breakthrough response after testosterone suppression on day 49 (112 ng./dl.) regained suppression (27 ng./dl.) 14 days after the second injection (day 98).,A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12187267/),ng,112,142437,DB00624,Testosterone
,16487220,"AUC(0,12 h)","The mean AUC(0,12 h) was higher following application of TDS-testosterone (61.8 ng ml-1 h), compared with Androgel (57.7 ng ml-1 h) and TDS-placebo (50.7 ng ml-1 h.","Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487220/),[h·ng] / [ml],61.8,142443,DB00624,Testosterone
,16487220,"AUC(0,12 h)","The mean AUC(0,12 h) was higher following application of TDS-testosterone (61.8 ng ml-1 h), compared with Androgel (57.7 ng ml-1 h) and TDS-placebo (50.7 ng ml-1 h.","Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487220/),[h·ng] / [ml],57.7,142444,DB00624,Testosterone
,16487220,"AUC(0,12 h)","The mean AUC(0,12 h) was higher following application of TDS-testosterone (61.8 ng ml-1 h), compared with Androgel (57.7 ng ml-1 h) and TDS-placebo (50.7 ng ml-1 h.","Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487220/),[h·ng] / [ml],50.7,142445,DB00624,Testosterone
,16487220,"Cmax (0,12 h)","The mean Cmax (0,12 h) was similar for TDS-testosterone (6.6 ng ml-1) and Androgel (6.5 ng ml-1) and these values were higher than those for TDS-placebo (5.7 ng ml-1).","Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487220/),[ng] / [ml],6.6,142446,DB00624,Testosterone
,16487220,"Cmax (0,12 h)","The mean Cmax (0,12 h) was similar for TDS-testosterone (6.6 ng ml-1) and Androgel (6.5 ng ml-1) and these values were higher than those for TDS-placebo (5.7 ng ml-1).","Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487220/),[ng] / [ml],6.5,142447,DB00624,Testosterone
,16487220,"Cmax (0,12 h)","The mean Cmax (0,12 h) was similar for TDS-testosterone (6.6 ng ml-1) and Androgel (6.5 ng ml-1) and these values were higher than those for TDS-placebo (5.7 ng ml-1).","Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487220/),[ng] / [ml],5.7,142448,DB00624,Testosterone
,29436172,clearance,The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution.,Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436172/),[kl] / [d],2.6,143911,DB00624,Testosterone
,29436172,volume of distribution,The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution.,Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436172/),kl,14.4,143912,DB00624,Testosterone
,29436172,potency,The estimated potency of total testosterone (tT) with respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL.,Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436172/),[ng] / [ml],9.33,143913,DB00624,Testosterone
,12637247,elimination half-life,"2. Following a single i.v. dose (15 mg kg(-1)), the elimination half-life of EP was 0.80 and 1.14 h in male and female rats, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),h,0.80,145548,DB00624,Testosterone
,12637247,elimination half-life,"2. Following a single i.v. dose (15 mg kg(-1)), the elimination half-life of EP was 0.80 and 1.14 h in male and female rats, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),h,1.14,145549,DB00624,Testosterone
,12637247,Plasma clearances (CL),"Plasma clearances (CL) of EP were 1.62 and 1.20 l kg(-1) h(-1) in males and females, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),[l] / [h·kg],1.62,145550,DB00624,Testosterone
,12637247,Plasma clearances (CL),"Plasma clearances (CL) of EP were 1.62 and 1.20 l kg(-1) h(-1) in males and females, respectively.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),[l] / [h·kg],1.20,145551,DB00624,Testosterone
,12637247,C(max),"Following a single oral dose (15 mg kg(-1)), C(max) and T(max) of EP were 1.71 micro g ml(-1) and 0.5 h in male rats.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),[μg] / [ml],1.71,145552,DB00624,Testosterone
,12637247,T(max),"Following a single oral dose (15 mg kg(-1)), C(max) and T(max) of EP were 1.71 micro g ml(-1) and 0.5 h in male rats.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),h,0.5,145553,DB00624,Testosterone
,12637247,systemic availability,"The systemic availability of EP was 25.6% in male rats and 66.4% in female rats, demonstrating sex differences in the pharmacokinetics of EP.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),%,25.6,145554,DB00624,Testosterone
,12637247,systemic availability,"The systemic availability of EP was 25.6% in male rats and 66.4% in female rats, demonstrating sex differences in the pharmacokinetics of EP.","Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637247/),%,66.4,145555,DB00624,Testosterone
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,78,146690,DB00624,Testosterone
,1686651,half-life,Higher doses of the levo enantiomer prolonged aminopyrine half-life to 78 (1 mg/kg) and 162 min. (10 mg/kg).,Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,162,146691,DB00624,Testosterone
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,128,146692,DB00624,Testosterone
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,20,146693,DB00624,Testosterone
,1686651,sleeping time,"The hexobarbital sleeping time was prolonged by the dose of 1 mg/kg of the levo enantiomer (128 min. versus 20 min. in controls), while the dose of 0.1 mg/kg had no effect (23 versus 20 min.).",Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686651/),min,23,146694,DB00624,Testosterone
,28334510,peak concentration,"Serum DHT displayed a time- (p < 0.0001), but not dose-dependent, increase in concentration reaching a peak concentration of 1.2 ng/mL (4.1 nm) at 4.9 h which was delayed by 2 h after peak serum testosterone.",Pharmacokinetics of testosterone cream applied to scrotal skin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334510/),[ng] / [ml],1.2,147136,DB00624,Testosterone
,31343176,IC50,"Compound 24 is a nanomolar potent inhibitor of human 17β-HSD2 (IC50 of 6.1 nM) and rodent 17β-HSD2 with low in vitro cellular toxicity, devoid of detectable estrogen receptor α affinity, displays high aqueous solubility and in vitro metabolic stability, and has an excellent oral pharmacokinetic profile for testing in a rat osteoporosis model.","Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31343176/),nM,6.1,148007,DB00624,Testosterone
less,15531493,trough levels,"In the TE group, mean trough levels of serum T were always less than 10 nmol/liter before the next injection, whereas in the TU group, mean trough levels of serum T were 14.1 +/- 4.5 nmol/liter after the first two doses (6-wk intervals) and 16.3 +/- 5.7 nmol/liter after the 9-wk interval at wk 30.",Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531493/),[nM] / [l],10,149364,DB00624,Testosterone
,15531493,trough levels,"In the TE group, mean trough levels of serum T were always less than 10 nmol/liter before the next injection, whereas in the TU group, mean trough levels of serum T were 14.1 +/- 4.5 nmol/liter after the first two doses (6-wk intervals) and 16.3 +/- 5.7 nmol/liter after the 9-wk interval at wk 30.",Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531493/),[nM] / [l],14.1,149365,DB00624,Testosterone
,15531493,trough levels,"In the TE group, mean trough levels of serum T were always less than 10 nmol/liter before the next injection, whereas in the TU group, mean trough levels of serum T were 14.1 +/- 4.5 nmol/liter after the first two doses (6-wk intervals) and 16.3 +/- 5.7 nmol/liter after the 9-wk interval at wk 30.",Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531493/),[nM] / [l],16.3,149366,DB00624,Testosterone
,15531493,serum trough levels,This regimen resulted in stable mean serum trough levels of T (ranging from 14.9 +/- 5.2 to 16.5 +/- 8.0 nmol/liter) and estradiol (ranging from 98.5 +/- 45.2 to 80.4 +/- 14.4 pmol/liter).,Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531493/),[nM] / [l],14.9,149367,DB00624,Testosterone
,15531493,serum trough levels,This regimen resulted in stable mean serum trough levels of T (ranging from 14.9 +/- 5.2 to 16.5 +/- 8.0 nmol/liter) and estradiol (ranging from 98.5 +/- 45.2 to 80.4 +/- 14.4 pmol/liter).,Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531493/),[nM] / [l],16.5,149368,DB00624,Testosterone
,15531493,serum trough levels,This regimen resulted in stable mean serum trough levels of T (ranging from 14.9 +/- 5.2 to 16.5 +/- 8.0 nmol/liter) and estradiol (ranging from 98.5 +/- 45.2 to 80.4 +/- 14.4 pmol/liter).,Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531493/),[pM] / [l],98.5,149369,DB00624,Testosterone
,15531493,serum trough levels,This regimen resulted in stable mean serum trough levels of T (ranging from 14.9 +/- 5.2 to 16.5 +/- 8.0 nmol/liter) and estradiol (ranging from 98.5 +/- 45.2 to 80.4 +/- 14.4 pmol/liter).,Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15531493/),[pM] / [l],80.4,149370,DB00624,Testosterone
,12470572,absolute bioavailability,"After intramuscular or subcutaneous administration (absolute bioavailability, 40-50% for both), rHCG pharmacokinetics could be described by a first-order absorption, one-compartment model.",Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12470572/),%,40-50,149396,DB00624,Testosterone
,10872648,peak teverilix plasma concentrations,Geometric means of peak teverilix plasma concentrations were 4.5 ng/mL (0.5 mg teverelix) to 49.0 ng/mL (5 mg teverelix) and tmax occurred between 1 and 4 hours after dosing.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[ng] / [ml],4.5,150159,DB00624,Testosterone
,10872648,peak teverilix plasma concentrations,Geometric means of peak teverilix plasma concentrations were 4.5 ng/mL (0.5 mg teverelix) to 49.0 ng/mL (5 mg teverelix) and tmax occurred between 1 and 4 hours after dosing.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[ng] / [ml],49.0,150160,DB00624,Testosterone
,10872648,tmax,Geometric means of peak teverilix plasma concentrations were 4.5 ng/mL (0.5 mg teverelix) to 49.0 ng/mL (5 mg teverelix) and tmax occurred between 1 and 4 hours after dosing.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),h,1 and 4,150161,DB00624,Testosterone
,10872648,area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)],Geometric means of the area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)] were 54.9 ng x h/mL (0.5 mg teverelix) to 881.8 ng x h/mL (5 mg teverelix).,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[h·ng] / [ml],54.9,150162,DB00624,Testosterone
,10872648,area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)],Geometric means of the area under the teverelix plasma concentration-time course from zero to time of the last quantifiable plasma concentration [AUC(O-tlast)] were 54.9 ng x h/mL (0.5 mg teverelix) to 881.8 ng x h/mL (5 mg teverelix).,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),[h·ng] / [ml],881.8,150163,DB00624,Testosterone
,10872648,apparent terminal half-lives,Median values for apparent terminal half-lives ranged from 24 to 75 hours.,Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872648/),h,24 to 75,150164,DB00624,Testosterone
exceeded,125164,Production rate (PR),"Production rate (PR) of testosterone exceeded 417 mug/24 h (1 SD above the mean reported for normal women), in nineteen of the twenty-five patients.",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],417,150467,DB00624,Testosterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],509,150468,DB00624,Testosterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],356,150469,DB00624,Testosterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],612,150470,DB00624,Testosterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],345,150471,DB00624,Testosterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],528,150472,DB00624,Testosterone
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],148,150473,DB00624,Testosterone
,24710899,IC50,"In the in vitro cytochrome P450 inhibition study, the rate of disappearance of testosterone was significantly reduced in the presence of 10 µM PU, while that of other cytochrome P450 substrates was not significantly affected in both human and rat liver microsomes, suggesting that puerarin inhibits the in vitro hepatic CYP3A-mediated metabolism in the human and rat systems (IC50 = 15.5 ± 3.9 µM).",In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710899/),μM,15.5,150775,DB00624,Testosterone
,31429205,steady-state Tmax,"In 12 evaluable patients (part A), TAK-385 was rapidly absorbed after a single loading dose; on day 28 (maintenance dose), median steady-state Tmax was ~1-2 hours and mean t1/2z was 67-79 hours.",Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31429205/),h,1-2,151779,DB00624,Testosterone
,31429205,t1/2z,"In 12 evaluable patients (part A), TAK-385 was rapidly absorbed after a single loading dose; on day 28 (maintenance dose), median steady-state Tmax was ~1-2 hours and mean t1/2z was 67-79 hours.",Phase I trial of TAK-385 in hormone treatment-naïve Japanese patients with nonmetastatic prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31429205/),h,67-79,151780,DB00624,Testosterone
,12709720,time to reach peak concentration,"After a continuous subcutaneous infusion of 50 microg x kg(-1) x d(-1), abarelix concentrations peaked with the median observed time to reach peak concentration at approximately 28 days.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),d,28,152804,DB00624,Testosterone
,12709720,observed maximum plasma drug concentration,"The mean observed maximum plasma drug concentration and average plasma concentration were 56.1 and 48.6 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),[ng] / [ml],56.1,152805,DB00624,Testosterone
,12709720,average plasma concentration,"The mean observed maximum plasma drug concentration and average plasma concentration were 56.1 and 48.6 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),[ng] / [ml],48.6,152806,DB00624,Testosterone
,12709720,observed half-life,The mean observed half-life of abarelix was 10.0 days.,"Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),d,10.0,152807,DB00624,Testosterone
,12709720,50% inhibitory concentration,"The population pharmacodynamic estimates (percent coefficient of variation) of the 50% inhibitory concentration, maximum organ extraction ratio, and slope and sigmoidicity of the effect-concentration curve of abarelix to testosterone were 3.47 ng/mL (12.4%), 94.9 (1.3%), and 2.92 (16.2%), respectively.","Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709720/),[ng] / [ml],3.47,152808,DB00624,Testosterone
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],2.08,153078,DB00624,Testosterone
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],3.42,153079,DB00624,Testosterone
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],6.43,153080,DB00624,Testosterone
,15102870,IC(50)s,"The mean IC(50)s of abarelix for T, DHT, FSH, and LH were 2.08, 3.42, 6.43, 4.25 ng/mL, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),[ng] / [ml],4.25,153081,DB00624,Testosterone
,15102870,relative bioavailability,The mean relative bioavailability of the depot formulation in reference to the injectable solution was 0.52.,"Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),,0.52,153082,DB00624,Testosterone
,15102870,t(max),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),h,1,153083,DB00624,Testosterone
,15102870,t(max),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),d,0.22,153084,DB00624,Testosterone
,15102870,terminal t(1/2),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),h,5.3,153085,DB00624,Testosterone
,15102870,terminal t(1/2),"The mean t(max) and terminal t(1/2) for abarelix after administration of abarelix injectable solution and abarelix depot injection were 1 hour and 3 days and 0.22 days (5.3 h) and 13.2 days, respectively.","Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102870/),d,13.2,153086,DB00624,Testosterone
,31744668,flow rate,"Using testosterone as internal standard, the plasma samples were prepared by precipitation with acetonitrile and separated using an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with a mobile phase composed of acetonitrile and 0.1 % (v/v) formic acid aqueous solution by gradient elution at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31744668/),[ml] / [min],0.3,155222,DB00624,Testosterone
,16416302,k (inact),All five macrolides inactivated testosterone 6beta-hydroxylation by HLM and recombinant CYP3A4 with k (inact) values in the range of 0.023 to 0.058 min(-1).,Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416302/),1/[min],0.023 to 0.058,155592,DB00624,Testosterone
,10720024,area under the curve (AUC0-24h),"The application of T gel at four sites (application skin area approximately four times that of one site) resulted in a mean area under the curve (AUC0-24h) for serum T levels on the 7th day (868 +/- 72 nmol*h/L, mean +/- SEM), which was 23% higher but not significantly different (P = 0.06) than repeated application at one site (706 +/- 59 nmol*h/L).",Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720024/),[h·nM] / [l],868,156379,DB00624,Testosterone
,10720024,area under the curve (AUC0-24h),"The application of T gel at four sites (application skin area approximately four times that of one site) resulted in a mean area under the curve (AUC0-24h) for serum T levels on the 7th day (868 +/- 72 nmol*h/L, mean +/- SEM), which was 23% higher but not significantly different (P = 0.06) than repeated application at one site (706 +/- 59 nmol*h/L).",Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720024/),[h·nM] / [l],706,156380,DB00624,Testosterone
,19356392,relative bioavailability,"The relative bioavailability comparison of the AUC and Cmax, showed that the TDS-testosterone and Androgel was bioequivalent by using uncorrected data (CI: 93 - 120%; AUC0-12 and 88 - 117%; Cmax).",Correcting endogenous concentrations of testosterone influences bioequivalence and shows the superiority of TDS(R)-testosterone versus Androgel(R). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356392/),%,93 - 120,156769,DB00624,Testosterone
,19356392,relative bioavailability,"The relative bioavailability comparison of the AUC and Cmax, showed that the TDS-testosterone and Androgel was bioequivalent by using uncorrected data (CI: 93 - 120%; AUC0-12 and 88 - 117%; Cmax).",Correcting endogenous concentrations of testosterone influences bioequivalence and shows the superiority of TDS(R)-testosterone versus Androgel(R). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19356392/),%,88 - 117,156770,DB00624,Testosterone
,12501882,maximal concentration,"LA had a mean (SD) maximal concentration of 26.3 (12.6) ng/mL at 4.66 (1.44) hours and was detected for a mean of 37 days (range, 28-49 days).","A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12501882/),[ng] / [ml],26.3,157399,DB00624,Testosterone
,7500470,objective response rate,The objective response rate (modified European Organization for Research in Cancer Therapy criteria) was 70%.,"Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7500470/),%,70,157594,DB00624,Testosterone
,7500470,drug plasma concentration,"Mean drug plasma concentration was 8,528 +/- 2,928 ng/ml.","Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7500470/),[ng] / [ml],"8,528",157595,DB00624,Testosterone
,8865317,absolute bioavailability,"The mean absolute bioavailability of testosterone from the bioadhesive tablet was 14.1%, while the mean relative bioavailability was 1370%.",Buccal absorption of testosterone and its esters using a bioadhesive tablet in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865317/),%,14.1,158888,DB00624,Testosterone
,8865317,relative bioavailability,"The mean absolute bioavailability of testosterone from the bioadhesive tablet was 14.1%, while the mean relative bioavailability was 1370%.",Buccal absorption of testosterone and its esters using a bioadhesive tablet in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865317/),%,1370,158889,DB00624,Testosterone
,2108885,peak concentration,"Serum leuprorelin concentrations increased immediately after injection, reaching a peak concentration (range 13.1-54.5 ng/ml), which was directly proportional to dose, within 3 h.",Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108885/),[ng] / [ml],13.1-54.5,159487,DB00624,Testosterone
,33340279,IC50,PC945 only inhibited CYP3A4/5 substrate metabolism (IC50 : 1.33 µM [testosterone] and 0.085 µM [midazolam]).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),μM,1.33,159670,DB00624,Testosterone
,33340279,IC50,PC945 only inhibited CYP3A4/5 substrate metabolism (IC50 : 1.33 µM [testosterone] and 0.085 µM [midazolam]).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),μM,0.085,159671,DB00624,Testosterone
,33340279,Cmax,Geometric mean Cmax was 322 pg/mL (healthy subjects) and 335 pg/mL (subjects with mild asthma) 4-5 hours (median tmax ) after a single inhalation (5 mg).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),[pg] / [ml],322,159672,DB00624,Testosterone
,33340279,Cmax,Geometric mean Cmax was 322 pg/mL (healthy subjects) and 335 pg/mL (subjects with mild asthma) 4-5 hours (median tmax ) after a single inhalation (5 mg).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),[pg] / [ml],335,159673,DB00624,Testosterone
,33340279,tmax,Geometric mean Cmax was 322 pg/mL (healthy subjects) and 335 pg/mL (subjects with mild asthma) 4-5 hours (median tmax ) after a single inhalation (5 mg).,"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),h,4-5,159674,DB00624,Testosterone
,33340279,Cmax,"Following repeat, once daily inhalation (5 mg), Day 7 Cmax was 951 pg/mL (0.0016 µM) 45 minutes after dosing.","Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33340279/),[pg] / [ml],951,159675,DB00624,Testosterone
,15126518,serum test,The average serum testosterone concentration over 24 h showed a mean of 18.74 nmol/liter (SD =; 5.90) in the buccal system group and 12.15 nmol/liter (SD =; 5.55) in the transdermal patch group (P < 0.01).,"A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15126518/),[nM] / [l],18.74,159787,DB00624,Testosterone
,15126518,serum test,The average serum testosterone concentration over 24 h showed a mean of 18.74 nmol/liter (SD =; 5.90) in the buccal system group and 12.15 nmol/liter (SD =; 5.55) in the transdermal patch group (P < 0.01).,"A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15126518/),[nM] / [l],12.15,159788,DB00624,Testosterone
,15126518,steady-state testosterone concentrations,"Of the patients treated with the buccal system, 97% had average steady-state testosterone concentrations within the physiological range (10.41-36.44 nmol/liter), whereas only 56% of the transdermal patch patients achieved physiological total testosterone concentrations (P < 0.001 between groups).","A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15126518/),[nM] / [l],10.41-36.44,159789,DB00624,Testosterone
,7616407,apparent terminal half-life,"The apparent terminal half-life of L-754,394 in rats increased from 20 min at 0.5 mg/kg i.v. to 118 min at 10 mg/kg i.v.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),min,20,160709,DB00624,Testosterone
,7616407,apparent terminal half-life,"The apparent terminal half-life of L-754,394 in rats increased from 20 min at 0.5 mg/kg i.v. to 118 min at 10 mg/kg i.v.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),min,118,160710,DB00624,Testosterone
,7616407,apparent clearance,"After chronic i.v. doses for 7 days (1 mg/kg/dose/day), the apparent clearance of L-754,394 in rats decreased from 87 ml/min/kg after the first dose to 25 ml/min/kg after the last dose.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),[ml] / [kg·min],87,160711,DB00624,Testosterone
,7616407,apparent clearance,"After chronic i.v. doses for 7 days (1 mg/kg/dose/day), the apparent clearance of L-754,394 in rats decreased from 87 ml/min/kg after the first dose to 25 ml/min/kg after the last dose.","Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616407/),[ml] / [kg·min],25,160712,DB00624,Testosterone
,1430080,maximal serum levels,"However, in group II androgens increased significantly and were maintained in the normal range up to 12 weeks with maximal serum levels of 13.1 +/- 0.9 nmol/L (mean +/- SE) in study week 6.",Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1430080/),[nM] / [l],13.1,161180,DB00624,Testosterone
,1430080,terminal elimination t1/2 beta,Pharmacokinetic analysis revealed a terminal elimination t1/2 beta of 29.5 +/- 3.9 days and a mean residence time of 65.0 +/- 9.9 days in group II.,Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1430080/),d,29.5,161181,DB00624,Testosterone
,1430080,mean residence time,Pharmacokinetic analysis revealed a terminal elimination t1/2 beta of 29.5 +/- 3.9 days and a mean residence time of 65.0 +/- 9.9 days in group II.,Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1430080/),d,65.0,161182,DB00624,Testosterone
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],15.8,162229,DB00624,Testosterone
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],16.3,162230,DB00624,Testosterone
,11055323,time to peak plasma level,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.2,162231,DB00624,Testosterone
,11055323,half life,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.17,162232,DB00624,Testosterone
,11055323,apparent clearance,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[l] / [h],172,162233,DB00624,Testosterone
,11055323,apparent mean volume of distribution,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),l,540,162234,DB00624,Testosterone
,8789729,metabolic clearance rate,The mean +/- SE metabolic clearance rate of the intravenous DHA was 404 +/- 49 L/day.,Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),[l] / [d],404,163060,DB00624,Testosterone
,8789729,metabolic clearance rate,"The mean metabolic clearance rate was 2,601 +/- 261 L/day after oral administration, and the calculated absorption was 16.3 +/- 2.5%.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),[l] / [d],"2,601",163061,DB00624,Testosterone
,8789729,absorption,"The mean metabolic clearance rate was 2,601 +/- 261 L/day after oral administration, and the calculated absorption was 16.3 +/- 2.5%.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),%,16.3,163062,DB00624,Testosterone
,8789729,conversion ratio,"DHA to DHAS, as the conversion ratio of the orally administered DHA measured in the blood as [4-14C]DHAS was 63.3 +/- 13.6, whereas the conversion ratio of intravenously administered DHA to DHAS was 9.3 +/- 2.0.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),,63.3,163063,DB00624,Testosterone
,8789729,conversion ratio,"DHA to DHAS, as the conversion ratio of the orally administered DHA measured in the blood as [4-14C]DHAS was 63.3 +/- 13.6, whereas the conversion ratio of intravenously administered DHA to DHAS was 9.3 +/- 2.0.",Dehydroepiandrosterone metabolism in the female rhesus monkey: oral versus intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789729/),,9.3,163064,DB00624,Testosterone
,523537,circulating half-life,"This difference is not due to a sex difference in plasma testosterone removal rates, since the circulating half-life of 3H-testosterone measured by testosterone-specific radioassay was not different in castrated males (72 +/- 5 min) and females (66 +/- 4 min).",Effects of sustained-release testosterone on marking behavior in the Mongolian gerbil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523537/),min,72,163133,DB00624,Testosterone
,523537,circulating half-life,"This difference is not due to a sex difference in plasma testosterone removal rates, since the circulating half-life of 3H-testosterone measured by testosterone-specific radioassay was not different in castrated males (72 +/- 5 min) and females (66 +/- 4 min).",Effects of sustained-release testosterone on marking behavior in the Mongolian gerbil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523537/),min,66,163134,DB00624,Testosterone
,10434286,maximum concentration (Cmax),"Pharmacokinetic analysis of plasma testosterone profiles in minipigs indicated a significant difference (p < 0.001) in daily dose of testosterone delivered (1.20 versus 4.83 mg/day), maximum concentration (Cmax) (54.2 versus 218.0 ng/dl), and area under concentration-time curve (AUC0-28)[665 versus 3208 (ng/dl) x hr] between these T-TDSs.",Transdermal testosterone delivery: comparison between scrotal and nonscrotal delivery systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434286/),[ng] / [dl],54.2,164468,DB00624,Testosterone
,10434286,maximum concentration (Cmax),"Pharmacokinetic analysis of plasma testosterone profiles in minipigs indicated a significant difference (p < 0.001) in daily dose of testosterone delivered (1.20 versus 4.83 mg/day), maximum concentration (Cmax) (54.2 versus 218.0 ng/dl), and area under concentration-time curve (AUC0-28)[665 versus 3208 (ng/dl) x hr] between these T-TDSs.",Transdermal testosterone delivery: comparison between scrotal and nonscrotal delivery systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434286/),[ng] / [dl],218.0,164469,DB00624,Testosterone
,10434286,area under concentration-time curve (AUC0-28),"Pharmacokinetic analysis of plasma testosterone profiles in minipigs indicated a significant difference (p < 0.001) in daily dose of testosterone delivered (1.20 versus 4.83 mg/day), maximum concentration (Cmax) (54.2 versus 218.0 ng/dl), and area under concentration-time curve (AUC0-28)[665 versus 3208 (ng/dl) x hr] between these T-TDSs.",Transdermal testosterone delivery: comparison between scrotal and nonscrotal delivery systems. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434286/),[ng] / [dl)·h],665,164470,DB00624,Testosterone
,10434286,area under concentration-time curve (AUC0-28),"Pharmacokinetic analysis of plasma testosterone profiles in minipigs indicated a significant difference (p < 0.001) in daily dose of testosterone delivered (1.20 versus 4.83 mg/day), maximum concentration (Cmax) (54.2 versus 218.0 ng/dl), and area under concentration-time curve (AUC0-28)[665 versus 3208 (ng/dl) x hr] between these T-TDSs.",Transdermal testosterone delivery: comparison between scrotal and nonscrotal delivery systems. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434286/),[ng] / [dl)·h],3208,164471,DB00624,Testosterone
,2115044,half-duration,Absorption of testosterone from 100 mg and 200 mg pellets closely approximated zero-order throughout the effective life of the pellets and exhibited a half-duration of 2.5 months.,Pharmacokinetics and pharmacodynamics of testosterone pellets in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115044/),month,2.5,164707,DB00624,Testosterone
,2115044,rate of release,The estimated rate of release of testosterone was 1.5 (95% confidence limits 1.3-1.6) mg/day.,Pharmacokinetics and pharmacodynamics of testosterone pellets in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115044/),[mg] / [d],1.5,164708,DB00624,Testosterone
,15830721,permeation rate,"When 3% dodecylamine was used in combination with 10% span 80, the in vitro rat permeation rate increased from 2.29 microg/cm2/hr to 6.51 microg/cm2/ hr as the TS loading dose increased from 2% to 6%.",In vitro and in vivo evaluation of a novel nonscrotal matrix-type transdermal delivery system of testosterone. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830721/),[μg] / [cm2·h],2.29,165158,DB00624,Testosterone
,15830721,permeation rate,"When 3% dodecylamine was used in combination with 10% span 80, the in vitro rat permeation rate increased from 2.29 microg/cm2/hr to 6.51 microg/cm2/ hr as the TS loading dose increased from 2% to 6%.",In vitro and in vivo evaluation of a novel nonscrotal matrix-type transdermal delivery system of testosterone. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15830721/),[μg] / [·cm2·h],6.51,165159,DB00624,Testosterone
,9753206,volume of distribution (Vdarea),"The volume of distribution (Vdarea) was 80.36 +/- 24.51 L, and the elimination half-life was 55.93 +/- 23.06 minutes.",The pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9753206/),l,80.36,165404,DB00624,Testosterone
,9753206,elimination half-life,"The volume of distribution (Vdarea) was 80.36 +/- 24.51 L, and the elimination half-life was 55.93 +/- 23.06 minutes.",The pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9753206/),min,55.93,165405,DB00624,Testosterone
,10801222,Absolute bioavailability,Absolute bioavailability of cetrorelix was 100% in rats and 97% in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),%,100,167024,DB00624,Testosterone
,10801222,Absolute bioavailability,Absolute bioavailability of cetrorelix was 100% in rats and 97% in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),%,97,167025,DB00624,Testosterone
,10801222,population elimination half-lives,The population elimination half-lives after iv-dose were 3.0 h in rats and 9.3 h in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),h,3.0,167026,DB00624,Testosterone
,10801222,population elimination half-lives,The population elimination half-lives after iv-dose were 3.0 h in rats and 9.3 h in dogs.,"Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),h,9.3,167027,DB00624,Testosterone
,10801222,IC50,"Population mean estimates of IC50 were 1.39 and 1.24 ng/ml in rats and dogs, respectively.","Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),[ng] / [ml],1.39,167028,DB00624,Testosterone
,10801222,IC50,"Population mean estimates of IC50 were 1.39 and 1.24 ng/ml in rats and dogs, respectively.","Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801222/),[ng] / [ml],1.24,167029,DB00624,Testosterone
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.357,167174,DB00624,Testosterone
,25791895,absorption rate constant,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),1/[day],0.017,167175,DB00624,Testosterone
,25791895,mean transit time,"Typical population values of the absorption rate constant of the immediate and delayed processes were estimated to be 0.357 and 0.017 day(-1), respectively, with a mean transit time of 9.5 days.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),d,9.5,167176,DB00624,Testosterone
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.3,167177,DB00624,Testosterone
,25791895,equilibrium dissociation constant,"The equilibrium dissociation constant of leuprolide and the typical leuprolide plasma concentration required to achieve a castration testosterone level of ≤0.5 ng/mL were 0.3 and 0.03 ng/mL, respectively.",A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25791895/),[ng] / [ml],0.03,167178,DB00624,Testosterone
,8585889,maximal concentration (Cmax),The maximal concentration (Cmax) of T was 19.56 7.64 ng/mL (mean +/- SD; 5.3-fold increase from the baseline) at< 30 min (Tmax) after administration.,Pharmacokinetics of a single dose of buccal testosterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585889/),[ng] / [ml],19.56,168433,DB00624,Testosterone
,8585889,elimination half-life,The elimination half-life of Buccal T was about 1.75 h.,Pharmacokinetics of a single dose of buccal testosterone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585889/),h,1.75,168434,DB00624,Testosterone
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],1.44,169553,DB00624,Testosterone
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],0.82,169554,DB00624,Testosterone
,2556239,plasma half-life,It has a plasma half-life of approximately 25-30 hr and approximately 70% of dose is excreted in the urine unchanged.,Review of fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556239/),h,25-30,169591,DB00624,Testosterone
,22533605,peak serum concentrations,"Thus, peak serum concentrations of 240, 36, and 29 ng/dL were observed at 0.2, 5, and 16.8 h after application of the preferred lotion formulation, and 89, 65, and 64 ng/dL at 1, 16.4, and 48.8 h after patches.",Episodic transdermal delivery of testosterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533605/),[ng] / [dl],240,170259,DB00624,Testosterone
,22533605,peak serum concentrations,"Thus, peak serum concentrations of 240, 36, and 29 ng/dL were observed at 0.2, 5, and 16.8 h after application of the preferred lotion formulation, and 89, 65, and 64 ng/dL at 1, 16.4, and 48.8 h after patches.",Episodic transdermal delivery of testosterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533605/),[ng] / [dl],36,170260,DB00624,Testosterone
,22533605,peak serum concentrations,"Thus, peak serum concentrations of 240, 36, and 29 ng/dL were observed at 0.2, 5, and 16.8 h after application of the preferred lotion formulation, and 89, 65, and 64 ng/dL at 1, 16.4, and 48.8 h after patches.",Episodic transdermal delivery of testosterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533605/),[ng] / [dl],29,170261,DB00624,Testosterone
,22533605,peak serum concentrations,"Thus, peak serum concentrations of 240, 36, and 29 ng/dL were observed at 0.2, 5, and 16.8 h after application of the preferred lotion formulation, and 89, 65, and 64 ng/dL at 1, 16.4, and 48.8 h after patches.",Episodic transdermal delivery of testosterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533605/),[ng] / [dl],89,170262,DB00624,Testosterone
,22533605,peak serum concentrations,"Thus, peak serum concentrations of 240, 36, and 29 ng/dL were observed at 0.2, 5, and 16.8 h after application of the preferred lotion formulation, and 89, 65, and 64 ng/dL at 1, 16.4, and 48.8 h after patches.",Episodic transdermal delivery of testosterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533605/),[ng] / [dl],65,170263,DB00624,Testosterone
,22533605,peak serum concentrations,"Thus, peak serum concentrations of 240, 36, and 29 ng/dL were observed at 0.2, 5, and 16.8 h after application of the preferred lotion formulation, and 89, 65, and 64 ng/dL at 1, 16.4, and 48.8 h after patches.",Episodic transdermal delivery of testosterone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533605/),[ng] / [dl],64,170264,DB00624,Testosterone
,1657611,times to reach peak plasma concentrations (Tmax),"The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, 50 and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively.","Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657611/),h,1.8 to 2.8,175821,DB00624,Testosterone
,1657611,peak plasma concentrations (Cmax),"The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, 50 and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively.","Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657611/),[ng] / [ml],38.1,175822,DB00624,Testosterone
,1657611,peak plasma concentrations (Cmax),"The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, 50 and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively.","Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657611/),[ng] / [ml],81.5,175823,DB00624,Testosterone
,1657611,peak plasma concentrations (Cmax),"The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, 50 and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively.","Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657611/),[ng] / [ml],147.1,175824,DB00624,Testosterone
,1657611,peak plasma concentrations (Cmax),"The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, 50 and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively.","Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657611/),[ng] / [ml],442.0,175825,DB00624,Testosterone
,1657611,peak plasma concentrations (Cmax),"The mean times to reach peak plasma concentrations (Tmax) of (I) at doses of 5, 10, 20, 50 and 100 mg ranged from 1.8 to 2.8 h, and the corresponding mean peak plasma concentrations (Cmax) were 38.1, 81.5, 147.1, 442.0 and 835.5 ng/ml, respectively.","Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657611/),[ng] / [ml],835.5,175826,DB00624,Testosterone
,1657611,half-lives (t1/2),The drug disappeared from the systemic circulation with half-lives (t1/2) of 4.7-7.1 h.,"Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657611/),h,4.7-7.1,175827,DB00624,Testosterone
,10594381,terminal t(1/2),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,12.94,176194,DB00624,Testosterone
,10594381,terminal t(1/2),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,13.03,176195,DB00624,Testosterone
,10594381,mean residence time (MRT),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,6. 85,176196,DB00624,Testosterone
,10594381,mean residence time (MRT),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,8.72,176197,DB00624,Testosterone
,10594381,C(max),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),[ng] / [ml],277.72,176198,DB00624,Testosterone
,10594381,C(max),"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),[ng] / [ml],274. 23,176199,DB00624,Testosterone
,10594381,t,"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,1,176200,DB00624,Testosterone
,10594381,t,"After i.t. administration the mean terminal t(1/2) was 12.94+/-1.74 (0.5 mg/kg) and 13.03+/-3.15 h (1 mg/kg); mean residence time (MRT) was 6. 85+/-3.01 and 8.72+/-2.33 h; the C(max) (277.72+/-252.11 and 274. 23+/-113.49 ng/ml) were observed in the first or the second plasma sample, suggesting that the drug was rapidly absorbed (t=1 and 2 h).",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),h,2,176201,DB00624,Testosterone
,10594381,bioavailability,"Comparing the plasma concentration after i.t. administration with data after i.v. administration from a previous study undertaken in the same laboratory, the mean i.t. bioavailability was calculated as 75.80+/-45.42 and 58.97+/-18.25%.",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),%,75.80,176202,DB00624,Testosterone
,10594381,bioavailability,"Comparing the plasma concentration after i.t. administration with data after i.v. administration from a previous study undertaken in the same laboratory, the mean i.t. bioavailability was calculated as 75.80+/-45.42 and 58.97+/-18.25%.",Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594381/),%,58.97,176203,DB00624,Testosterone
>,34269421,maximum concentration,"This translated into an ≈10% increase in the percentage of patients predicted to have a last observed concentration during a dosing interval before a subsequent dose >300 ng/dL, minimal change in the percentage of patients with average concentration in the normal range, and a low likelihood of maximum concentration >2500 ng/dL.",Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34269421/),[ng] / [dl],2500,176809,DB00624,Testosterone
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],108.3,177886,DB00624,Testosterone
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],43.4,177887,DB00624,Testosterone
,12782545,AUC,Analysis of integrated area under the curve (AUC) and time 0 hormonal concentrations by repeated measures multivariate analysis of variance (p<0.05) and Fisher's post hoc analysis showed a significant increase in AUC for serum androstenedione at day 0 (108.3 (27.6) nmol/l) in the supplemented condition as compared with day 28 (43.4 (13.1) nmol/l) and placebo (2.1 (0.8) nmol/l) conditions.,Four weeks of androstenedione supplementation diminishes the treatment response in middle aged men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12782545/),[nM] / [l],2.1,177888,DB00624,Testosterone
,15783070,total body clearance,"After paclitaxel was administered intravenously, total body clearance was significantly reduced by 73% and 34% relative to each control value in CCl4-treated and 5/6 Nx rats, respectively (control, 1.82+/-0.42 vs.",Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15783070/),,1,179805,DB00624,Testosterone
,14713280,peak concentration,"After COL 1621, means+/-S.D. serum testosterone level increased to a peak concentration of 26.6+/-5.8 nmol/l (7.7+/-1.7 ng/ml) at 4.8+/-5.8 h and stayed in the eugonadal range.",Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713280/),[nM] / [l],26.6,180843,DB00624,Testosterone
,14713280,peak concentration,"After COL 1621, means+/-S.D. serum testosterone level increased to a peak concentration of 26.6+/-5.8 nmol/l (7.7+/-1.7 ng/ml) at 4.8+/-5.8 h and stayed in the eugonadal range.",Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713280/),[ng] / [ml],7.7,180844,DB00624,Testosterone
,8131397,maximum concentrations,"After single dose administration, maximum concentrations of CPA in the serum were 15.2 +/- 6.6 ng/ml.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[ng] / [ml],15.2,181084,DB00624,Testosterone
,8131397,half-lives,"Post maximum drug levels declined biphasically with half-lives of 0.8 +/- 0.4 h and 54.0 +/- 26.0 h, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),h,0.8,181085,DB00624,Testosterone
,8131397,half-lives,"Post maximum drug levels declined biphasically with half-lives of 0.8 +/- 0.4 h and 54.0 +/- 26.0 h, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),h,54.0,181086,DB00624,Testosterone
,8131397,apparent clearance,The apparent clearance was calculated to be 3.6 +/- 0.9 ml x min-1 x kg-1 and the volume of distribution (Vz) was 986 +/- 4371.,Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[ml] / [kg·min],3.6,181087,DB00624,Testosterone
,8131397,volume of distribution (Vz),The apparent clearance was calculated to be 3.6 +/- 0.9 ml x min-1 x kg-1 and the volume of distribution (Vz) was 986 +/- 4371.,Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),,986,181088,DB00624,Testosterone
,8131397,free fraction,"The free fraction of CPA was 3.5 +/- 1.9% and the fractions bound to heat labile proteins and albumin were 4.6 +/- 2.2% and 92.0 +/- 3.5%, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),%,3.5,181089,DB00624,Testosterone
,8131397,fractions,"The free fraction of CPA was 3.5 +/- 1.9% and the fractions bound to heat labile proteins and albumin were 4.6 +/- 2.2% and 92.0 +/- 3.5%, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),%,4.6,181090,DB00624,Testosterone
,8131397,fractions,"The free fraction of CPA was 3.5 +/- 1.9% and the fractions bound to heat labile proteins and albumin were 4.6 +/- 2.2% and 92.0 +/- 3.5%, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),%,92.0,181091,DB00624,Testosterone
,8131397,terminal half-life,"At the end of treatment cycle three, the terminal half-life of CPA had increased to a mean value of 78.6 +/- 16.0 h and the volume of distribution to a value of 1304 +/- 427 1.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),h,78.6,181092,DB00624,Testosterone
,8131397,volume of distribution,"At the end of treatment cycle three, the terminal half-life of CPA had increased to a mean value of 78.6 +/- 16.0 h and the volume of distribution to a value of 1304 +/- 427 1.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),1,1304,181093,DB00624,Testosterone
,8131397,apparent clearance,"The apparent clearance showed a small, although significant decrease to a value of 3.0 +/- 0.4 ml x min-1 x kg-1.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[ml] / [kg·min],3.0,181094,DB00624,Testosterone
,8131397,AUC(0-4h),The AUC(0-4h) values of EE2 following single dose administration of the combination oral contraceptive were found to be 187.5 +/- 79.7 pg x ml-1 x h.,Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[h·pg] / [ml],187.5,181095,DB00624,Testosterone
,8131397,AUC(0-4h),"On the last day of cycles one and three, the AUC(0-4h) values were 311.2 +/- 109.3 and 304.8 +/- 121.5 pg x ml-1 x h, respectively, which corresponds to an about 60% increase as compared to single dose administration.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[h·pg] / [ml],311.2,181096,DB00624,Testosterone
,8131397,AUC(0-4h),"On the last day of cycles one and three, the AUC(0-4h) values were 311.2 +/- 109.3 and 304.8 +/- 121.5 pg x ml-1 x h, respectively, which corresponds to an about 60% increase as compared to single dose administration.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[h·pg] / [ml],304.8,181097,DB00624,Testosterone
,15175422,Rate of elimination (k(10)),"Rate of elimination (k(10)) for erythromycin and those with inhibitors was found to be similar (141 +/- 23 min), suggesting that elimination pathways were not altered.",Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175422/),min,141,181611,DB00624,Testosterone
,9506008,Area under the concentration-time curve from 0 to 27 hours (AUC0-27),"Area under the concentration-time curve from 0 to 27 hours (AUC0-27) values for testosterone after one-day applications to the upper buttocks, upper arm, and back were 9,560 ng.hr/dL, 8,651 ng.hr/dL, and 8,988 ng.hr/dL, respectively.",Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506008/),[h·ng] / [dl],"9,560",182020,DB00624,Testosterone
,9506008,Area under the concentration-time curve from 0 to 27 hours (AUC0-27),"Area under the concentration-time curve from 0 to 27 hours (AUC0-27) values for testosterone after one-day applications to the upper buttocks, upper arm, and back were 9,560 ng.hr/dL, 8,651 ng.hr/dL, and 8,988 ng.hr/dL, respectively.",Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506008/),[h·ng] / [dl],"8,651",182021,DB00624,Testosterone
,9506008,Area under the concentration-time curve from 0 to 27 hours (AUC0-27),"Area under the concentration-time curve from 0 to 27 hours (AUC0-27) values for testosterone after one-day applications to the upper buttocks, upper arm, and back were 9,560 ng.hr/dL, 8,651 ng.hr/dL, and 8,988 ng.hr/dL, respectively.",Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506008/),[h·ng] / [dl],"8,988",182022,DB00624,Testosterone
,9506008,Maximum observed concentration (Cmax),"Maximum observed concentration (Cmax) values were 482 ng/dL, 462 ng/dL, and 499 ng/dL, respectively.",Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506008/),[ng] / [dl],482,182023,DB00624,Testosterone
,9506008,Maximum observed concentration (Cmax),"Maximum observed concentration (Cmax) values were 482 ng/dL, 462 ng/dL, and 499 ng/dL, respectively.",Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506008/),[ng] / [dl],462,182024,DB00624,Testosterone
,9506008,Maximum observed concentration (Cmax),"Maximum observed concentration (Cmax) values were 482 ng/dL, 462 ng/dL, and 499 ng/dL, respectively.",Transdermal testosterone administration in hypogonadal men: comparison of pharmacokinetics at different sites of application and at the first and fifth days of application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506008/),[ng] / [dl],499,182025,DB00624,Testosterone
,1428196,peak plasma concentration (Cmax),"This occurred when the drug concentrations in cauda epididymal fluid and seminal plasma were at their peak (18.0 +/- 7.3 and 13.5 +/- 3.0 micrograms ml-1, respectively), and which was preceded by a peak plasma concentration (Cmax) of 64.82 +/- 2.47 micrograms ml-1 at 5.15 +/- 0.68 h (Tmax).",Pharmacokinetic and pharmacodynamic studies of the effect of ketoconazole on reproductive function in male rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428196/),[μg] / [ml],64.82,183380,DB00624,Testosterone
,1428196,Tmax,"This occurred when the drug concentrations in cauda epididymal fluid and seminal plasma were at their peak (18.0 +/- 7.3 and 13.5 +/- 3.0 micrograms ml-1, respectively), and which was preceded by a peak plasma concentration (Cmax) of 64.82 +/- 2.47 micrograms ml-1 at 5.15 +/- 0.68 h (Tmax).",Pharmacokinetic and pharmacodynamic studies of the effect of ketoconazole on reproductive function in male rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428196/),h,5.15,183381,DB00624,Testosterone
,2278844,Ka,"The antiserum, raised against 7 alpha-methyl-19-nortestosterone-3-O-oxime-bovine serum albumin, had a low titer (final dilution = 1:4500) and low affinity (Ka = 1.17 x 10(9) l/mol) but showed little or no cross-reactivity with several of the steroids tested.",Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[l] / [mol],1.17 x 10(9),183725,DB00624,Testosterone
,2278844,sensitivity,The sensitivity of the RIA was 28.2 pg/ml and the mean recovery of added cold steroid was 86 to 100%.,Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[pg] / [ml],28.2,183726,DB00624,Testosterone
,2278844,metabolic clearance rates (MCR),"The metabolic clearance rates (MCR) of 7MENT as determined from the plasma disappearance curve for rats and rabbits were 50 l/day and 336 l/day, respectively.",Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[l] / [d],50,183727,DB00624,Testosterone
,2278844,metabolic clearance rates (MCR),"The metabolic clearance rates (MCR) of 7MENT as determined from the plasma disappearance curve for rats and rabbits were 50 l/day and 336 l/day, respectively.",Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[l] / [d],336,183728,DB00624,Testosterone
,3346356,maximum frequency,The maximum frequency (0.7 pulses/h) occurred between 2400 and 0200 h.,Increased luteinizing hormone pulse frequency during sleep in early to midpubertal boys: effects of testosterone infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346356/),[pulses] / [h],0.7,184890,DB00624,Testosterone
,3346356,maximum value,Plasma testosterone rose during the night to a mean maximum value of 2.4 +/- 0.5 (+/- SE) ng/mL (8.3 +/- 1.7 nmol/L).,Increased luteinizing hormone pulse frequency during sleep in early to midpubertal boys: effects of testosterone infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346356/),[ng] / [ml],2.4,184891,DB00624,Testosterone
,3346356,maximum value,Plasma testosterone rose during the night to a mean maximum value of 2.4 +/- 0.5 (+/- SE) ng/mL (8.3 +/- 1.7 nmol/L).,Increased luteinizing hormone pulse frequency during sleep in early to midpubertal boys: effects of testosterone infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346356/),[nM] / [l],8.3,184892,DB00624,Testosterone
,32887542,Area Under the Curve (AUC),"Furthermore, in vivo pharmacokinetic (PK) studies in Sprague-Dawley (SD) rats showed that the Area Under the Curve (AUC) of the solid TU-SEDDS (487.54±208.80 μg/L×h) was higher than that of Andriol Testocaps® (418.93±273.52 μg/L×h, P < 0.05).",Solid Self-Emulsifying Drug Delivery System (Solid SEDDS) for Testosterone Undecanoate: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887542/),[μg] / [h·l],487.54,185305,DB00624,Testosterone
,32887542,Area Under the Curve (AUC),"Furthermore, in vivo pharmacokinetic (PK) studies in Sprague-Dawley (SD) rats showed that the Area Under the Curve (AUC) of the solid TU-SEDDS (487.54±208.80 μg/L×h) was higher than that of Andriol Testocaps® (418.93±273.52 μg/L×h, P < 0.05).",Solid Self-Emulsifying Drug Delivery System (Solid SEDDS) for Testosterone Undecanoate: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887542/),[μg] / [h·l],418.93,185306,DB00624,Testosterone
,32887542,AUC,"In beagles not fed a high-fat diet, the AUC of the solid TU-SEDDS (5.81±4.03 μg/L×h) was higher than that of Andriol Testocaps ® (5.53±3.43 μg/L×h, P > 0.05).",Solid Self-Emulsifying Drug Delivery System (Solid SEDDS) for Testosterone Undecanoate: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887542/),[μg] / [h·l],5.81,185307,DB00624,Testosterone
,32887542,AUC,"In beagles not fed a high-fat diet, the AUC of the solid TU-SEDDS (5.81±4.03 μg/L×h) was higher than that of Andriol Testocaps ® (5.53±3.43 μg/L×h, P > 0.05).",Solid Self-Emulsifying Drug Delivery System (Solid SEDDS) for Testosterone Undecanoate: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887542/),[μg] / [h·l],5.53,185308,DB00624,Testosterone
,32887542,AUC,"In beagles fed a high-fat diet, the AUC of the solid TUSEDDS (38.18±21.90 μg/L×h) was higher than that of Andriol Testocaps® (37.17±13.79 μg/L×h, P > 0.05).",Solid Self-Emulsifying Drug Delivery System (Solid SEDDS) for Testosterone Undecanoate: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887542/),[μg] / [h·l],38.18,185309,DB00624,Testosterone
,32887542,AUC,"In beagles fed a high-fat diet, the AUC of the solid TUSEDDS (38.18±21.90 μg/L×h) was higher than that of Andriol Testocaps® (37.17±13.79 μg/L×h, P > 0.05).",Solid Self-Emulsifying Drug Delivery System (Solid SEDDS) for Testosterone Undecanoate: In Vitro and In Vivo Evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887542/),[μg] / [h·l],37.17,185310,DB00624,Testosterone
,12807999,absolute bioavailability,"When administered as either Andriol or Andriol Testocaps, the mean (+/-S.E., n = 4) absolute bioavailability of TU was 3.25 +/- 0.48 and 2.88 +/- 0.88%, respectively, and lymphatically transported TU accounted for between 91.5 and 99.7% of the systemically available ester.",Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807999/),%,3.25,185401,DB00624,Testosterone
,12807999,absolute bioavailability,"When administered as either Andriol or Andriol Testocaps, the mean (+/-S.E., n = 4) absolute bioavailability of TU was 3.25 +/- 0.48 and 2.88 +/- 0.88%, respectively, and lymphatically transported TU accounted for between 91.5 and 99.7% of the systemically available ester.",Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12807999/),%,2.88,185402,DB00624,Testosterone
,15550721,steady-state blood concentration,The steady-state plasma concentration of CER increased 1.4-fold when coadministered with CsA up to a steady-state blood concentration of 4 microM.,In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,4,187603,DB00624,Testosterone
,15550721,Ki,CsA competitively inhibited the uptake of [14C]CER with a Ki of 0.3 microM.,In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,0.3,187604,DB00624,Testosterone
,15550721,IC50,"The IC50 for the uptake of [14C]CER in the absence and presence of rat plasma was 0.2 and 2.3 microM, respectively.",In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,0.2,187605,DB00624,Testosterone
,15550721,IC50,"The IC50 for the uptake of [14C]CER in the absence and presence of rat plasma was 0.2 and 2.3 microM, respectively.",In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,2.3,187606,DB00624,Testosterone
,2761263,metabolic clearance,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[body·d·l·surface] / [area(m2],447,187721,DB00624,Testosterone
,2761263,metabolic clearance,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[l] / [d·m2],346,187722,DB00624,Testosterone
,2761263,production rates,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[mg] / [d·m2],2.21,187723,DB00624,Testosterone
,2761263,production rates,"The metabolic clearance and production rates of testosterone were significantly (P = 0.008 and P = 0.013, respectively) higher in patients [447 +/- 26 L/day/body surface area(m2) and 2.21 +/- 0.17 mg/day/m2, n = 38] than in controls [346 +/- 20 L/day/m2 and 1.70 +/- 0.11 mg/day/m2, n = 22].",Estradiol and testosterone metabolism and production in men with prostatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2761263/),[mg] / [d·m2],1.70,187724,DB00624,Testosterone
,9280401,plasma clearance,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[ml] / [kg·min],27,189830,DB00624,Testosterone
,9280401,terminal half-life,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[ml] / [kg·min],34,189831,DB00624,Testosterone
,9280401,terminal half-life,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),h,2.3,189832,DB00624,Testosterone
,9280401,volume of distribution at steady state,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[l] / [kg],4.0,189833,DB00624,Testosterone
,9280401,volume of distribution at steady state,"The mean values for its plasma clearance, terminal half-life, and volume of distribution at steady state were 27 ml/min/kg, 1.8 hr, and 4.0 liters/kg in rats and 34 ml/min/kg, 2.3 hr, and 5 liters/kg in rhesus monkeys.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),[l] / [kg],5,189834,DB00624,Testosterone
,9280401,bioavailability,The bioavailability of a 10 mg/kg oral dose was higher in rats (65%) than in rhesus monkeys (39%).,"Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,65,189835,DB00624,Testosterone
,9280401,bioavailability,The bioavailability of a 10 mg/kg oral dose was higher in rats (65%) than in rhesus monkeys (39%).,"Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,39,189836,DB00624,Testosterone
,9280401,T(max),"In monkeys a protracted plasma concentration-time profile was observed at 40 mg/kg, characterized by a delayed T(max) (8-24 hr) and a long terminal half-life (6 hr).","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),h,8-24,189837,DB00624,Testosterone
,9280401,terminal half-life,"In monkeys a protracted plasma concentration-time profile was observed at 40 mg/kg, characterized by a delayed T(max) (8-24 hr) and a long terminal half-life (6 hr).","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),h,6,189838,DB00624,Testosterone
,9280401,recovery of,"[3H]L-694,458 was well absorbed after oral dosing to rats at 10 mg/kg, as indicated by the high recovery of radioactivity in bile (83%) and urine (6%) of bile duct-cannulated rats.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,83,189839,DB00624,Testosterone
,9280401,recovery of,"[3H]L-694,458 was well absorbed after oral dosing to rats at 10 mg/kg, as indicated by the high recovery of radioactivity in bile (83%) and urine (6%) of bile duct-cannulated rats.","Orally active inhibitors of human leukocyte elastase. Disposition of L-694,458 in rats and rhesus monkeys. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280401/),%,6,189840,DB00624,Testosterone
,2917360,half-life,"The half-life of 4-OHA p.o. was approximately 3 h, whereas the apparent half-life of injected drug was between 5 and 10 days after a more rapid clearance during the first 4 days after injection.",Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917360/),h,3,190671,DB00624,Testosterone
,2917360,apparent half-life,"The half-life of 4-OHA p.o. was approximately 3 h, whereas the apparent half-life of injected drug was between 5 and 10 days after a more rapid clearance during the first 4 days after injection.",Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917360/),d,5 and 10,190672,DB00624,Testosterone
,15347734,K(i),C-6 was identified as an androgen receptor (AR) agonist with high AR binding affinity (K(i) = 4.9 nM).,A selective androgen receptor modulator for hormonal male contraception. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347734/),nM,4.9,190930,DB00624,Testosterone
,15347734,ED(50),"The doses required to maintain the weight of the prostate, seminal vesicles, and levator ani muscle to half the size of the maximum effects (i.e., ED(50)) were 0.78 +/- 0.06, 0.88 +/- 0.1, and 0.17 +/- 0.04 mg/day, respectively.",A selective androgen receptor modulator for hormonal male contraception. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347734/),,0.88,190931,DB00624,Testosterone
,15347734,ED(50),"The doses required to maintain the weight of the prostate, seminal vesicles, and levator ani muscle to half the size of the maximum effects (i.e., ED(50)) were 0.78 +/- 0.06, 0.88 +/- 0.1, and 0.17 +/- 0.04 mg/day, respectively.",A selective androgen receptor modulator for hormonal male contraception. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347734/),,0.17,190932,DB00624,Testosterone
,15347734,bioavailability,"Pharmacokinetic studies of C-6 in male rats revealed that C-6 was well absorbed after oral administration (bioavailability 76%), with a long (6.3 h) half-life at a dose of 10 mg/kg.",A selective androgen receptor modulator for hormonal male contraception. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347734/),%,76,190933,DB00624,Testosterone
,15347734,half-life,"Pharmacokinetic studies of C-6 in male rats revealed that C-6 was well absorbed after oral administration (bioavailability 76%), with a long (6.3 h) half-life at a dose of 10 mg/kg.",A selective androgen receptor modulator for hormonal male contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15347734/),h,6.3,190934,DB00624,Testosterone
,16967346,plasma half-life,The plasma half-life of LH (2.6-3.3 hr) and T (2.7 hr) match well with the literature reports.,"Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16967346/),h,2.6-3.3,191101,DB00624,Testosterone
,16967346,plasma half-life,The plasma half-life of LH (2.6-3.3 hr) and T (2.7 hr) match well with the literature reports.,"Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16967346/),h,2.7,191102,DB00624,Testosterone
,16263817,total,"In both groups, the 4.4-mg dose increased Cav total and free testosterone into the mid- to high-normal range, whereas 8.8- and 13.2-mg doses raised total (Cav: 22.3, 51.6, 80.3, and 92.0 ng/dl in group I; 22.7, 59.8, 82.0, and 114.3 ng/dl in group II at 0, 4.4, 8.8, and 13. 2 mg, respectively) and free testosterone (5.9, 8.4, 11.5,12.8 pg/ml in group I and 5.0,7.6,11.1,10.8 in group II, respectively, at the various doses) above the physiological range.",Pharmacokinetics of a testosterone gel in healthy postmenopausal women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16263817/),[ng] / [dl],22.3,193030,DB00624,Testosterone
,16299163,Km,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),μM,25.5,193543,DB00624,Testosterone
,16299163,Vmax,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),[nM] / [mg·min],2.45,193544,DB00624,Testosterone
,16299163,Vmax,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),μM,5.52,193545,DB00624,Testosterone
,16299163,Ki,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),μM,5.52,193546,DB00624,Testosterone
,11543729,K(i),Inhibition of r5AR1 by GI198745 was competitive with testosterone and followed Michaelis-Menten kinetics with a K(i) value of 0.3 +/- 0.02 nM.,Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543729/),nM,0.3,194421,DB00624,Testosterone
,11543729,rate constant (k(3)/K(i)),The pseudo-bimolecular rate constant (k(3)/K(i)) for the association of GI198745 with r5AR2 was (2.0 +/- 0.4) x 10(7) M(-1) sec(-1).,Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11543729/),1/[M·sec],2.0,194422,DB00624,Testosterone
,9435413,serum T concentration,"Acute pharmacokinetic testing showed peak serum hormone levels at 30 min, with a mean serum T concentration of 2688 +/- 147 ng/dL (range, 1820-3770 ng/dL).","Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435413/),[ng] / [dl],2688,195423,DB00624,Testosterone
,9435413,total T area under the curve,"Levels returned to baseline in 4-6 h, resulting in a total T area under the curve level of 3865 ng/hn.","Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435413/),[ng] / [hn],3865,195424,DB00624,Testosterone
,6643639,sensitivity,"A sensitivity of 20 ng/ml for both testolactone and 4,5-dihydrotestolactone is easily achieved using only 0.5 ml of sample.","Quantitation of testolactone and 4,5-dihydrotestolactone in plasma and urine using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6643639/),[ng] / [ml],20,195773,DB00624,Testosterone
,6643639,recoveries,"Mean recoveries for testolactone and its metabolite are 95.0% and 81.8%, respectively, and the mean coefficient of variation of the procedure is 3.5% for the drug and 7.1% for the metabolite.","Quantitation of testolactone and 4,5-dihydrotestolactone in plasma and urine using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6643639/),%,95.0,195774,DB00624,Testosterone
,6643639,recoveries,"Mean recoveries for testolactone and its metabolite are 95.0% and 81.8%, respectively, and the mean coefficient of variation of the procedure is 3.5% for the drug and 7.1% for the metabolite.","Quantitation of testolactone and 4,5-dihydrotestolactone in plasma and urine using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6643639/),%,81.8,195775,DB00624,Testosterone
,6643639,recoveries,"Mean recoveries for testolactone and its metabolite are 95.0% and 81.8%, respectively, and the mean coefficient of variation of the procedure is 3.5% for the drug and 7.1% for the metabolite.","Quantitation of testolactone and 4,5-dihydrotestolactone in plasma and urine using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6643639/),%,7.1,195776,DB00624,Testosterone
,8610057,half-life,Thereafter serum E2 declined monophasically with a mean half-life of 70 days.,Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610057/),d,70,196075,DB00624,Testosterone
,9743895,tmax,"Furthermore, tmax tended to decrease (from 1.6 to 0.9 h), whereas the elimination half-life (t1/2) tended to increase (from on average 45 to 57 h) with increasing dose.","Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743895/),h,1,196456,DB00624,Testosterone
,9743895,elimination half-life (t1/2),"Furthermore, tmax tended to decrease (from 1.6 to 0.9 h), whereas the elimination half-life (t1/2) tended to increase (from on average 45 to 57 h) with increasing dose.","Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743895/),h,45,196457,DB00624,Testosterone
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),,4.5,196526,DB00624,Testosterone
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),pg,5,196527,DB00624,Testosterone
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),,5.0,196528,DB00624,Testosterone
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),pg,1,196529,DB00624,Testosterone
,19201664,S/N ratio,"The detection limit of the present GC-MS-SIM method was found to be 1 pg per injection for AD (S/N ratio=4.5), 5 pg for 11beta-OHAD (S/N ratio=5.0), and 1 pg for TS (S/N ratio=4.4), respectively.","Simultaneous determination of androstenedione, 11beta-hydroxyandrostenedione, and testosterone in human plasma by stable isotope dilution mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19201664/),,4.4,196530,DB00624,Testosterone
,24434282,IC50,"In an enzymatic assay in homogenized and whole HEK-293 cells overexpressing 17β-HSD3, the inhibitor RM-532-105 efficiently inhibited the conversion of natural substrate 4-dione (50nM) into T with an IC50 of 26nM and 5nM, respectively.",In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24434282/),nM,26,197900,DB00624,Testosterone
,24434282,IC50,"In an enzymatic assay in homogenized and whole HEK-293 cells overexpressing 17β-HSD3, the inhibitor RM-532-105 efficiently inhibited the conversion of natural substrate 4-dione (50nM) into T with an IC50 of 26nM and 5nM, respectively.",In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24434282/),nM,5,197901,DB00624,Testosterone
,24434282,AUC 24h,"Moreover, the inhibitor RM-532-105 (10mg/kg) reached a plasma concentration of 250ng/mL at 7h (AUC 24h: 3485ngh/mL) after subcutaneous (s.c.) injection in the rat.",In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24434282/),[ngh] / [ml],3485,197902,DB00624,Testosterone
,23340005,PFS times,"The median PFS times were 11.9 weeks and 35.9 weeks, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),weeks,11.9,200375,DB00624,Testosterone
,23340005,PFS times,"The median PFS times were 11.9 weeks and 35.9 weeks, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),weeks,35.9,200376,DB00624,Testosterone
,23340005,response rates,"PSA response rates were 0% and 14.3%, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),%,0,200377,DB00624,Testosterone
,23340005,response rates,"PSA response rates were 0% and 14.3%, respectively.",Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23340005/),%,14.3,200378,DB00624,Testosterone
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],336,200510,DB00624,Testosterone
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],153,200511,DB00624,Testosterone
,8530600,half-lives,"The calculated half-lives were 60.3 +/- 7.5 and 68.8 +/- 5.0 min after a single dose of 2.5 and 5.0 mg SLT, respectively.","Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530600/),min,60.3,202323,DB00624,Testosterone
,8530600,half-lives,"The calculated half-lives were 60.3 +/- 7.5 and 68.8 +/- 5.0 min after a single dose of 2.5 and 5.0 mg SLT, respectively.","Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530600/),min,68.8,202324,DB00624,Testosterone
,29662027,absorption rate constant,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),1/[h],16.67,202805,DB00624,Testosterone
,29662027,total body clearance,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),[ml] / [h],514.46,202806,DB00624,Testosterone
,29662027,volume of distribution,"The absorption rate constant, the total body clearance, and the volume of distribution were estimated at 16.67 h-1, 514.46 mL/h, and 487.40 mL.",Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29662027/),ml,487.40,202807,DB00624,Testosterone
,7401040,metabolic clearance rate,"The metabolic clearance rate of testosterone was low in November and January, and significantly increased in March and June (about 2000 1/24 h).",Seasonal variations in plasma testosterone and dihydrotestosterone levels and in metabolic clearance rate of testosterone in rams in Algeria. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7401040/),[1] / [24·h],2000,203602,DB00624,Testosterone
,2123133,time to peak,The median time to peak was 1.5 h for both preparations and the elimination rate constants were similar (0.31 for micronized 4-OHA and 0.36 h-1 for formulated 4-OHA).,Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123133/),h,1.5,203603,DB00624,Testosterone
,2123133,elimination rate constants,The median time to peak was 1.5 h for both preparations and the elimination rate constants were similar (0.31 for micronized 4-OHA and 0.36 h-1 for formulated 4-OHA).,Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123133/),1/[h],0.31,203604,DB00624,Testosterone
,2123133,elimination rate constants,The median time to peak was 1.5 h for both preparations and the elimination rate constants were similar (0.31 for micronized 4-OHA and 0.36 h-1 for formulated 4-OHA).,Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123133/),1/[h],0.36,203605,DB00624,Testosterone
,9763410,elimination half-life,The calculated elimination half-life was 51 +/- 6 hr (mean +/- SE) after testosterone enanthate administration.,"Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763410/),h,51,204131,DB00624,Testosterone
,9763410,elimination half-life,"To determine if CYP2C11 expression was responsive to a more periodic pattern of androgen release, ovariectomized rats were injected subcutaneously once or twice daily with unesterified testosterone (elimination half-life was 2.0 +/- 0.3 hr, mean +/- SE).","Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763410/),h,2.0,204132,DB00624,Testosterone
,9563139,peak serum concentration (Cmax),"The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.",Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563139/),[ng] / [ml],20.8,204441,DB00624,Testosterone
,9563139,peak serum concentration (Cmax),"The 3-month depot showed a higher median peak serum concentration (Cmax) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels.",Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563139/),[ng] / [ml],10.7,204442,DB00624,Testosterone
,24678113,Cmax,"Absorption was rapid; mean Cmax was 195.56 (31.12) μgEq/mL, and mean Tmax was 2 hours.","Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678113/),[μgeq] / [ml],195.56,204954,DB00624,Testosterone
,24678113,Tmax,"Absorption was rapid; mean Cmax was 195.56 (31.12) μgEq/mL, and mean Tmax was 2 hours.","Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678113/),h,2,204955,DB00624,Testosterone
,24678113,t1/2α,"Thereafter, a biphasic decay of TR was found: a rapid first phase (t1/2α, 1.33 hours), followed by a slower second elimination phase (t1/2β, 36.07 hours).","Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678113/),h,1.33,204956,DB00624,Testosterone
,24678113,t1/2β,"Thereafter, a biphasic decay of TR was found: a rapid first phase (t1/2α, 1.33 hours), followed by a slower second elimination phase (t1/2β, 36.07 hours).","Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678113/),h,36.07,204957,DB00624,Testosterone
,24678113,peak radioactivity,Mean peak radioactivity in the prostate (562.41 μgEq/g) was reached at 4 hours and decreased slowly thereafter.,"Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678113/),[μgeq] / [g],562.41,204958,DB00624,Testosterone
,24678113,TR,"Mean (SD) TR was similar in feces (33.48% [4.90%]) and urine (28.96% [5.32%]), with total excretion being 62.40% (5.90%) of the administered dose.","Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678113/),%,33.,204959,DB00624,Testosterone
,24678113,TR,"Mean (SD) TR was similar in feces (33.48% [4.90%]) and urine (28.96% [5.32%]), with total excretion being 62.40% (5.90%) of the administered dose.","Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678113/),%,28.96,204960,DB00624,Testosterone
,25074865,C(max),"After multiple doses, mean (± SD) finasteride C(max) and AUC(0-t) corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet.",A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25074865/),[ng] / [ml],0.46,205157,DB00624,Testosterone
,25074865,C(max),"After multiple doses, mean (± SD) finasteride C(max) and AUC(0-t) corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet.",A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25074865/),[ng] / [ml],6.86,205158,DB00624,Testosterone
,25074865,AUC(0-t),"After multiple doses, mean (± SD) finasteride C(max) and AUC(0-t) corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet.",A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25074865/),[ng] / [h·ml],6.64,205159,DB00624,Testosterone
,25074865,AUC(0-t),"After multiple doses, mean (± SD) finasteride C(max) and AUC(0-t) corresponded to 0.46 ± 0.28 ng/mL and 6.64 ± 7.50 ng/mL x h for the topical solution and to 6.86 ± 1.78 ng/mL and 57.93 ± 29.38 ng/mL x h for the tablet.",A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25074865/),[ng] / [h·ml],57.93,205160,DB00624,Testosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],27,207812,DB00624,Testosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],221,207813,DB00624,Testosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],343,207814,DB00624,Testosterone
,1394219,Peak plasma exemestane concentrations,"Peak plasma exemestane concentrations of 27, 221, 343, and 414 ng/ml were reached within 2 h after administration of 50, 200, 400, and 800 mg, respectively.","Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394219/),[ng] / [ml],414,207815,DB00624,Testosterone
,3326845,MCR,The mean MCR in the obese and nonobese groups were similar (571 +/- 29 vs 578 +/- 31 ml/min/m2).,Relationship of body fat distribution to the metabolic clearance of insulin in premenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3326845/),[ml] / [m2·min],571,208256,DB00624,Testosterone
,3326845,MCR,The mean MCR in the obese and nonobese groups were similar (571 +/- 29 vs 578 +/- 31 ml/min/m2).,Relationship of body fat distribution to the metabolic clearance of insulin in premenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3326845/),[ml] / [m2·min],578,208257,DB00624,Testosterone
,30296416,total testosterone concentration,"The primary end point was met since 92.7% of patients achieved an average total testosterone concentration of 300 to 1,100 ng/dl (mean ± SD 553.3 ± 127.29) at week 12.",A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30296416/),ng,"300 to 1,100",214005,DB00624,Testosterone
less,30296416,maximum concentration,"A maximum concentration of less than 1,500 ng/dl was achieved by 91.3% of patients and no patient had a level greater than 1,800 ng/dl at week 12.",A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30296416/),[ng] / [dl],"1,500",214006,DB00624,Testosterone
,30296416,trough concentration,The mean total testosterone trough concentration was 487.2 ± 153.33 ng/dl at week 52.,A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30296416/),[ng] / [dl],487.2,214007,DB00624,Testosterone
,24694337,plasma clearance,"Estradiol treatment, in contrast, reduced VLDL-TG concentration by approximately 30% due to accelerated VLDL-TG plasma clearance (25.1 ± 2.5 vs. 17.4 ± 2.7 mL/min; P < .01).","Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694337/),[ml] / [min],25.1,214776,DB00624,Testosterone
,24694337,plasma clearance,"Estradiol treatment, in contrast, reduced VLDL-TG concentration by approximately 30% due to accelerated VLDL-TG plasma clearance (25.1 ± 2.5 vs. 17.4 ± 2.7 mL/min; P < .01).","Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694337/),[ml] / [min],17.4,214777,DB00624,Testosterone
,31091478,oral bioavailability,"Furthermore, Preliminary pharmacokinetics evaluation also indicated an excellent oral bioavailability of 29.",Synthesis and biological evaluation of methylpyrimidine-fused tricyclic diterpene analogs as novel oral anti-late-onset hypogonadism agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31091478/),,29,215736,DB00624,Testosterone
,1782837,clearance,The uncorrected antipyrine clearance was significantly lower in the immature group (mean +/- SD 22.65 +/- 6.04 ml/min) than in others (mean +/- SD 41.30 +/- 13.26; p less than 0.01).,"Changes in salivary antipyrine pharmacokinetics during adolescence, correlated with age, hormonal levels and Tanner stage. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782837/),[ml] / [min],22.65,216250,DB00624,Testosterone
,1782837,clearance,The uncorrected antipyrine clearance was significantly lower in the immature group (mean +/- SD 22.65 +/- 6.04 ml/min) than in others (mean +/- SD 41.30 +/- 13.26; p less than 0.01).,"Changes in salivary antipyrine pharmacokinetics during adolescence, correlated with age, hormonal levels and Tanner stage. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782837/),[ml] / [min],41.30,216251,DB00624,Testosterone
,1798729,terminal half-life,After i.v. administration the disposition of unchanged 1 was found biphasically with a terminal half-life of 16 h.,[The pharmacokinetics of Oral-Turinabol in humans]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1798729/),h,16,216817,DB00624,Testosterone
,5020435,MCR(,"In eight normal men, the MCR(T) (516+/-108 [SD] liters/m(2)/day) was significantly greater than the MCR(DHT) (391+/-71 [SD] liters/m(2)/day).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],516,219256,DB00624,Testosterone
,5020435,MCR,"In eight normal men, the MCR(T) (516+/-108 [SD] liters/m(2)/day) was significantly greater than the MCR(DHT) (391+/-71 [SD] liters/m(2)/day).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],391,219257,DB00624,Testosterone
,5020435,MCR(T),"In seven females, the MCR(T) (304+/-53 [SD] liters/m(2)/day) was also greater than the MCR(DHT) (209+/-45 [SD] liters/m(2)/day) and both values were less than their respective values in men (P < 0.001).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],304,219258,DB00624,Testosterone
,5020435,MCR(,"In seven females, the MCR(T) (304+/-53 [SD] liters/m(2)/day) was also greater than the MCR(DHT) (209+/-45 [SD] liters/m(2)/day) and both values were less than their respective values in men (P < 0.001).","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],209,219259,DB00624,Testosterone
,5020435,MCR(T),"In five pregnant females the MCR(T) (192+/-36 [SD] liters/m(2)/day), the MCR(DHT) (89+/-30 [SD] liters/m(2)/day) and the conversion of testosterone into dihydrotestosterone (0.72+/-0.15%) (SD) were significantly less than the values found in nonpregnant women.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],192,219260,DB00624,Testosterone
,5020435,MCR(DHT),"In five pregnant females the MCR(T) (192+/-36 [SD] liters/m(2)/day), the MCR(DHT) (89+/-30 [SD] liters/m(2)/day) and the conversion of testosterone into dihydrotestosterone (0.72+/-0.15%) (SD) were significantly less than the values found in nonpregnant women.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[l] / [d·m(2)],89,219261,DB00624,Testosterone
,5020435,production,"In men the production of dihydrotestosterone was 0.39+/-0.1 (SD) mg/day, 50% being derived from the transformation of plasma testosterone.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[mg] / [d],0.39,219262,DB00624,Testosterone
,5020435,production,"In women the production of DHT was 0.05+/-0.028 (SD) mg/day, only 10% coming from testosterone.","Metabolic clearance rate and blood production rate of testosterone and dihydrotestosterone in normal subjects, during pregnancy, and in hyperthyroidism. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5020435/),[mg] / [d],0.05,219263,DB00624,Testosterone
,8846625,terminal elimination half-life (t1/2z),"The terminal elimination half-life (t1/2z) is 4.7 to 7.1 hours; but despite this, slow accumulation occurs with multiple doses.",Clinical pharmacokinetics and pharmacodynamics of finasteride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846625/),h,4.7 to 7.1,220598,DB00624,Testosterone
,18325758,half-life,"Testosterone concentrations rose during the first 9h following patch application, remained relatively sustained until 48 h and then decreased abruptly after patch removal, with a half-life of 1.3h.",Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18325758/),h,1.3,220923,DB00624,Testosterone
,18325758,C av,"C av were 3.39, 4.03 and 4.58 ng/mL and Cmax were 4.33, 5.29 and 6.18 ng/mL according to the doses.",Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18325758/),[ng] / [ml],3.39,220924,DB00624,Testosterone
,18325758,C av,"C av were 3.39, 4.03 and 4.58 ng/mL and Cmax were 4.33, 5.29 and 6.18 ng/mL according to the doses.",Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18325758/),[ng] / [ml],4.03,220925,DB00624,Testosterone
,18325758,C av,"C av were 3.39, 4.03 and 4.58 ng/mL and Cmax were 4.33, 5.29 and 6.18 ng/mL according to the doses.",Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18325758/),[ng] / [ml],4.58,220926,DB00624,Testosterone
,18325758,Cmax,"C av were 3.39, 4.03 and 4.58 ng/mL and Cmax were 4.33, 5.29 and 6.18 ng/mL according to the doses.",Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18325758/),[ng] / [ml],4.33,220927,DB00624,Testosterone
,18325758,Cmax,"C av were 3.39, 4.03 and 4.58 ng/mL and Cmax were 4.33, 5.29 and 6.18 ng/mL according to the doses.",Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18325758/),[ng] / [ml],5.29,220928,DB00624,Testosterone
,18325758,Cmax,"C av were 3.39, 4.03 and 4.58 ng/mL and Cmax were 4.33, 5.29 and 6.18 ng/mL according to the doses.",Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18325758/),[ng] / [ml],6.18,220929,DB00624,Testosterone
,32946574,terminal elimination half-life,The terminal elimination half-life ranged between 9.8 and 12.5 hours independent of dose.,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),h,9.8 and 12.5,221815,DB00624,Testosterone
,32946574,maximal T,Maximal LH reduction was 70 ± 7% (mean ± sd) at 6 hours after 30 mg SJX-653 versus 10 ± 43% for placebo (P = 0.0006); maximal T reduction was of 68 ± 5% at 8 hours after 60 mg SJX-653 versus 18 ± 11% for placebo (P < 0.0001).,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),%,68,221816,DB00624,Testosterone
,32946574,maximal T,Maximal LH reduction was 70 ± 7% (mean ± sd) at 6 hours after 30 mg SJX-653 versus 10 ± 43% for placebo (P = 0.0006); maximal T reduction was of 68 ± 5% at 8 hours after 60 mg SJX-653 versus 18 ± 11% for placebo (P < 0.0001).,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),%,18,221817,DB00624,Testosterone
,32946574,plasma IC50,The plasma IC50 for LH reduction was 33 ng/mL.,Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32946574/),[ng] / [ml],33,221818,DB00624,Testosterone
,12919178,apparent oral clearance,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],3.8,222107,DB00624,Testosterone
,12919178,apparent oral clearance,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],11.0,222108,DB00624,Testosterone
,12919178,Cmax,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],93,222109,DB00624,Testosterone
,12919178,Cmax,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],40,222110,DB00624,Testosterone
,12919178,half-life,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,2.7,222111,DB00624,Testosterone
,12919178,half-life,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,1.5,222112,DB00624,Testosterone
,12919178,oral clearance,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],3.0,222113,DB00624,Testosterone
,12919178,oral clearance,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],5.8,222114,DB00624,Testosterone
,12919178,Cmax,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],108,222115,DB00624,Testosterone
,12919178,Cmax,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],60,222116,DB00624,Testosterone
,12919178,t1/2,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,2.3,222117,DB00624,Testosterone
,12919178,t1/2,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,2.4,222118,DB00624,Testosterone
,8222659,terminal half-life,"Following single dose administration, a mean terminal half-life of 18 h was observed for GEST.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),h,18,222309,DB00624,Testosterone
,8222659,total clearance,The total clearance was 0.9 ml x min-1 x kg-1 and the volume of distribution was 84 l.,Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],0.9,222310,DB00624,Testosterone
,8222659,volume of distribution,The total clearance was 0.9 ml x min-1 x kg-1 and the volume of distribution was 84 l.,Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),l,84,222311,DB00624,Testosterone
,8222659,terminal half-life,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),h,20 to 22,222312,DB00624,Testosterone
,8222659,total,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],0.16,222313,DB00624,Testosterone
,8222659,free clearance,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],27,222314,DB00624,Testosterone
,8222659,volume of distribution,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),l,18,222315,DB00624,Testosterone
,8222659,free fraction,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,1.3,222316,DB00624,Testosterone
,8222659,fractions,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,69.4,222317,DB00624,Testosterone
,8222659,fractions,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,29.3,222318,DB00624,Testosterone
,8222659,free fraction,"At the end of cycle one, the free fraction was only 0.6% and the fractions bound to SHBG and albumin were 81.4% and 18.0%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,0.6,222319,DB00624,Testosterone
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],299.2,222320,DB00624,Testosterone
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],278.1,222321,DB00624,Testosterone
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],216.1,222322,DB00624,Testosterone
,2146284,"drug inhibitory constant, KI","The drug inhibitory constant, KI, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[ng] / [ml],3.0,222325,DB00624,Testosterone
,2146284,"drug inhibitory constant, KI","The drug inhibitory constant, KI, for the estrone synthetic pathway, was 3.0 ng/mL (13.4 nmol/L) and was of similar magnitude as that determined under in vitro conditions.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[nM] / [l],13.4,222326,DB00624,Testosterone
,2146284,KI,The KI for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L).,"The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[ng] / [ml],5.3,222327,DB00624,Testosterone
,2146284,KI,The KI for the estradiol synthetic pathway was 5.3 ng/mL (23.7 nmol/L).,"The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[nM] / [l],23.7,222328,DB00624,Testosterone
,2146284,half-life,"The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),h,10.5,222329,DB00624,Testosterone
,2146284,oral clearance,"The average half-life and oral clearance values were 10.5 h and 621 mL/min, respectively.","The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146284/),[ml] / [min],621,222330,DB00624,Testosterone
,16815963,clearance,"S-4 showed linear pharmacokinetics after both intravenous (i.v.) and oral (p.o.) administrations at pharmacologically relevant doses, with a mean clearance of 4.6 ml/min/kg and a mean half-life of about 200 min.",In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815963/),[ml] / [kg·min],4.6,224359,DB00624,Testosterone
,16815963,half-life,"S-4 showed linear pharmacokinetics after both intravenous (i.v.) and oral (p.o.) administrations at pharmacologically relevant doses, with a mean clearance of 4.6 ml/min/kg and a mean half-life of about 200 min.",In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815963/),min,200,224360,DB00624,Testosterone
,16815963,oral bioavailability,"However, at pharmacologically relevant doses, the oral bioavailability of S-4 was 91%.",In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815963/),%,91,224361,DB00624,Testosterone
,20133964,trough T concentrations,"After the first injection, patients maintained average trough T concentrations in the adult male range (300-1000 ng/dL or 10.4-34.7 nmol/L) before each injection and at multiple time points measured after the third and fourth injections.",Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133964/),[ng] / [dl],300-1000,224741,DB00624,Testosterone
,20133964,trough T concentrations,"After the first injection, patients maintained average trough T concentrations in the adult male range (300-1000 ng/dL or 10.4-34.7 nmol/L) before each injection and at multiple time points measured after the third and fourth injections.",Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20133964/),[nM] / [l],10.4-34.7,224742,DB00624,Testosterone
,11312643,half-life,"The half-life for EB was significantly increased from 8 h in intact rats to 14 h in HX rats, suggesting higher plasma EB concentrations after EB administration to HX rats.",Effect of hypophysectomy and growth hormone replacement on the modulation of p450 expression after treatment with the aromatic hydrocarbon ethylbenzene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312643/),h,8,224869,DB00624,Testosterone
,11312643,half-life,"The half-life for EB was significantly increased from 8 h in intact rats to 14 h in HX rats, suggesting higher plasma EB concentrations after EB administration to HX rats.",Effect of hypophysectomy and growth hormone replacement on the modulation of p450 expression after treatment with the aromatic hydrocarbon ethylbenzene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312643/),h,14,224870,DB00624,Testosterone
,15647410,maximum levels,"At the highest dose (0.3 mg), total and free testosterone increased from baseline (mean +/- SD, 0.6 +/- 0.3 nmol/L, 2.5 +/- 1.0 pmol/L) to maximum levels of 62.6 +/- 20.4 nmol/L (total) and 168.2 +/- 50.2 pmol/L(free), occurring 1 to 2 minutes after dosing.",Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647410/),[nM] / [l],62.6,224982,DB00624,Testosterone
,15647410,maximum levels,"At the highest dose (0.3 mg), total and free testosterone increased from baseline (mean +/- SD, 0.6 +/- 0.3 nmol/L, 2.5 +/- 1.0 pmol/L) to maximum levels of 62.6 +/- 20.4 nmol/L (total) and 168.2 +/- 50.2 pmol/L(free), occurring 1 to 2 minutes after dosing.",Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15647410/),[pM] / [l],168.2,224983,DB00624,Testosterone
,8971134,plasma clearance (CLp,"The rat had the highest plasma clearance (CLp; 41-89 ml/min/kg), and the dog had the lowest CLp (15-26 ml/min/kg), with the monkey exhibiting an intermediate value (36-39 ml/min/kg).",Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971134/),[ml] / [kg·min],41-89,227110,DB00624,Testosterone
,8971134,CLp,"The rat had the highest plasma clearance (CLp; 41-89 ml/min/kg), and the dog had the lowest CLp (15-26 ml/min/kg), with the monkey exhibiting an intermediate value (36-39 ml/min/kg).",Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971134/),[ml] / [kg·min],15-26,227111,DB00624,Testosterone
,8971134,CLp,"The rat had the highest plasma clearance (CLp; 41-89 ml/min/kg), and the dog had the lowest CLp (15-26 ml/min/kg), with the monkey exhibiting an intermediate value (36-39 ml/min/kg).",Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971134/),[ml] / [kg·min],36-39,227112,DB00624,Testosterone
,8971134,CLp,The CLp was 89 ml/min/kg for male rats and 41 ml/min/kg for female rats.,Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971134/),[ml] / [kg·min],89,227113,DB00624,Testosterone
,8971134,CLp,The CLp was 89 ml/min/kg for male rats and 41 ml/min/kg for female rats.,Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971134/),[ml] / [kg·min],41,227114,DB00624,Testosterone
,8971134,CLp,"In contrast to rats, female dogs cleared indinavir more rapidly than male dogs; the CLp was 26 ml/min/kg for female dogs and 15 ml/min/kg for male dogs.",Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971134/),[ml] / [kg·min],26,227115,DB00624,Testosterone
,8971134,CLp,"In contrast to rats, female dogs cleared indinavir more rapidly than male dogs; the CLp was 26 ml/min/kg for female dogs and 15 ml/min/kg for male dogs.",Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971134/),[ml] / [kg·min],15,227116,DB00624,Testosterone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,58,227698,DB00624,Testosterone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,50,227699,DB00624,Testosterone
,29590007,PFS,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),month,9,227700,DB00624,Testosterone
,10372727,area under the curve (AUC) 0-12 h,"The intake of 50 mg DHEA led to an increase in serum DHEAS to mean levels of young adult men, whereas 100 mg DHEA induced supraphysiological concentrations [placebo vs. 50 mg DHEA vs. 100 mg DHEA; area under the curve (AUC) 0-12 h (mean +/- SD) for DHEA, 108 +/- 22 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,108,228141,DB00624,Testosterone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],33,228142,DB00624,Testosterone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],114,228143,DB00624,Testosterone
,10372727,AUC 0-12 h,"349 +/- 72 nmol/L x h; AUC 0-12 h for DHEAS, 33 +/- 9 vs. 114 +/- 19 vs. 164 +/- 36 micromol/L x h].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[μM] / [h·l],164,228144,DB00624,Testosterone
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,510,228145,DB00624,Testosterone
,10372727,AUC 0-12 h,"In contrast, 17beta-estradiol and estrone significantly increased in a dose-dependent manner to concentrations still within the upper normal range for men [placebo vs. 50 mg DHEA vs. 100 mg DHEA; AUC 0-12 h for 17beta-estradiol, 510 +/- 198 vs. 635 +/- 156 vs.",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),,635,228146,DB00624,Testosterone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],1443,228147,DB00624,Testosterone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],2537,228148,DB00624,Testosterone
,10372727,AUC 0-12 h,"700 +/- 209 pmol/L x h (P < 0.0001); AUC 0-12 h for estrone, 1443 +/- 269 vs. 2537 +/- 434 vs. 3254 +/- 671 pmol/L x h (P < 0.0001)].",Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10372727/),[pM] / [h·l],3254,228149,DB00624,Testosterone
,10229906,half-life,The castor oil preparation had a longer half-life than TU in tea seed oil (33.9+/-4.9 vs 20.9+/-6.0 days (mean pm S.E.M.)).,Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10229906/),d,33.9,228837,DB00624,Testosterone
,10229906,half-life,The castor oil preparation had a longer half-life than TU in tea seed oil (33.9+/-4.9 vs 20.9+/-6.0 days (mean pm S.E.M.)).,Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10229906/),d,20.9,228838,DB00624,Testosterone
,12210048,release rate,The release rate of testosterone from optimal WFCs (3/8-in. diameter) per unit surface area was 5.6 microg x cm(2) x mL(-1) x min(-1) and was zero-order.,Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[cm(2·μg] / [min·ml],5.6,230463,DB00624,Testosterone
,12210048,C(max),"Rabbits (n = 3) injected intravenously had C(max) and area under the curve values of 1200 +/- 46 ng/mL, and 48,227 +/- 12,995 ng x min/mL, respectively.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[ng] / [ml],1200,230464,DB00624,Testosterone
,12210048,area under the curve,"Rabbits (n = 3) injected intravenously had C(max) and area under the curve values of 1200 +/- 46 ng/mL, and 48,227 +/- 12,995 ng x min/mL, respectively.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[min·ng] / [ml],"48,227",230465,DB00624,Testosterone
,12210048,C(max),"Rabbits (n = 3) dosed via the buccal pouch had C(max), T(max), and area under the curve values of 127 +/- 13 ng/mL, 200 +/- 35 min, and 24,221 +/- 1543 ng x min/mL.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[ng] / [ml],127,230466,DB00624,Testosterone
,12210048,T(max),"Rabbits (n = 3) dosed via the buccal pouch had C(max), T(max), and area under the curve values of 127 +/- 13 ng/mL, 200 +/- 35 min, and 24,221 +/- 1543 ng x min/mL.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),min,200,230467,DB00624,Testosterone
,12210048,area under the curve,"Rabbits (n = 3) dosed via the buccal pouch had C(max), T(max), and area under the curve values of 127 +/- 13 ng/mL, 200 +/- 35 min, and 24,221 +/- 1543 ng x min/mL.",Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),[min·ng] / [ml],"24,221",230468,DB00624,Testosterone
,12210048,relative bioavailability,The relative bioavailability for rabbits treated with the WFC was 50.2 +/- 3.2% with a coefficient of variation of 6.4%.,Transmucosal delivery of testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite disks. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12210048/),%,50.2,230469,DB00624,Testosterone
,16406989,time to castrate suppression,Mean time to castrate suppression was 21.2 days (median 21).,A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406989/),d,21.2,230642,DB00624,Testosterone
,10902784,bioavailability,"Testosterone bioavailability, expressed as the mean +/- SEM baseline-subtracted area under the total testosterone curve, was significantly greater in healthy women than in HIV-infected women [3323 +/- 566 ng/dL x h (115 +/- 20 nmol/L x h) vs. 1506 +/- 316 ng/dL x h (52 +/- 11 nmol/ L x h); P = 0.016].","Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902784/),[ng] / [dl·h],3323,231345,DB00624,Testosterone
,10902784,bioavailability,"Testosterone bioavailability, expressed as the mean +/- SEM baseline-subtracted area under the total testosterone curve, was significantly greater in healthy women than in HIV-infected women [3323 +/- 566 ng/dL x h (115 +/- 20 nmol/L x h) vs. 1506 +/- 316 ng/dL x h (52 +/- 11 nmol/ L x h); P = 0.016].","Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902784/),[nM] / [h·l],115,231346,DB00624,Testosterone
,10902784,bioavailability,"Testosterone bioavailability, expressed as the mean +/- SEM baseline-subtracted area under the total testosterone curve, was significantly greater in healthy women than in HIV-infected women [3323 +/- 566 ng/dL x h (115 +/- 20 nmol/L x h) vs. 1506 +/- 316 ng/dL x h (52 +/- 11 nmol/ L x h); P = 0.016].","Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902784/),[ng] / [dl·h],1506,231347,DB00624,Testosterone
,10902784,bioavailability,"Testosterone bioavailability, expressed as the mean +/- SEM baseline-subtracted area under the total testosterone curve, was significantly greater in healthy women than in HIV-infected women [3323 +/- 566 ng/dL x h (115 +/- 20 nmol/L x h) vs. 1506 +/- 316 ng/dL x h (52 +/- 11 nmol/ L x h); P = 0.016].","Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902784/),[nM] / [h·l],52,231348,DB00624,Testosterone
,10902784,apparent plasma clearance,"Assuming a daily testosterone delivery rate of 300 microg/day, the apparent plasma clearance was significantly higher in HIV-infected women than in healthy women (2531 +/- 469 vs. 1127 +/- 217 L/day1 P = 0.022), respectively.","Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902784/),[l] / [d],2531,231349,DB00624,Testosterone
,10902784,apparent plasma clearance,"Assuming a daily testosterone delivery rate of 300 microg/day, the apparent plasma clearance was significantly higher in HIV-infected women than in healthy women (2531 +/- 469 vs. 1127 +/- 217 L/day1 P = 0.022), respectively.","Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10902784/),[l] / [d],1127,231350,DB00624,Testosterone
,17644497,flow rate,"Chromatographic separation was carried out on a Shimadzu VP-ODS column (250 mm x 2.0 mm, 5 microm) with a mobile phase of methanol-water (95:5, v/v) at a flow rate of 0.2 ml/min.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),[ml] / [min],0.2,231472,DB00624,Testosterone
,17644497,m/z,The corresponding parent ions were m/z 446 and m/z 345.,Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),,446,231473,DB00624,Testosterone
,17644497,m/z,The corresponding parent ions were m/z 446 and m/z 345.,Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),,345,231474,DB00624,Testosterone
,17644497,extraction-efficiency,"The extraction-efficiency at three concentrations was 100.7, 93.6, and 99.7%.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),%,100.7,231475,DB00624,Testosterone
,17644497,extraction-efficiency,"The extraction-efficiency at three concentrations was 100.7, 93.6, and 99.7%.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),%,93.6,231476,DB00624,Testosterone
,17644497,extraction-efficiency,"The extraction-efficiency at three concentrations was 100.7, 93.6, and 99.7%.",Development and validation of a LC-MS/MS method for the determination of viaminate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17644497/),%,99.7,231477,DB00624,Testosterone
,6933259,half-life (t 1/2),"The mean half-life (t 1/2) of antipyrine in group 3 (15.6 +/- 4.8 hr) was significantly longer than that in group 1 (8.1 +/- 0.9 hr, P < 0.01).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),h,15.6,232250,DB00624,Testosterone
,6933259,half-life (t 1/2),"The mean half-life (t 1/2) of antipyrine in group 3 (15.6 +/- 4.8 hr) was significantly longer than that in group 1 (8.1 +/- 0.9 hr, P < 0.01).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),h,8.1,232251,DB00624,Testosterone
,6933259,metabolic clearance rate (MCR),"Similarly, the mean metabolic clearance rate (MCR) in group 3 (246 +/- 78 ml/hr/kg) was significantly lower than that in group 1 (498 +/- 175 ml/hr/kg, P < 0.02).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),[ml] / [h·kg],246,232252,DB00624,Testosterone
,6933259,metabolic clearance rate (MCR),"Similarly, the mean metabolic clearance rate (MCR) in group 3 (246 +/- 78 ml/hr/kg) was significantly lower than that in group 1 (498 +/- 175 ml/hr/kg, P < 0.02).",Effect of age on antipyrine metabolism in patients with gastric cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6933259/),[ml] / [h·kg],498,232253,DB00624,Testosterone
,1352203,excretion,"Mean excretion of radioactivity equivalents in urine and feces equaled 39.1 +/- 4.7% and 56.8 +/- 5.0% of the dose, respectively.",Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352203/),%,39.1,233368,DB00624,Testosterone
,1352203,excretion,"Mean excretion of radioactivity equivalents in urine and feces equaled 39.1 +/- 4.7% and 56.8 +/- 5.0% of the dose, respectively.",Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352203/),%,56.8,233369,DB00624,Testosterone
,1352203,peak plasma concentrations,"The mean peak plasma concentrations reached for total radioactivity (ng equivalents), finasteride, and omega-hydroxyfinasteride were 596.5 +/- 88.3, 313.8 +/- 99.4, and 73.7 +/- 11.8 ng/ml, respectively, at approximately 2 hr; the mean terminal half-life for drug and metabolite was 5.9 +/- 1.3 and 8.4 +/- 1.7 hr, respectively.",Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352203/),[ng] / [ml],596.5,233370,DB00624,Testosterone
,1352203,peak plasma concentrations,"The mean peak plasma concentrations reached for total radioactivity (ng equivalents), finasteride, and omega-hydroxyfinasteride were 596.5 +/- 88.3, 313.8 +/- 99.4, and 73.7 +/- 11.8 ng/ml, respectively, at approximately 2 hr; the mean terminal half-life for drug and metabolite was 5.9 +/- 1.3 and 8.4 +/- 1.7 hr, respectively.",Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352203/),[ng] / [ml],313.8,233371,DB00624,Testosterone
,1352203,peak plasma concentrations,"The mean peak plasma concentrations reached for total radioactivity (ng equivalents), finasteride, and omega-hydroxyfinasteride were 596.5 +/- 88.3, 313.8 +/- 99.4, and 73.7 +/- 11.8 ng/ml, respectively, at approximately 2 hr; the mean terminal half-life for drug and metabolite was 5.9 +/- 1.3 and 8.4 +/- 1.7 hr, respectively.",Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352203/),[ng] / [ml],73.7,233372,DB00624,Testosterone
,1352203,terminal half-life,"The mean peak plasma concentrations reached for total radioactivity (ng equivalents), finasteride, and omega-hydroxyfinasteride were 596.5 +/- 88.3, 313.8 +/- 99.4, and 73.7 +/- 11.8 ng/ml, respectively, at approximately 2 hr; the mean terminal half-life for drug and metabolite was 5.9 +/- 1.3 and 8.4 +/- 1.7 hr, respectively.",Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352203/),h,5.9,233373,DB00624,Testosterone
,1352203,terminal half-life,"The mean peak plasma concentrations reached for total radioactivity (ng equivalents), finasteride, and omega-hydroxyfinasteride were 596.5 +/- 88.3, 313.8 +/- 99.4, and 73.7 +/- 11.8 ng/ml, respectively, at approximately 2 hr; the mean terminal half-life for drug and metabolite was 5.9 +/- 1.3 and 8.4 +/- 1.7 hr, respectively.",Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352203/),h,8.4,233374,DB00624,Testosterone
,24346850,V max,Streptozotocin-induced diabetes resulted in a remarkable induction of testosterone hydroxylation as the V max for 6β-hydroxytestosterone production in the diabetic rats (77.3 ± 8.6 pM/min/mg) was significantly higher than that in the control animals (45.9 ± 5.9 pM/min/mg).,Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],77.3,234749,DB00624,Testosterone
,24346850,V max,Streptozotocin-induced diabetes resulted in a remarkable induction of testosterone hydroxylation as the V max for 6β-hydroxytestosterone production in the diabetic rats (77.3 ± 8.6 pM/min/mg) was significantly higher than that in the control animals (45.9 ± 5.9 pM/min/mg).,Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],45.9,234750,DB00624,Testosterone
,24346850,V max,"Moreover, SMN-treated animals showed a significant (P < 0.05) reduction of V max (59.4 ± 6.1 pM/min/mg).",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[pM] / [mg·min],59.4,234751,DB00624,Testosterone
,24346850,AUC,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[h·mg] / [ml],6.98,234752,DB00624,Testosterone
,24346850,AUC,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[h·mg] / [ml],4.35,234753,DB00624,Testosterone
,24346850,C max,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[μg] / [ml],0.52,234754,DB00624,Testosterone
,24346850,C max,"Diabetes resulted in a significant reduction of AUC (control 6.98 ± 0.58 vs diabetic rats 4.35 ± 0.24 h mg/ml) and C max values (control 0.52 ± 0.03 vs diabetic group 0.33 ± 0.01 μg/ml), while the SMN-received group showed remarkable recovery of diabetes-reduced values of AUC and C max.",Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24346850/),[μg] / [ml],0.33,234755,DB00624,Testosterone
,15204699,Clearances,3: Clearances ranged between 1.0 and 2.1 ml min(-1) kg(-1) and varied with dose.,"Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15204699/),[ml] / [kg·min],1.0 and 2.1,235068,DB00624,Testosterone
,15204699,volume of distribution,The volume of distribution was approximately 0.448 l kg(-1) in all treatment groups.,"Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15204699/),[l] / [kg],0.448,235069,DB00624,Testosterone
,15204699,half-life,The half-life of S-4 over the dose range tested was between 2.6 and 5.3 h.,"Pharmacokinetics of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulator. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15204699/),h,2.6 and 5.3,235070,DB00624,Testosterone
,9876028,terminal elimination half-life,"Pharmacokinetic analysis showed a terminal elimination half-life of 18.3+/-2.3 and 23.7+/-2.7 days and showed a mean residence time of 21.7+/-1.1 and 23.0+/-0.8 days for the lower and higher doses, respectively.",A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876028/),d,18.3,235473,DB00624,Testosterone
,9876028,terminal elimination half-life,"Pharmacokinetic analysis showed a terminal elimination half-life of 18.3+/-2.3 and 23.7+/-2.7 days and showed a mean residence time of 21.7+/-1.1 and 23.0+/-0.8 days for the lower and higher doses, respectively.",A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876028/),d,23.7,235474,DB00624,Testosterone
,9876028,mean residence time,"Pharmacokinetic analysis showed a terminal elimination half-life of 18.3+/-2.3 and 23.7+/-2.7 days and showed a mean residence time of 21.7+/-1.1 and 23.0+/-0.8 days for the lower and higher doses, respectively.",A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876028/),d,21.7,235475,DB00624,Testosterone
,9876028,mean residence time,"Pharmacokinetic analysis showed a terminal elimination half-life of 18.3+/-2.3 and 23.7+/-2.7 days and showed a mean residence time of 21.7+/-1.1 and 23.0+/-0.8 days for the lower and higher doses, respectively.",A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876028/),d,23.0,235476,DB00624,Testosterone
≥,26502357,time to achieve,Loading doses up to 360 mg on day 1 or 360 mg on day 1 followed by 240 mg on day 2 reduced the time to achieve castrate testosterone levels from ≥ 7 to <3 days.,Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26502357/),d,7,235929,DB00624,Testosterone
<,26502357,time to achieve,Loading doses up to 360 mg on day 1 or 360 mg on day 1 followed by 240 mg on day 2 reduced the time to achieve castrate testosterone levels from ≥ 7 to <3 days.,Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26502357/),d,3,235930,DB00624,Testosterone
>,26502357,trough TAK-385 concentrations,TAK-385 doses ≥ 80 mg/d achieved sustained medical castration and trough TAK-385 concentrations >4 ng/mL.,Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26502357/),[ng] / [ml],4,235931,DB00624,Testosterone
,18079079,concentration,"In the high progesterone group (n=11), the mean concentration was 11.1+/-3.5ng/ml and in the low progesterone group (n=50) the mean was 0.6+/-0.3ng/ml.",The influence of sex hormones on the elimination kinetics of ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[ng] / [ml],11.1,236249,DB00624,Testosterone
,18079079,concentration,"In the high progesterone group (n=11), the mean concentration was 11.1+/-3.5ng/ml and in the low progesterone group (n=50) the mean was 0.6+/-0.3ng/ml.",The influence of sex hormones on the elimination kinetics of ethanol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[ng] / [ml],0.6,236250,DB00624,Testosterone
,18079079,hourly elimination rate (beta60),The mean hourly elimination rate (beta60) was 0.1677+/-0.0311g/kg/h in men.,The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.1677,236251,DB00624,Testosterone
,18079079,hourly elimination rate,"In women, the mean hourly elimination rate was 0.2044+/-0.0414g/kg/h in the high progesterone group and 0.1850+/-0.0276g/kg/h in the low progesterone group (p<0.05).",The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.2044,236252,DB00624,Testosterone
,18079079,hourly elimination rate,"In women, the mean hourly elimination rate was 0.2044+/-0.0414g/kg/h in the high progesterone group and 0.1850+/-0.0276g/kg/h in the low progesterone group (p<0.05).",The influence of sex hormones on the elimination kinetics of ethanol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18079079/),[g] / [h·kg],0.1850,236253,DB00624,Testosterone
,3279409,minimal basal level,"The plasma concentration of Flu-OH measured at months 6, 12, and 18 of treatment shows a minimal basal level of 3.4 microM with a maximal increase at 6.8 to 8.5 microM at 2 to 4 hours.",Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3279409/),μM,3.4,236332,DB00624,Testosterone
,3279409,maximal increase,"The plasma concentration of Flu-OH measured at months 6, 12, and 18 of treatment shows a minimal basal level of 3.4 microM with a maximal increase at 6.8 to 8.5 microM at 2 to 4 hours.",Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3279409/),μM,6.8,236333,DB00624,Testosterone
,12788872,concentrations,"Mean average concentrations at d 90 T were 13.8, 17.1, 11.9, and 7.3 nmol/liter for 50 mg/d AA2500, 100 mg/d AA2500, testosterone patch, and placebo, respectively.",AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12788872/),[nM] / [l],13.8,236493,DB00624,Testosterone
,12788872,concentrations,"Mean average concentrations at d 90 T were 13.8, 17.1, 11.9, and 7.3 nmol/liter for 50 mg/d AA2500, 100 mg/d AA2500, testosterone patch, and placebo, respectively.",AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12788872/),[nM] / [l],17.1,236494,DB00624,Testosterone
,12788872,concentrations,"Mean average concentrations at d 90 T were 13.8, 17.1, 11.9, and 7.3 nmol/liter for 50 mg/d AA2500, 100 mg/d AA2500, testosterone patch, and placebo, respectively.",AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12788872/),[nM] / [l],11.9,236495,DB00624,Testosterone
,12788872,concentrations,"Mean average concentrations at d 90 T were 13.8, 17.1, 11.9, and 7.3 nmol/liter for 50 mg/d AA2500, 100 mg/d AA2500, testosterone patch, and placebo, respectively.",AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12788872/),[nM] / [l],7.3,236496,DB00624,Testosterone
,2570847,release rate,The release of the drug in rats after a single subcutaneous injection exhibited pseudo-zero-order kinetics for one month in doses ranging from 0.0135 to 1.35 mg/rat; the release rate at a dose of 1.35 mg/rat was 2.8% of dose/day; after intramuscular injection the response was similar.,"Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2570847/),%,2.8,236929,DB00624,Testosterone
,2333732,areas under,The areas under the testosterone- and dihydrotestosterone-curves did not differ significantly 2290 +/- 340 (dihydrotestosterone-enanthate) vs 2920 +/- 485 (testosterone-enanthate) suggesting that similar amounts of steroid had been released from the respective ester preparation.,Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),,2290,237195,DB00624,Testosterone
,2333732,areas under,The areas under the testosterone- and dihydrotestosterone-curves did not differ significantly 2290 +/- 340 (dihydrotestosterone-enanthate) vs 2920 +/- 485 (testosterone-enanthate) suggesting that similar amounts of steroid had been released from the respective ester preparation.,Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),,2920,237196,DB00624,Testosterone
,2333732,half-life,"Mean half-life estimates of the terminal elimination phase were 4 and 7 days for testosterone-enanthate and dihydrotestosterone-enanthate, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,4,237197,DB00624,Testosterone
,2333732,half-life,"Mean half-life estimates of the terminal elimination phase were 4 and 7 days for testosterone-enanthate and dihydrotestosterone-enanthate, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,7,237198,DB00624,Testosterone
,2333732,half-life,"Mean half-life estimates for testosterone-enanthate and dihydrotestosterone were 5 and 7 days, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,5,237199,DB00624,Testosterone
,2333732,half-life,"Mean half-life estimates for testosterone-enanthate and dihydrotestosterone were 5 and 7 days, respectively.",Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333732/),d,7,237200,DB00624,Testosterone
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],2.5,237316,DB00624,Testosterone
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],3,237317,DB00624,Testosterone
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],3.6,237318,DB00624,Testosterone
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],12,237319,DB00624,Testosterone
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],3.2,237320,DB00624,Testosterone
,32030892,EC50,"In reporter assays, the EC50 values of SARM-2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[nM] / [l],11,237321,DB00624,Testosterone
,32030892,maximal plasma concentration,"A single oral administration (10 mg/kg SARM-2f) produced a maximal plasma concentration of 3011 ng/mL, with an area under the 24 hours concentration-time curve of 8152 ng·h/mL in monkeys.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[ng] / [ml],3011,237322,DB00624,Testosterone
,32030892,area under the 24 hours concentration-time curve,"A single oral administration (10 mg/kg SARM-2f) produced a maximal plasma concentration of 3011 ng/mL, with an area under the 24 hours concentration-time curve of 8152 ng·h/mL in monkeys.","A selective androgen receptor modulator SARM-2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32030892/),[h·ng] / [ml],8152,237323,DB00624,Testosterone
,24771350,half-life (t1/2),"PK demonstrated a half-life (t1/2) ranging from 16 to 35 h, rapid absorption and dose proportionality.","Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771350/),h,16 to 35,237567,DB00624,Testosterone
,26004317,Cmax,"Pharmacokinetic data confirmed that serum free testosterone concentrations were raised significantly above baseline levels, by assessment of maximum hormone concentration (Cmax) and area under the curve (AUC) parameters: free testosterone Cmax was significantly raised from a mean of 2.64pg/mL to 3.91pg/mL (p<0.05), and 24hour free testosterone AUC was significantly raised from a mean of 35.0pg-hr/mL to 53.89pg-hr/mL.",Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004317/),[pg] / [ml],2.64,237747,DB00624,Testosterone
,26004317,Cmax,"Pharmacokinetic data confirmed that serum free testosterone concentrations were raised significantly above baseline levels, by assessment of maximum hormone concentration (Cmax) and area under the curve (AUC) parameters: free testosterone Cmax was significantly raised from a mean of 2.64pg/mL to 3.91pg/mL (p<0.05), and 24hour free testosterone AUC was significantly raised from a mean of 35.0pg-hr/mL to 53.89pg-hr/mL.",Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004317/),[pg] / [ml],3.91,237748,DB00624,Testosterone
,26004317,AUC,"Pharmacokinetic data confirmed that serum free testosterone concentrations were raised significantly above baseline levels, by assessment of maximum hormone concentration (Cmax) and area under the curve (AUC) parameters: free testosterone Cmax was significantly raised from a mean of 2.64pg/mL to 3.91pg/mL (p<0.05), and 24hour free testosterone AUC was significantly raised from a mean of 35.0pg-hr/mL to 53.89pg-hr/mL.",Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004317/),[pg-hr] / [ml],35.0,237749,DB00624,Testosterone
,26004317,AUC,"Pharmacokinetic data confirmed that serum free testosterone concentrations were raised significantly above baseline levels, by assessment of maximum hormone concentration (Cmax) and area under the curve (AUC) parameters: free testosterone Cmax was significantly raised from a mean of 2.64pg/mL to 3.91pg/mL (p<0.05), and 24hour free testosterone AUC was significantly raised from a mean of 35.0pg-hr/mL to 53.89pg-hr/mL.",Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004317/),[pg-hr] / [ml],53.89,237750,DB00624,Testosterone
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00624,Testosterone
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00624,Testosterone
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00624,Testosterone
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00624,Testosterone
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00624,Testosterone
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00624,Testosterone
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00624,Testosterone
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00624,Testosterone
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00624,Testosterone
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00624,Testosterone
,18513900,maximal plasma concentrations,"The maximal plasma concentrations of paclitaxel after an oral dose were 1.77+/-0.17 and 3.39+/-0.49microg/ml for Cremophor/ethanol and TPGS 400/ethanol formulations, respectively, with a similar time at 40-47min to reach the maximal plasma concentrations.",Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),[μg] / [ml],1.77,238991,DB00624,Testosterone
,18513900,maximal plasma concentrations,"The maximal plasma concentrations of paclitaxel after an oral dose were 1.77+/-0.17 and 3.39+/-0.49microg/ml for Cremophor/ethanol and TPGS 400/ethanol formulations, respectively, with a similar time at 40-47min to reach the maximal plasma concentrations.",Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),[μg] / [ml],3.39,238992,DB00624,Testosterone
,18513900,oral bioavailability,The oral bioavailability of paclitaxel in TPGS 400/ethanol (7.8%) was 3-fold higher than that in Cremophor/ethanol (2.5%).,Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),%,7.8,238993,DB00624,Testosterone
,18513900,oral bioavailability,The oral bioavailability of paclitaxel in TPGS 400/ethanol (7.8%) was 3-fold higher than that in Cremophor/ethanol (2.5%).,Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18513900/),%,2.5,238994,DB00624,Testosterone
,19342702,maximal concentrations,Men showing the most rapid and consistent declines in LH and FSH levels received a slightly higher dose per body weight of TU (13.1 +/- 0.6 vs 11.3 +/- 0.6 mg/kg; P = NS) and reached higher maximal concentrations of total T (40 +/- 4.8 vs 18.4 +/- 2.4 nmol/L; P < .001) and free T as well as estradiol.,Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342702/),[nM] / [l],40,239537,DB00624,Testosterone
,19342702,maximal concentrations,Men showing the most rapid and consistent declines in LH and FSH levels received a slightly higher dose per body weight of TU (13.1 +/- 0.6 vs 11.3 +/- 0.6 mg/kg; P = NS) and reached higher maximal concentrations of total T (40 +/- 4.8 vs 18.4 +/- 2.4 nmol/L; P < .001) and free T as well as estradiol.,Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342702/),[nM] / [l],18.4,239538,DB00624,Testosterone
>,15336360,recovery,The mean recovery was >86.7%.,High-performance liquid chromatographic analysis of a selective cyclooxygenase-1 inhibitor SC-560 in rat serum: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15336360/),%,86.7,239840,DB00624,Testosterone
,15336360,limit of detection,The limit of detection was 10 ng/ml for a 0.1 ml sample.,High-performance liquid chromatographic analysis of a selective cyclooxygenase-1 inhibitor SC-560 in rat serum: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15336360/),[ng] / [ml],10,239841,DB00624,Testosterone
,22019954,bioavailable,3-39 pmol/L) and bioavailable (0.06-1.35 vs. 0.06-0.81 nmol/L) testosterone.,Reference ranges for total and calculated free and bioavailable testosterone in a young healthy women population with normal menstrual cycles or using oral contraception. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019954/),[nM] / [l],0.06-1.35,240247,DB00624,Testosterone
,22019954,bioavailable,3-39 pmol/L) and bioavailable (0.06-1.35 vs. 0.06-0.81 nmol/L) testosterone.,Reference ranges for total and calculated free and bioavailable testosterone in a young healthy women population with normal menstrual cycles or using oral contraception. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22019954/),[nM] / [l],0.06-0.81,240248,DB00624,Testosterone
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.53,241459,DB00624,Testosterone
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.59,241460,DB00624,Testosterone
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.25,241461,DB00624,Testosterone
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.29,241462,DB00624,Testosterone
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,8.8,241463,DB00624,Testosterone
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,3.9,241464,DB00624,Testosterone
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.62,241465,DB00624,Testosterone
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,13,241466,DB00624,Testosterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[g%] / [h],0.0194,243003,DB00624,Testosterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[mg] / [h·l],0.0975,243004,DB00624,Testosterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[g%] / [h],0.0193,243005,DB00624,Testosterone
,20570083,hourly elimination rate ss(60),"In 10 of the volunteers, who had a normal increase in progesterone in the luteal phase, the average hourly elimination rate ss(60) in the follicular phase amounted to 0.0194+/-0.0020g%/h (BAC) and 0.0975+/-0.0068mg/L/h (BrAC), and in the luteal phase to 0.0193+/-0.0031g%/h (BAC) and 0.1026+/-0.0101mg/L/h (BrAC).",The influence of the luteal and follicular phases on major pharmacokinetic parameters of blood and breath alcohol kinetics in women. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570083/),[mg] / [h·l],0.1026,243006,DB00624,Testosterone
,18930255,maximum serum testosterone,"Following the week 14 injection mean +/- SD average serum testosterone was 494.9 +/- 141.46 ng/dl during the 70-day dosing interval and mean +/- SD maximum serum testosterone was 890.6 +/- 345.11 ng/dl with a mean concentration within the young healthy adult male range (300 to 1,000 ng/dl) in 94% of patients and a mean maximum concentration of below 1,500 ng/dl in 92%.",Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18930255/),[ng] / [dl],890.6,243311,DB00624,Testosterone
below,18930255,maximum concentration,"Following the week 14 injection mean +/- SD average serum testosterone was 494.9 +/- 141.46 ng/dl during the 70-day dosing interval and mean +/- SD maximum serum testosterone was 890.6 +/- 345.11 ng/dl with a mean concentration within the young healthy adult male range (300 to 1,000 ng/dl) in 94% of patients and a mean maximum concentration of below 1,500 ng/dl in 92%.",Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18930255/),[ng] / [dl],"1,500",243312,DB00624,Testosterone
,25038408,flow rate,"The conditions for the separation of these two compounds were achieved on a ZORBAX Eclipse Plus C18 column (Agilent, 2.1 × 50 mm, 1.8 μm, Stockport, UK) in a single chromatographic run at a flow rate of 400 μL/min.",An LC-MS/MS method for the simultaneous determination of goserelin and testosterone in rat plasma for pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25038408/),[μl] / [min],400,244629,DB00624,Testosterone
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],37,244832,DB00624,Testosterone
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],25,244833,DB00624,Testosterone
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],19,244834,DB00624,Testosterone
,17691921,peak plasma concentration,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[nM] / [l],18,244835,DB00624,Testosterone
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],118,244836,DB00624,Testosterone
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],84,244837,DB00624,Testosterone
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],64,244838,DB00624,Testosterone
,17691921,area under the plasma concentration-time curve,"The geometric mean and 90% confidence intervals of pharmacokinetic parameters for human oral felodipine with G, P, H and W were respectively as follows: peak plasma concentration (nmol.L(-1)), 37 (32-44), 25 (21-29), 19 (16-22) and 18 (15-21); area under the plasma concentration-time curve (nmol.h.L(-1)), 118 (103-136), 84 (73-97), 64 (56-74) and 59 (51-68).",Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17691921/),[h·nM] / [l],59,244839,DB00624,Testosterone
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,83.2,244934,DB00624,Testosterone
,30048731,recoveries,The intra and inter-assay accuracy and precision of the method were within ± 14.9% and the recoveries ranged from 83.2% to 106.1%.,"Effects of Baoyuan decoction, a traditional Chinese medicine formula, on the activities and mRNA expression of seven CYP isozymes in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30048731/),%,106.1,244935,DB00624,Testosterone
,8943796,metabolic clearance rate (MCR),"DHEA is cleared rapidly from the blood, with a metabolic clearance rate (MCR) in the range of 2000 I/day, but the clearance of DHEAS is much slower and its MCR is in the range of 131/day.",Dehydroepiandrosterone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943796/),[i] / [d],2000,245145,DB00624,Testosterone
,8943796,MCR,"DHEA is cleared rapidly from the blood, with a metabolic clearance rate (MCR) in the range of 2000 I/day, but the clearance of DHEAS is much slower and its MCR is in the range of 131/day.",Dehydroepiandrosterone metabolism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8943796/),1/[d],131,245146,DB00624,Testosterone
,7666079,duration of response,The median duration of response was 12 months.,Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666079/),month,12,246781,DB00624,Testosterone
,14764781,velocity,"LLL velocity in the treatment blocks (median, 0.64 mm/wk; range, 0.1-1.08 mm/wk) was significantly higher than during the run-in and washout periods (median, 0.48 mm/wk; range, -0.06 to 0.92 mm/wk) (P < 0.001).","Transdermal testosterone application: pharmacokinetics and effects on pubertal status, short-term growth, and bone turnover. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764781/),[mm] / [wk],0.64,247408,DB00624,Testosterone
,14764781,velocity,"LLL velocity in the treatment blocks (median, 0.64 mm/wk; range, 0.1-1.08 mm/wk) was significantly higher than during the run-in and washout periods (median, 0.48 mm/wk; range, -0.06 to 0.92 mm/wk) (P < 0.001).","Transdermal testosterone application: pharmacokinetics and effects on pubertal status, short-term growth, and bone turnover. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14764781/),[mm] / [wk],0.48,247409,DB00624,Testosterone
,20082577,inactivation constant (K(I)),"For human CYP3A, the inactivation constant (K(I)) is 12 microM, and the maximum inactivation rate (k(inact)) is 0.037 min(-1).",Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20082577/),μM,12,249994,DB00624,Testosterone
,20082577,maximum inactivation rate (k(inact)),"For human CYP3A, the inactivation constant (K(I)) is 12 microM, and the maximum inactivation rate (k(inact)) is 0.037 min(-1).",Mechanism-based inhibition of human cytochrome P4503A4 by domperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20082577/),1/[min],0.037,249995,DB00624,Testosterone
,31805693,globule size,"The average globule size for the optimized TDL-PSO SNEDDS was 204.8 ± 18.76 nm, with a zeta-potential value of 7.86 ± 1.21 mV.",Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31805693/),nm,204.8,250003,DB00624,Testosterone
,31805693,zeta-potential,"The average globule size for the optimized TDL-PSO SNEDDS was 204.8 ± 18.76 nm, with a zeta-potential value of 7.86 ± 1.21 mV.",Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31805693/),mv,7.86,250004,DB00624,Testosterone
,22691297,K(D),"The typical population values of K(D), the receptor equilibrium dissociation constant of triptorelin, and C(TRP_min) to keep 95% of the patients castrated were 0.931 and 0.0609 ng/ml, respectively.",Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691297/),[ng] / [ml],0.931,250493,DB00624,Testosterone
,22691297,receptor equilibrium dissociation constant,"The typical population values of K(D), the receptor equilibrium dissociation constant of triptorelin, and C(TRP_min) to keep 95% of the patients castrated were 0.931 and 0.0609 ng/ml, respectively.",Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691297/),[ng] / [ml],0.0609,250494,DB00624,Testosterone
,22691297,C(TRP_min),"The typical population values of K(D), the receptor equilibrium dissociation constant of triptorelin, and C(TRP_min) to keep 95% of the patients castrated were 0.931 and 0.0609 ng/ml, respectively.",Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691297/),[ng] / [ml],0.0609,250495,DB00624,Testosterone
,3770015,metabolic clearance rate,Due to the high metabolic clearance rate of 24.5 ml/min/kg absolute systemic availability of free testosterone was calculated to 3.56 +/- 2.45%.,Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770015/),[ml] / [kg·min],24.5,250610,DB00624,Testosterone
,3770015,absolute systemic availability,Due to the high metabolic clearance rate of 24.5 ml/min/kg absolute systemic availability of free testosterone was calculated to 3.56 +/- 2.45%.,Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770015/),%,3.56,250611,DB00624,Testosterone
,3770015,absolute,Oral administration of testosterone undecanoate leads only to an absolute testosterone bioavailability of 6.83 +/- 3.32%.,Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770015/),%,6.83,250612,DB00624,Testosterone
,8474030,rates,"In addition, microsomes from rats administered high-dose AG catalyzed increased rates of androst-4-ene-3,17-dione 16 beta-hydroxylation (from 0.72 +/- 0.10 nmol/min/mg in control to 3.51 +/- 0.47 nmol/min/mg protein).",Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474030/),[nM] / [mg·min],0.72,251406,DB00624,Testosterone
,8474030,rates,"In addition, microsomes from rats administered high-dose AG catalyzed increased rates of androst-4-ene-3,17-dione 16 beta-hydroxylation (from 0.72 +/- 0.10 nmol/min/mg in control to 3.51 +/- 0.47 nmol/min/mg protein).",Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8474030/),[nM] / [mg·min],3.51,251407,DB00624,Testosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h],799,252501,DB00624,Testosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h·m·sq],470,252502,DB00624,Testosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h],751,252503,DB00624,Testosterone
,6290048,metabolic clearance rate,The metabolic clearance rate for five subjects was 799 +/- 89 liters/24 hr (470 +/- 47 liters/24 hr/sq m) before and 751 +/- 93 liters/24 hr (444 +/- 57 liters/24 hr/sq m) during therapy.,Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6290048/),[l] / [24·h·m·sq],444,252504,DB00624,Testosterone
,34379604,AUC ratio,"In dogs, 40 mg NT was well absorbed under fasted conditions whereas 40 mg TU required a high-fat meal: for NT, the mean fed/fasted AUC ratio was 1.63 and for TU 7.05.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),,1.63,254097,DB00624,Testosterone
,34379604,AUC ratio,"In dogs, 40 mg NT was well absorbed under fasted conditions whereas 40 mg TU required a high-fat meal: for NT, the mean fed/fasted AUC ratio was 1.63 and for TU 7.05.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),,7.05,254098,DB00624,Testosterone
,34379604,Cmax,"In hypogonadal men, fed and fasted NT had similar pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0-10 h 87 vs 88.6 h nmol/L. NT (fed state) showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0-10 h to TU 80 mg: 87 vs 64.8 h nmol/L.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),[nM] / [l],26.5,254099,DB00624,Testosterone
,34379604,Cmax,"In hypogonadal men, fed and fasted NT had similar pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0-10 h 87 vs 88.6 h nmol/L. NT (fed state) showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0-10 h to TU 80 mg: 87 vs 64.8 h nmol/L.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),[nM] / [l],30.4,254100,DB00624,Testosterone
,34379604,Cmax,"In hypogonadal men, fed and fasted NT had similar pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0-10 h 87 vs 88.6 h nmol/L. NT (fed state) showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0-10 h to TU 80 mg: 87 vs 64.8 h nmol/L.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),[ng] / [dl],769,254101,DB00624,Testosterone
,34379604,Cmax,"In hypogonadal men, fed and fasted NT had similar pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0-10 h 87 vs 88.6 h nmol/L. NT (fed state) showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0-10 h to TU 80 mg: 87 vs 64.8 h nmol/L.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),[ng] / [dl],882,254102,DB00624,Testosterone
,34379604,AUC0-10 h,"In hypogonadal men, fed and fasted NT had similar pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0-10 h 87 vs 88.6 h nmol/L. NT (fed state) showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0-10 h to TU 80 mg: 87 vs 64.8 h nmol/L.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),[h·nM] / [l],87,254103,DB00624,Testosterone
,34379604,AUC0-10 h,"In hypogonadal men, fed and fasted NT had similar pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0-10 h 87 vs 88.6 h nmol/L. NT (fed state) showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0-10 h to TU 80 mg: 87 vs 64.8 h nmol/L.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),[h·nM] / [l],88.6,254104,DB00624,Testosterone
,34379604,AUC0-10 h,"In hypogonadal men, fed and fasted NT had similar pharmacokinetics: Cmax mean 26.5 vs 30.4 nmol/L (769 vs 882 ng/dL), AUC0-10 h 87 vs 88.6 h nmol/L. NT (fed state) showed a testosterone AUC increase of 45% between 120 and 200 mg, and NT 200 mg gave a similar mean AUC0-10 h to TU 80 mg: 87 vs 64.8 h nmol/L.",An oral lipidic native testosterone formulation that is absorbed independent of food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),[h·nM] / [l],64.8,254105,DB00624,Testosterone
,34379604,AUC0-10 h ratio,The DHT: testosterone AUC0-10 h ratio was more physiological for NT than TU being 0.19 vs 0.36.,An oral lipidic native testosterone formulation that is absorbed independent of food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),,0.19,254106,DB00624,Testosterone
,34379604,AUC0-10 h ratio,The DHT: testosterone AUC0-10 h ratio was more physiological for NT than TU being 0.19 vs 0.36.,An oral lipidic native testosterone formulation that is absorbed independent of food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34379604/),,0.36,254107,DB00624,Testosterone
,31298497,area under curve from time zero to 24 hours (AUC0-24 ),"The geometric mean (%CV) of area under curve from time zero to 24 hours (AUC0-24 ), maximum concentration (Cmax ), and C24 of E2 at weeks 3 and 5 were 775.13 (26.2) pg h/mL, 51.47 (26.9) pg/mL, and 15.15 (42.0) pg/mL; and 782.84 (39.6), 55.76 (32.9), and 14.32 (67.4), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),[h·pg] / [ml],775.13,254657,DB00624,Testosterone
,31298497,maximum concentration (Cmax ),"The geometric mean (%CV) of area under curve from time zero to 24 hours (AUC0-24 ), maximum concentration (Cmax ), and C24 of E2 at weeks 3 and 5 were 775.13 (26.2) pg h/mL, 51.47 (26.9) pg/mL, and 15.15 (42.0) pg/mL; and 782.84 (39.6), 55.76 (32.9), and 14.32 (67.4), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),[pg] / [ml],51.47,254658,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of area under curve from time zero to 24 hours (AUC0-24 ), maximum concentration (Cmax ), and C24 of E2 at weeks 3 and 5 were 775.13 (26.2) pg h/mL, 51.47 (26.9) pg/mL, and 15.15 (42.0) pg/mL; and 782.84 (39.6), 55.76 (32.9), and 14.32 (67.4), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),[pg] / [ml],15.15,254659,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of area under curve from time zero to 24 hours (AUC0-24 ), maximum concentration (Cmax ), and C24 of E2 at weeks 3 and 5 were 775.13 (26.2) pg h/mL, 51.47 (26.9) pg/mL, and 15.15 (42.0) pg/mL; and 782.84 (39.6), 55.76 (32.9), and 14.32 (67.4), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),,782.84,254660,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of area under curve from time zero to 24 hours (AUC0-24 ), maximum concentration (Cmax ), and C24 of E2 at weeks 3 and 5 were 775.13 (26.2) pg h/mL, 51.47 (26.9) pg/mL, and 15.15 (42.0) pg/mL; and 782.84 (39.6), 55.76 (32.9), and 14.32 (67.4), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),,55.76,254661,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of area under curve from time zero to 24 hours (AUC0-24 ), maximum concentration (Cmax ), and C24 of E2 at weeks 3 and 5 were 775.13 (26.2) pg h/mL, 51.47 (26.9) pg/mL, and 15.15 (42.0) pg/mL; and 782.84 (39.6), 55.76 (32.9), and 14.32 (67.4), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),,14.32,254662,DB00624,Testosterone
,31298497,AUC0-24,"The geometric mean (%CV) of TFV AUC0-24 , Cmax , and C24 at weeks 5 and 8 were 2242.1 (26.5) ng h/mL, 353.9 (34.0) ng/mL, and 40.9 (31.4) ng/mL; and 2530.2 (31.3), 311.4 (30.0), and 49.8 (29.6), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),[h·ng] / [ml],2242.1,254663,DB00624,Testosterone
,31298497,Cmax,"The geometric mean (%CV) of TFV AUC0-24 , Cmax , and C24 at weeks 5 and 8 were 2242.1 (26.5) ng h/mL, 353.9 (34.0) ng/mL, and 40.9 (31.4) ng/mL; and 2530.2 (31.3), 311.4 (30.0), and 49.8 (29.6), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),[ng] / [ml],353.9,254664,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of TFV AUC0-24 , Cmax , and C24 at weeks 5 and 8 were 2242.1 (26.5) ng h/mL, 353.9 (34.0) ng/mL, and 40.9 (31.4) ng/mL; and 2530.2 (31.3), 311.4 (30.0), and 49.8 (29.6), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),[ng] / [ml],40.9,254665,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of TFV AUC0-24 , Cmax , and C24 at weeks 5 and 8 were 2242.1 (26.5) ng h/mL, 353.9 (34.0) ng/mL, and 40.9 (31.4) ng/mL; and 2530.2 (31.3), 311.4 (30.0), and 49.8 (29.6), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),,2530.2,254666,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of TFV AUC0-24 , Cmax , and C24 at weeks 5 and 8 were 2242.1 (26.5) ng h/mL, 353.9 (34.0) ng/mL, and 40.9 (31.4) ng/mL; and 2530.2 (31.3), 311.4 (30.0), and 49.8 (29.6), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),,311.4,254667,DB00624,Testosterone
,31298497,C24,"The geometric mean (%CV) of TFV AUC0-24 , Cmax , and C24 at weeks 5 and 8 were 2242.1 (26.5) ng h/mL, 353.9 (34.0) ng/mL, and 40.9 (31.4) ng/mL; and 2530.2 (31.3), 311.4 (30.0), and 49.8 (29.6), respectively.",Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298497/),,49.8,254668,DB00624,Testosterone
,12860027,LOQs,The LOQs for T and d(3)T were 0.5 ng/ml and 0.05 ng/ml.,Liquid chromatography-tandem mass spectrometry assay for human serum testosterone and trideuterated testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860027/),[ng] / [ml],0.5,256276,DB00624,Testosterone
,12860027,LOQs,The LOQs for T and d(3)T were 0.5 ng/ml and 0.05 ng/ml.,Liquid chromatography-tandem mass spectrometry assay for human serum testosterone and trideuterated testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860027/),[ng] / [ml],0.05,256277,DB00624,Testosterone
,12860027,recoveries,The recoveries for T and d(3)T were 91.5 and 96.4%.,Liquid chromatography-tandem mass spectrometry assay for human serum testosterone and trideuterated testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860027/),%,91.5,256278,DB00624,Testosterone
,12860027,recoveries,The recoveries for T and d(3)T were 91.5 and 96.4%.,Liquid chromatography-tandem mass spectrometry assay for human serum testosterone and trideuterated testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860027/),%,96.4,256279,DB00624,Testosterone
,12860027,concentrations,The concentrations of T in the 38 healthy subjects ranged from 2.5 to 14.0 ng/ml (mean 6.2 ng/ml).,Liquid chromatography-tandem mass spectrometry assay for human serum testosterone and trideuterated testosterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860027/),[ng] / [ml],6.2,256280,DB00624,Testosterone
,31384715,time of peak testosterone concentration,The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after SC vs IM injection (8.0 vs 3.3 days) but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/mL) or mean resident time (183 vs 110 days).,Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384715/),d,8.0,258165,DB00624,Testosterone
,31384715,time of peak testosterone concentration,The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after SC vs IM injection (8.0 vs 3.3 days) but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/mL) or mean resident time (183 vs 110 days).,Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384715/),d,3.3,258166,DB00624,Testosterone
,31384715,peak testosterone concentration,The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after SC vs IM injection (8.0 vs 3.3 days) but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/mL) or mean resident time (183 vs 110 days).,Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384715/),[ng] / [ml],8.4,258167,DB00624,Testosterone
,31384715,peak testosterone concentration,The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after SC vs IM injection (8.0 vs 3.3 days) but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/mL) or mean resident time (183 vs 110 days).,Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384715/),[ng] / [ml],9.6,258168,DB00624,Testosterone
,31384715,resident time,The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after SC vs IM injection (8.0 vs 3.3 days) but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/mL) or mean resident time (183 vs 110 days).,Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384715/),d,183,258169,DB00624,Testosterone
,31384715,resident time,The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after SC vs IM injection (8.0 vs 3.3 days) but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/mL) or mean resident time (183 vs 110 days).,Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384715/),d,110,258170,DB00624,Testosterone
,6491955,bioavailability,"The bioavailability of the nasally administered drug was calculated to be 99% and 90% at the 25-micrograms and 50-micrograms doses, respectively.",Nasal absorption of testosterone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491955/),%,99,259817,DB00624,Testosterone
,6491955,bioavailability,"The bioavailability of the nasally administered drug was calculated to be 99% and 90% at the 25-micrograms and 50-micrograms doses, respectively.",Nasal absorption of testosterone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491955/),%,90,259818,DB00624,Testosterone
,6491955,bioavailability,The intraduodenal bioavailability was only 1% at the dose studied.,Nasal absorption of testosterone in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491955/),%,1,259819,DB00624,Testosterone
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260312,DB00624,Testosterone
,8636290,production rate,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260313,DB00624,Testosterone
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],2504,260314,DB00624,Testosterone
,8636290,distribution,"Five days of fasting induced a 1.8-fold increase in the 24-h endogenous cortisol production rate (fed, 2504 +/- 308; fasted, 4528 +/- 488 nmol/L distribution volume; P < 0.006).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],4528,260315,DB00624,Testosterone
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],115,260316,DB00624,Testosterone
,8636290,mass of,"This enhanced cortisol production rate was accounted for by a 1.6-fold increase in the mass of cortisol secreted per burst (fed, 115 +/- 12.1; fasted, 183 +/- 17.3 nmol/L; P < 0.02).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),[nM] / [l],183,260317,DB00624,Testosterone
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,22,260318,DB00624,Testosterone
,8636290,number,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),,25,260319,DB00624,Testosterone
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,65,260320,DB00624,Testosterone
,8636290,interburst interval,"Moreover, the number of computer-resolved cortisol secretory bursts per 24 h (fed, 22 +/- 1.4; fasted, 25 +/- 2.0; P = NS) and the interburst interval (fed, 65 +/- 4.0; fasted, 57 +/- 4.4 min) did not change significantly during a 5-day fast.",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,57,260321,DB00624,Testosterone
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,108,260322,DB00624,Testosterone
,8636290,half-life,"The calculated half-life of endogenous cortisol was not significantly altered by fasting (fed, 108 +/- 9.7; fasted, 129 +/- 11 min).",Fasting as a metabolic stress paradigm selectively amplifies cortisol secretory burst mass and delays the time of maximal nyctohemeral cortisol concentrations in healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8636290/),min,129,260323,DB00624,Testosterone
,22403285,TT,"Baseline TT level was 328 ± 202 ng/dL, FT 9.49 ± 27.8 pg/mL, and E2 25.1 ± 17.3 pg/mL.",Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403285/),[ng] / [dl],328,260751,DB00624,Testosterone
,22403285,FT,"Baseline TT level was 328 ± 202 ng/dL, FT 9.49 ± 27.8 pg/mL, and E2 25.1 ± 17.3 pg/mL.",Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403285/),[pg] / [ml],9.49,260752,DB00624,Testosterone
,22403285,E2,"Baseline TT level was 328 ± 202 ng/dL, FT 9.49 ± 27.8 pg/mL, and E2 25.1 ± 17.3 pg/mL.",Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22403285/),[pg] / [ml],25.1,260753,DB00624,Testosterone
,10499606,steady-state plasma concentration,The average steady-state plasma concentration of tamoxifen was 2.96+/-1.32 microM (mean +/- SD).,A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),μM,2.96,261401,DB00624,Testosterone
,10499606,partial response/,"One partial response (80% decline in prostate-specific antigen) was observed (3.3%), whereas disease stabilization was observed in six patients (20%), for a combined partial response/stable disease response rate of 23%.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),%,23,261402,DB00624,Testosterone
,10499606,stable disease response rate,"One partial response (80% decline in prostate-specific antigen) was observed (3.3%), whereas disease stabilization was observed in six patients (20%), for a combined partial response/stable disease response rate of 23%.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),%,23,261403,DB00624,Testosterone
,10499606,time to progression,"Median time to progression was 2.1 months, and median survival time was 10.5 months.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),month,2.1,261404,DB00624,Testosterone
,10499606,survival time,"Median time to progression was 2.1 months, and median survival time was 10.5 months.",A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499606/),month,10.5,261405,DB00624,Testosterone
,25117615,tmax,"Over the evaluated dose range, plasma abiraterone concentrations increased with dose, with median tmax 2-3 h.",Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117615/),h,2-3,262377,DB00624,Testosterone
,12033516,maximum level of testosterone concentration,"On the other hand, the maximum level of testosterone concentration (40.0 +/- 12.6 ng/ml) was observed 24 h after rectal administration of hCG (400 IU/kg body weight) in combination with alpha-CyD (30 mg/kg body weight).",Pharmacokinetics and pharmacodynamics of human chorionic gonadotropin (hCG) after rectal administration of hollow-type suppositories containing hCG. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12033516/),[ng] / [ml],40.0,262606,DB00624,Testosterone
,15370957,apparent K(m),"2. Midazolam was mainly metabolized by CYP3A in DEX-treated female rat liver microsomes from an immuno-inhibition study, and the apparent K(m) was 1.8 microM, similar to that in human microsomes.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,1.8,262842,DB00624,Testosterone
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,0.088,262843,DB00624,Testosterone
,15370957,apparent K(i),"3. Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.",Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15370957/),μM,91.2,262844,DB00624,Testosterone
,19088107,EC(50),Org 43553 is a potent stimulator of the human LH-R in vitro (EC(50) 3.7 nM).,"Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088107/),nM,3.7,265709,DB00624,Testosterone
,19088107,oral bioavailability,Pharmacokinetic analyses showed high oral bioavailability in rats (79%) and dogs (44%) with a shorter half-life compared with hCG (3.4 versus 5.6 h in the rat).,"Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088107/),%,79,265710,DB00624,Testosterone
,19088107,oral bioavailability,Pharmacokinetic analyses showed high oral bioavailability in rats (79%) and dogs (44%) with a shorter half-life compared with hCG (3.4 versus 5.6 h in the rat).,"Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088107/),%,44,265711,DB00624,Testosterone
,19088107,half-life,Pharmacokinetic analyses showed high oral bioavailability in rats (79%) and dogs (44%) with a shorter half-life compared with hCG (3.4 versus 5.6 h in the rat).,"Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088107/),h,3.4,265712,DB00624,Testosterone
,19088107,half-life,Pharmacokinetic analyses showed high oral bioavailability in rats (79%) and dogs (44%) with a shorter half-life compared with hCG (3.4 versus 5.6 h in the rat).,"Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19088107/),h,5.6,265713,DB00624,Testosterone
,9701702,time to reach,"After one single injection, the mean time to reach the surgical castration testosterone range is 22 days, and this effective testosterone suppression is maintained for the 3-month therapy.",Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701702/),d,22,266397,DB00624,Testosterone
,9701702,plasma level,"After a first plasma surge (35.70 ng/ml) occurring 2.5 h after injection and a rise between day 17 and day 31 (maximum on day 24: 0.32 ng/ml), the mean triptorelin plasma level is stable (0.06 +/- 0.05 ng/ml) and maintained until day 91.",Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9701702/),ng,0.06,266398,DB00624,Testosterone
,12604713,K(i),Acetothiolutamide displayed high AR binding affinity (K(i) = 4.9 +/- 0.2 nM) and full agonist activity in the in vitro studies.,"Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604713/),nM,4.9,268142,DB00624,Testosterone
,12604713,clearance,Acetothiolutamide was rapidly cleared from rat plasma (clearance of about 45 ml/min/kg) in a concentration-independent manner after i.v. dosing.,"Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604713/),[ml] / [kg·min],45,268143,DB00624,Testosterone
,22526411,maximum plasma concentrations,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[ng] / [ml],26 to 112,269176,DB00624,Testosterone
,22526411,maximum plasma concentrations,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[ng] / [ml],40 to 125,269177,DB00624,Testosterone
,22526411,area under the plasma concentration-time curve from 0 to the last measurable plasma concentration,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[h·ng] / [ml],155 to 610,269178,DB00624,Testosterone
,22526411,area under the plasma concentration-time curve from 0 to the last measurable plasma concentration,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[h·ng] / [ml],195 to 607,269179,DB00624,Testosterone
,11438316,maximum testosterone levels,Mean maximum testosterone levels obtained with the lozenge occurred 1 hour after administration on days 1 (692 +/- 236 ng/dL) and 14 (836 +/- 309 ng/dL) of treatment and fell precipitously thereafter.,Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],692,269515,DB00624,Testosterone
,11438316,maximum testosterone levels,Mean maximum testosterone levels obtained with the lozenge occurred 1 hour after administration on days 1 (692 +/- 236 ng/dL) and 14 (836 +/- 309 ng/dL) of treatment and fell precipitously thereafter.,Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],836,269516,DB00624,Testosterone
,11438316,maximal levels,"In contrast, testosterone levels obtained with the gel showed a prolonged rise reaching maximal levels of 97 +/- 78 and 100 +/- 60 ng/dL after 18 hours.",Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],97,269517,DB00624,Testosterone
,11438316,maximal levels,"In contrast, testosterone levels obtained with the gel showed a prolonged rise reaching maximal levels of 97 +/- 78 and 100 +/- 60 ng/dL after 18 hours.",Pharmacokinetics of testosterone after percutaneous gel or buccal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11438316/),[ng] / [dl],100,269518,DB00624,Testosterone
,29589341,AUC,"Moreover, the AUC of solid TU-NLC formulations (4304±550.50 μg/L*min) was higher than commercial product Andriol Testocaps® (3075±372.50 μg/L*min).",Solidification of Nanostructured Lipid Carriers Loaded Testosterone Undecanoate: In Vivo and In Vitro Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589341/),[μg] / [l·min],4304,269699,DB00624,Testosterone
,29589341,AUC,"Moreover, the AUC of solid TU-NLC formulations (4304±550.50 μg/L*min) was higher than commercial product Andriol Testocaps® (3075±372.50 μg/L*min).",Solidification of Nanostructured Lipid Carriers Loaded Testosterone Undecanoate: In Vivo and In Vitro Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29589341/),[μg] / [l·min],3075,269700,DB00624,Testosterone
,32382745,Cavg,"Sodium fluoride-ethylenediamine tetra-acetate plasma T Cavg (mean ± standard deviation) for the oral TU group was 403 ± 128 ng/dL (~14 ± 4 nmol/L); serum T equivalent, ~489 ± 155 ng/dL (17 ± 5 nmol/L); and topical T, 391 ± 140 ng/dL (~14 ± 5 nmol/L).",A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32382745/),[ng] / [dl],403,271295,DB00624,Testosterone
,32382745,Cavg,"Sodium fluoride-ethylenediamine tetra-acetate plasma T Cavg (mean ± standard deviation) for the oral TU group was 403 ± 128 ng/dL (~14 ± 4 nmol/L); serum T equivalent, ~489 ± 155 ng/dL (17 ± 5 nmol/L); and topical T, 391 ± 140 ng/dL (~14 ± 5 nmol/L).",A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32382745/),[nM] / [l],14,271296,DB00624,Testosterone
,32382745,serum T equivalent,"Sodium fluoride-ethylenediamine tetra-acetate plasma T Cavg (mean ± standard deviation) for the oral TU group was 403 ± 128 ng/dL (~14 ± 4 nmol/L); serum T equivalent, ~489 ± 155 ng/dL (17 ± 5 nmol/L); and topical T, 391 ± 140 ng/dL (~14 ± 5 nmol/L).",A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32382745/),[ng] / [dl],489,271297,DB00624,Testosterone
,32382745,serum T equivalent,"Sodium fluoride-ethylenediamine tetra-acetate plasma T Cavg (mean ± standard deviation) for the oral TU group was 403 ± 128 ng/dL (~14 ± 4 nmol/L); serum T equivalent, ~489 ± 155 ng/dL (17 ± 5 nmol/L); and topical T, 391 ± 140 ng/dL (~14 ± 5 nmol/L).",A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32382745/),[nM] / [l],17,271298,DB00624,Testosterone
,32382745,serum T equivalent,"Sodium fluoride-ethylenediamine tetra-acetate plasma T Cavg (mean ± standard deviation) for the oral TU group was 403 ± 128 ng/dL (~14 ± 4 nmol/L); serum T equivalent, ~489 ± 155 ng/dL (17 ± 5 nmol/L); and topical T, 391 ± 140 ng/dL (~14 ± 5 nmol/L).",A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32382745/),[ng] / [dl],391,271299,DB00624,Testosterone
,32382745,serum T equivalent,"Sodium fluoride-ethylenediamine tetra-acetate plasma T Cavg (mean ± standard deviation) for the oral TU group was 403 ± 128 ng/dL (~14 ± 4 nmol/L); serum T equivalent, ~489 ± 155 ng/dL (17 ± 5 nmol/L); and topical T, 391 ± 140 ng/dL (~14 ± 5 nmol/L).",A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32382745/),nm,14,271300,DB00624,Testosterone
